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Summary
Colorectal cancer remains the second commonest cause of cancer death in Western 
Europe and North America. Overall survival is poor. Even in those patients who 
undergo potentially curative resection more than one third will die within 5 years.
It has long been recognised that disease progression in cancer patients is not solely 
determined by the characteristics of the tumour but also by the host response. One 
aspect of the host response, which has recently generated interest, is the non-specific 
systemic inflammatory response, associated with primary operable colorectal cancer. 
There is evidence that the systemic inflammatory response (as evidenced by C-reactive 
protein) predicts recurrence, and overall and cancer specific survival, independent of 
stage, in patients who have undergone curative resection for colorectal cancer.
Another aspect of the host response is tumour lymphocytic infiltration, there is 
increasing evidence that both local and systemic inflammatory responses play an 
important role in the progression of a vaiiety of common solid tumours. In patients with 
colorectal cancer, there is good evidence that, on simple staining of tumour sections, the 
presence of a pronounced lymphocytic infiltration within the tumour is associated with 
improved survival.
In the first research chapter of this thesis we assessed the value of combining Dukes 
stage and C-reactive protein to form a new prognostic score in patients undergoing 
apparently curative resection for colorectal cancer. The results suggest that this simple 
prognostic score, which reflects both the contribution of the tumour and the host 
response, appears to differentiate between low risk and high risk Dukes B and C
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tumours and may therefore be useful in selecting appropriate patients for adjuvant 
chemotherapy.
In the second research chapter we examined the relationships between the systemic 
inflammatory response, tumour lymphocytic infiltration, tumour proliferative activity 
and cancer survival in patients with Dukes stage B and C colorectal cancer undergoing 
potentially curative resection. A poor tumour CD4+ and CD8+ T-lymphocyte infiltrate, 
an increased Ki-67 labelling index were associated with poorer cancer specific survival. 
Poor tumour CD4+ T-lymphocyte infiltrates, increased Ki-67 labelling index and 
increased tumour diameter were associated with an elevated circulating C-reactive 
protein.
Multivariate survival analysis showed that both local (tumour CD8+ T-lymphocyte 
infiltrate) and systemic (C-reactive protein) inflammatory responses, but not tumour 
proliferation (Ki-67 labelling index), were significantly associated with cancer specific 
survival. That tumour proliferation is a relatively poor predictor of survival compared 
with the systemic inflammatory responses, possibly relates to the fact that tumour 
dissemination, rather than tumour proliferation, is the primary determinant of survival in 
patients with colorectal cancer.
These results would suggest that local and systemic inflammatory responses are linked 
to tumour proliferation in patients with colorectal cancer and these responses are in turn 
linked to cancer specific survival, independent of tumour stage. This means that, both 
local and systemic inflammatory responses are intrinsically linked to cancer specific 
survival in patients who have undergone apparently curative surgery for colorectal
14
cancer. Furthermore, these results would suggest that the presence of a systemic 
inflammatory response reflects increased tumour bulk and compromised cell mediated 
immunity.
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1.0 COLORECTAL CANCER
1.1 Epidemiology of Colorectal Cancer
Colorectal cancer is the third most common malignancy in the developed world, 
(Coleman, 1999). Worldwide, approximately 780,000 new cases were diagnosed in 
1990, which represents 9.4% of all incident cancer in men and 10.1% in women (Boyle, 
2000).
Colorectal cancer is not uniformly distributed among all populations. The highest 
incidences are in Western Europe and North America, whereas intermediate rates 
prevail in Eastern Europe. The lowest rates are seen in Asia, Africa and South America. 
However, there is some evidence that the incidence of the disease in Africa is now 
increasing, probably as a result of improving lifestyle (Iliyasu et al, 1997).
In the UK, colorectal cancer is the third most common form of cancer after lung and 
breast cancer. More than 35,000 new cases are diagnosed annually. It is now second 
only to lung cancer as a cause of cancer death in the UK, with over 16,000 deaths each 
year, which accounts for 11% of the UK cancer related mortality (Cancer Research UK, 
2004, www.cancerresearchuk.org).
Colorectal cancer affects almost equal proportion of men and women, most commonly 
between the ages of 60 and 80 years, but when the incidences of cancer of colon and 
rectum are examined separately, certain differences in sex incidence emerge. The ratio 
between males and females in the UK for cancer of the colon is approximately 2:3 and 
for cancer of the rectum is approximately 8:7 (Keighley and Williams, 1999).
16
Most authors seem to agree about the distribution of tumours within the colon, Thus, 
approximately 50% of all colon cancers are in sigmoid, 25% are in right colon (caecum 
and ascending colon), and the remaining 25% are in the transverse colon, splenic 
flexure, descending colon and hepatic flexure, in descending order of frequency 
(McDermott et al, 1981).
The distribution of caneer within the rectum is difficult to determine because authors 
who have studied this subject have often used different measurements when dividing
the rectum into its upper, middle and lower segments. The consensus, however, seems
*
to be that, apart from minor variations, rectal cancers are equally distributed between 
the three segments of the rectum (Keighley and Williams, 1999).
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1.2 Aetiology
The development of colorectal cancer represent the culmination of a complex process in 
which both hereditary and environmental factors, acting either alone or in combination, 
cause changes in the regulatory genes and cellular dysfunction. Most of the colorectal 
cancer (90- 95%) arise from sporadic adenomas (polyps) and most of the remaining are 
accounted for by several hereditary cancer syndromes. Despite advances in 
understanding the biology and natural history of colorectal cancer survival has not 
significantly improved in recent years.
1.2.1 Genetic Factors
Adenomatous polyps are widely believed to be the precursors of most of the colorectal 
adenocarcinomas and this concept is supported by epidemiological, genetic and 
pathological studies. Patients with adenomatous polyps have a threefold higher risk of 
colon cancer over the general population and the risk increases to six-fold if the polyps 
are multiple. The evolution of a carcinoma from an adenoma is generally believed to be 
a multi-step process of tumorigenesis called the, “adenoma- carcinoma sequence”. This 
concept, postulated in the mid-seventies is now widely accepted and has been supported 
by molecular genetics studies (Tomlinson et al, 1997).
However, the genetics events that take place in the development of sporadic colorectal 
cancer are also being explained. Mutations of the adenomatous polyposis coli (APC) 
gene, which is probably involved in cell-cell adhesion, are thought to occur early as they 
are found in 60% of all adenomas and carcinomas (Powell et al, 1992). K~ras mutations, 
which probably stimulate cell growth by activating growth factor signal transduction, 
similarly occur in both adenomas and carcinomas. However, as they are more common
18
in large adenomas than small adenomas they are thought to represent a later event 
(Vogelstein et al, 1988; Scott et al, 1993). The deleted in colorectal cancer (DCQ gene 
is a tumour-suppressor gene that may be responsible for cell-matrix interactions (Fearon 
et al, 1990), and its deletion may be important in further progression towards the 
malignant state. Mutation of the P53 gene is common in invasive colonic cancers but 
rare in adenomas and is therefore deemed to be a late event which accompanies the 
development of the invasive phenotype (Kikuchi-Yanoshita et al, 1992). The P53 gene 
is a tumour suppressor gene that appears to be the most important deteiminant of 
malignancy in colorectal neoplasia. It is located on the short arm of chromosome 17 and 
is frequently lost in colorectal malignancy. It is considered to be a transcription factor 
because it activates other genes and promotes their expression. These genes are 
involved in growth inhibition and loss of the P53 gene may therefore lead to 
unregulated cellular growth. Mutations of P53 are found in more than 50% of all 
human cancers and more than 75% of colorectal adenocarcinomas, making it one of the 
most important factors in human carcinogenesis (Vogelstein et al, 1988; Greenblatt et al, 
1994). The varied functions of P53 including control of the cell cycle, DNA repair and 
the induction of programmes cell death (apoptosis) to prevent proliferation of cells with 
deleterious mutations (Bukholm et al, 2000). Mutant P53 protein has a half-life of 
approximately 24 hours compared to wild-type P53 protein which has a half-life of 20 
minutes. Studies have shown that mutation in P53 usually result in the accumulation of 
P55 proteins (overexpression), which in turn result in increased proliferation, loss of 
apoptotic function, and chromosomal instability (Buglioni et al, 1999; Bukholm et al,
2000).
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The sequence of events described above is shown in Figure 1.1 (Smith et ai, 2002), but 
it must be stressed that this merely illustrates one possible multistep process; indeed, 
there is now good evidence that ¥, -^ras and P53 mutations very rarely occur in the same 
tumour, suggesting alternative pathways to carcinogensis (Smith et al, 2002).
NORMAL
COLONIC
MUCOSA
HYPERPROLIFERATtVEEPITHELIUM
Sq21 «ll#l* Inactivation______
DNA hypotmthyfuUon
ADENOMA CARCINOMA METASTASIS
rns point mutation
17p/p53 Inactivation ^  
184 Inactivation
further accum ulation of
chrom oaom al abnorm alities
5 “ 10 years 3 -5  years■.. ...... ....... ....................
Figure 1.1 Adenoma- carcinoma sequences (adapted from Smith et al, 2002).
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1.2.2 Inherited Bowel Cancer
Hereditary non-polvposis colorectal cancer
HNPCC is responsible for about 2% of colorectal cancer and is the commonest of the 
main inherited bowel cancer syndromes. HNPCC was previously known as Lynch 
syndrome and is inherited in an autosomal dominant fashion.
HNPCC is characterised by early onset of colorectal tumour, the average age at 
diagnosis being 45 years compared with approximately 65 years in the general 
population. These tumours have certain distinguishing pathological features. There is a 
predilection for the proximal colon, and tumours are also frequently multiple 
(Synchronous and metachronous). They tend to be mucinous, poorly differentiated and 
of ‘signet-ring’ appearance, with marked infiltration by lymphocytes and lymphoid 
aggregation at their margins.
HNPCC is due to germline mutations in mismatch repair (MMR) genes, whose role is to 
correct errors in base-pair matching during replication of DNA or to initiate apoptosis 
when DNA damage is beyond repair. The MMR genes are tumour suppressor genes. 
Defective MMR genes result in the accumulation of mutations in a host of other genes, 
leading to tumour formation.
Defective MMR genes also results in micro satellite instability (MSI), a hallmark of 
tumour in HNPCC (Frayling, 1999). Micro satellites are regions where a short DNA 
sequence (up to five nucleotides) is repeated. There are large numbers of such sequence 
in the human genome, the majority in non-coding DNA. Base-pair mismatches 
occurring during DNA replication are normally repaired by the MMR proteins. In the
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tumour with deficiency of these proteins this mechanism fails and micro satellites 
become instable (micro satellite instability).
Familial Adenomatous polyposis (FAP)
Familial adenomatous polyposis (FAP) is an autosomal dominant, inherited disorder, 
less common than HNPCC, with 100% risk of developing colorectal cancer (Talbot,
2000). It is characterized by the development of hundreds of adenomas during the 
second and third decades of life. These occur predominantly in the large bowel, but 
adenomas may also occur in the upper gastrointestinal tract. Genetic studies have shown 
that FAP caused by mutation in the tumour-suppressor adenomatous polyposis coli 
(APC) gene on chromosome 5. The sub site distribution of colorectal carcinoma in 
patients with familial adenomatous polyposis (FAP) is similar to that in patients with 
sporadic colorectal cancer; in both, left-sided cancers are more frequent than right-sided 
cancer (Bufill, 1995).
1.2.3 Environmental Factors
Diet
Meat. Animal protein and Fat
Evidence from epidemiological studies seems to show consistently that there is a well- 
established relationship between intake of certain dietary constituents, especially meat, 
and colorectal cancer.
Armstrong and Doll (1975) first described the association between incidence and 
mortality rates of colorectal cancers in 32 countries with per capita consumption of 
meat, animal protein, and total fat consumption. The correlation coefficient for meat and
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animal protein consumption remained higher than 0.7 after adjusting for other variables. 
The correlation was stronger for colon rather than for rectal cancer.
More recently, Sinha and co-workers (1999) have shown that well done, grilled red 
meat increases the risk of colorectal cancer. This consistent with the hypothesis that 
carcinogenic compounds formed by high temperature cooking techniques, such as 
heterocyclic amines and polycyclic aromatic hydrocarbons, may contribute to the risk of 
developing cancer.
Population studies and the great majority of earlier case-control studies suggested that 
colorectal cancer risk increased with an increased intake of dietary fat (Miller et al, 
1983; Graham et al, 1988). Several more recent case-control studies have also shown 
that there was a positive correlation between dietary fat intake and colorectal cancer 
(Panel on Food, Nutrition and the Prevention of Cancer; 1997; Lipkin et al, 1999). Since 
then, a substantial amount of progress has been made in understanding the relationship 
between dietary fat and development of colorectal cancer in humans. In 1990, Willett 
and co-workers published the results from the US nurses health study involving follow 
up of almost 89, 000 women aged 34-59 years who were without cancer or 
inflammatory bowel disease at recruitment. After adjustment for total energy intake, 
consumption of animal fat was found to be associated with increased risk of colorectal 
cancer.
On the other hand, several large prospective studies have been reported in Europe and 
the United States up to 2001. None of these studies found a clear, positive association 
between fat and colorectal cancer (Slattery et al, 1997; Terry et al, 2001; Jarvinen et al,
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2001). Indeed, Giovannucci and co-workers (1994) noted that the increased risk 
associated with animal fat intake in the American nurses disappeared when red meat 
intake was taken into the account.
Furthermore, in a combined analysis of 13 case control studies, Howe and co-workers 
(1997) showed no measurable positive association between either total fat intake or 
intake of saturated fat and colon cancer after adjustment for total calorie intake. 
Therefore, while animal studies have suggested an aetiological role for high fat intake in 
colorectal carcinogenesis, such evidence is very hard to extrapolate to humans (Kono,
2001).
Fibre
Burkitt's hypothesis (1971), that a lack of dietary fibre is associated with the higher 
incidence rates of colorectal cancer in western countries, generated a vast amount of 
epidemiological research. Two meta-analyses of 13 and 20 case control studies 
appeared to show that high intake of fibre-rich food reduced the risk of colorectal cancer 
by one-half (McKeown-Eyssen, 1985; Howe, 1992). However, in a prospective cohort 
study, only fibre from fruit was associated with an appreciable reduction in risk, but this 
relation was not statistically independent from meat intake (Willett, 1990)
More recently, Fuchs and co-workers (1999) analysed outcome in the nurses’ study with 
regard to fibre intake. During a 16-year follow-up period, 787 cases of colorectal cancer 
were documented. Furthermore, adenomas were detected in 1012 patients out of 27,530 
participants who underwent endoscopies during the follow-up period. After adjustment 
for age, established risk factors, and total energy intake, they found no association
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between the intake of dietary fibre and the risk of colorectal cancer. The results of the 
more recent larger studies therefore, do not support the existence of an important 
protective effect of dietary fibre against colorectal cancer or adenoma.
Minor dietarv eonstituents
A number of dietary constituents have been found to inhibit carcinogenesis, including 
selenium, vitamin C, E, retinoids, carotenoids (fi-carotene, lycopene, lutein, B- 
cryptoxanthin, and «-carotene) and plant sterols. It is worth noting that, diets low in 
Vitamin C and carotenoids also tend to he low in fibre (Pritchard, 1996). Carotenoids, 
long recognized for their antioxidant properties, are of increasing interest in relation to 
cancer because of their effect on regulation of cell growth (Rock, 1997). Recent studies 
by Slattery and co-workers (2000) have suggested that there may be an association 
between the use of these supplements (lutein and a--carotene) and a low risk of 
developing colorectal cancer.
Tobacco and Alcohol
There is little evidence that colon cancer is associated with consumption of alcoholic 
beverages. Of 15 cohort studies published up to 1992, none showed significant alcohol- 
related increase in the risk of colon cancer. Rectal cancer, however, was positively 
associated with alcohol in number of cohort studies (McMichael and Giles, 1994).
Until recently there was little evidence that smoking was related to colorectal cancer 
(Sandler, 1988; Slattery, 1990; Kune, 1992). However, two reports using data from two 
large single-gender cohorts of health professionals concluded that for each gender the 
number of cigarettes smoked during the most recent 20 years was positively related to
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the prevalence of small adenomas, whereas pack years of smoking more than 20 years 
earlier was linked with an increase in large adenomas. Smoking was related to risk of 
colorectal cancer after allowing for an induction period of at least 35 years 
(Giovannucci, 1994a; Giovannucci, 1994b; Giovannucci, 2001).
On the other hand Nyren and coworkers (1996) carried out a large cohort study, which 
involved approximately 135,000 male construction workers, with an average follow up
17.6 years. This study did not support a high risk of colon cancer in males who were 
long-term heavy smokers and provided only weak support for an association with rectal 
cancer.
1.2.4 Biological markers and colorectal cancer
Apoptosis
The normal gastrointestinal epithelium is characterized by rapid cell turnover at the 
level of the colonic crypt, replacing the surface epithelium approximately every six 
days. The highly proliferative compartment is the lower third of the crypt. As the cells 
move up the crypt, they mature, differentiate, lose their dividing ability and eventually 
die (apoptosis).
Apoptosis, or programmed cell death, plays an important role in many physiologic and 
pathologic processes (Thompson, 1995). Among others, an important function of 
apoptosis lies in the elimination of damaged cells. For example, cells with genetic 
damage caused by exposure to carcinogens may be deleted by undergoing apoptosis, 
thereby preventing their replication and the accumulation of clones of abnormal cells. 
There is increasing evidence to support the hypothesis that failure of apoptosis may he
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an important factor in the evolution of colorectal cancer and its poor response to 
chemotherapy and radiation (Watson, 1995). Inhibition of apoptosis causes an 
imbalance in normal tissue homeostasis promoting cell growth and it also allows the 
survival of genetically damaged cells, both contributing to tumour development and 
progression (Hawkins et al, 1997).
Traditionally, an increase in cell proliferation, rather than a change in apoptosis, has 
been used to predict later tumour development and prognosis. While there is general 
agreement that the dysregulation of apoptosis eontributes to malignant transformation, 
the potential predictive or prognostic value of the degree of apoptosis in colorectal 
cancer is controversial. Several studies have examined the prognostic value of the 
apoptotic index in colorectal cancer, producing conflicting results (Hawkins et al, 1997; 
Hashimoto et al, 1997; Kawasaki et al, 1998; Evertsson et al, 1999; Sinicrope et al, 
1999; Tenjo et al, 2000; Schwandner et al, 2000; Paradiso et al, 2001). Schwandner and 
co-workers (2000) showed that the apoptotic index was not predictive of prognosis in a 
series of 160 cases of rectal cancer. In two studies, it was shown that a low apoptotic 
index in the tumour was associated with poor survival (Langlois et al, 1997; Kawasaki 
et al, 1998). Two reports showed that apoptotic indices were higher in tumours that 
were more highly differentiated and had not invaded or metastasised than in those that 
were poorly differentiated and invasive or metastasizing (Hashimoto et al, 1997; 
Sugamura et al, 1998).
The degree of apoptosis in colorectal tumours is not related to the degree of 
proliferation in most studies. The use of the apoptotic index in a tumour as a potential
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prognostic marker or indicator for the choice of therapy, as suggested by some, is 
currently not supported by the available data.
Proliferation
Ki-67 protein is a large nuclear antigen expressed in highest concentrations in all stages 
of the cell cycle but not in resting cells. It has a very complex and specific localization 
pattern within the nucleus, one which changes during the cell cycle. It has been known 
for some time that Ki-67 protein is associated with the dense fibrillary component (DFC) 
of the nucleolus (Verheijen et al, 1989). Although there is a vast amount of information 
known about the structure, localization and regulation of Ki-67 protein, but there is little 
information about the function of this protein apart from the fact that it is vital for cell 
proliferation (Brown and Gatter, 2002).
The original antibody raised against Ki-67 protein could be used only on fresh or frozen 
tissue, since fixation greatly interferes with immunostaining pattern. This prototypic 
antibody was succeeded by other antibodies which could recognize Ki-67 protein in 
conventional fixed tissue sections, treated with microwave irradiation (Rose et al, 
1994). The most widely used of these is monoclonal antibody MIB-1 (Molecular 
Immunology Borstel) (Cattoretti et al, 1992). There is no doubt that this antibody has 
been the single largest achievement in the investigation of Ki-67 protein's prognostic 
potential. Its arrival meant that retrospective studies using archived surgical histology 
material could be undertaken and large prospective studies became much easier to 
perform since there was no longer the need to collect fresh tissue. The 
immunohistochemical staining pattern of ki-67 antigen has been found to correlate well
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with tumour proliferative activity in various human malignancies (Brown and Gatter, 
2002).
It is well established that Ki-67 protein is of prognostic value for many types of 
malignant tumour as it represent tumour proliferative activity and for many tumour 
types, high proliferative activity has been shown to correlate with poor clinical 
outcome. For example, in breast cancer most studies showed a statistically significant 
correlation between high proliferative activity and clinical outcomes, both on univariate 
and multivariate analysis (Locker et al, 1992; Beck et al, 1995; Jaequemier et al, 1998; 
Chang et al, 1999). Other studies reveal an unclear and often contradictory pattern for 
certain tumours, e.g. cervix uteri, non-Hodgkin's lymphoma and prostate cancer (Brown 
and Gatter, 2002).
In colorectal cancer, the relation between proliferation marker and prognosis after 
resection are conflicting. For example, Brown and Gatter (2002) in their recent review 
of those studies, only three out of 12 studies reported a significant association with 
survival (Palmqvist et al, 1999; Saleh et al, 1999; Kimura et al, 2000). The results of the 
above studies which did show a correlation were also contradictory; for example, 
Palmqvist et al (1999) concluded that colorectal cai'cinomas with low Ki-67 protein 
expression at the invasive margin had a poor prognosis, whilst Saleh and co-workers 
(1999) and Kimura and co-workers (2000) showed that a high Ki-67 protein expression 
at the site of invasive margin had a worse prognosis. These apparently contradictory 
findings may be the result of the marked heterogeneity of Ki-67 protein expression in 
colorectal carcinomas (Ofner et al, 1996). However, many of these studies were based
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on small numbers; some included both primary operable and advanced disease and most 
used semi-quantitative techniques for the measurement of Ki-67.
Colorectal cancer with a high proliferative activity is more likely to respond to 
chemotherapy (Allegra et al, 2002; Allegra et al 2003; Ganity et al, 2004). Garrity and 
coworkers (2004) analysed the proliferative activity of colon cancer in the treatment and 
non treatment group separately. Within treatment group, patients with high ki-67 protein 
expression showed improved overall survival regardless of whether they received active 
treatment. According to these results, proliferative markers have the potential to 
distinguish patients with rapidly proliferating tumors that are likely to respond to 
chemotherapy from patients with slowly proliferating tumors who may not need 
aggressive treatment. Selection of those patients, by assessment of the proliferative 
activity, may be a reliable approach to predict which patients will respond to 
chemotherapy.
Recently, Valera and co-workers (2005) reported that, using a double 
immunohistochemical staining procedure and a quantitative teclmique in a cohort of 
106 patients who underwent curative resection for colorectal cancer, an increased Ki-67 
proliferation index was associated with poorer survival and it maintained significance as 
an independent predictor of long-term outcome in a multivariate analysis that included 
other prognostic factors. This study also showed a significant correlation between 
proliferative index and several pathological characteristics of colorectal carcinomas, 
such as tumour differentiation, metastatic disease and local invasiveness in keeping with 
earlier studies (Porschen et al, 1991; Kubota et al, 1992; Diebold et al, 1994; Kyzer et 
al, 1997).
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1.2.5 Inflam m atory disease and other risk factors
Inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) are at increased risk of developing 
colorectal cancer when compared with the general population (Table 1.2), whose 
average lifetime risk is 2 to 8 percent (Eaden, 2000; Eaden, 2001). Colorectal cancer 
represents the major cause of excess morbidity and mortality from malignant disease in 
patients with ulcerative colitis and to a lesser extent in Crohn's disease. Colorectal 
cancer was observed in 5.5-13.5 % of all patients with ulcerative colitis and 0.4-0.8 % 
of patients with Crohn’s disease (Pohl, 2000).
Established risk factors include long duration of disease (Eaden, 2001), extensive 
disease (Ekbom, 1990), young age at onset (Eaden, 2001), the presence of complicating 
primary sclerosing cholangitis (Brentnall et al, 1996; Kornfeld, 1997), persisting 
activity of the disease and inadequate pharmacological therapy (Bernstein, 2002).
C-reactive protein concentration
It is of interest therefore, that an increase in the marker of systemic inflammation, such 
as C-reactive protein is associated with an increase incidence of colorectal cancer in 
general population (Erlinger et al, 2004).
A recent epidemiologic study has raised the hypothesis that C-reactive protein 
concentration (CRP) might also be associated with incident colorectal carcinoma and 
considered as risk factor (Erlinger et al, 2004). This latter finding is supported by 
clinical observations of an increased risk for colorectal cancer in patients with chronic.
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relapsing and remitting inflammatory bowel diseases (Panes, 2001; Munkliolm, 2003). 
Erlinger and co-workers (2004) investigated the possibility that C-reactive protein, as a 
marker for inflammation, could help identify people at risk for the development of 
colorectal cancer. C-reactive protein was measured as (baseline) at the beginning of 
their prospective study. During 11 years follow-up period, a total of 172 subjects 
develop colorectal cancer, of these 131 had colon cancer and 41 had rectal cancer. For 
each colorectal cancer case, 1 or 2 case matched controls were found. Those apparently 
healthy subjects with the higher C-reactive protein concentration (top 25%) had twice 
the risk of colorectal cancer compared with those with lower C-reactive protein 
concentration (bottom 25%). However, depending on whether a case-control or cohort 
study design was used, these results have or have not been confirmed (Gunter et al, 
2006; Zhang et al, 2005).
In summary, there is some evidence that the presence of systemic inflammatory 
response, as evidenced by elevated C-reaetive protein concentration, plays a role in the 
development and or progression of colorectal cancer.
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Table 1.1 Established risk factors for colorectal cancer (adapted from DeVita, 2001). 
Genetic
Polyposis Syndromes 
Familial polyposis coli 
Gardner’s syndrome 
Turcot syndrome (CNS tumours)
Oldfield’s syndrome (sebaceous cysts)
Peutz-Jeghers syndrome (hamartomas)
Nonpolyposis syndromes 
Lynch syndrome I
Lynch syndrome II (associated extracolonic cancers)
Pre-existing disease and inflammation
Ulerative colitis 
Crohn’s disease 
Prior colorectal cancer 
Neoplastic polps 
Pelivic irradiation
General
Age >40 y
Family history of colorectal cancer
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1.2.6 Chem oprevention
Non-steroidal Anti-inflammatory drugs and colorectal cancer
There is evidence that the use of non-steroidal anti-inflammatory drugs (NSAID) is 
associated with reduced risks of colorectal cancer and adenomatus polyps (Rosenberg, 
1991; Peleg, 1994; Giovannucci, 1994). Firstly, several NSAIDs, including aspirin, 
inhibit the growth of chemically induced colonic tumours in rats and mice (Pollard, 
1983; Narisawa, 1983; Reddy, 1990). Secondly, the NSAID sulindac causes the 
regression of residual rectal polyp in patients with familial adenomatous polyposis and 
an ileoreçtal anastomosis (Nugent et al, 1992; Giardiello et al, 1993). Finally, in 
epidemiological studies, the use of aspirin and NSAIDs was associated with an 
approximate halving of the risk of developing or dying from colonic or colorectal 
cancer (Rosenberg, 1991; Thun, 1991).
In 1977, Bennett and co-workers noted increased concentrations of prostaglandins in 
colorectal cancer tissue when compared with normal colorectal mucosa. Given the 
pharmacological ability of non-steroidal anti-inflammatory drugs to inhibit the 
cyclooxygenase (COX-1) enzyme and thereby block prostaglandin synthesis, several 
studies evaluated the use of non-steroidal anti-inflammatory drugs and demonstrated 
that they could both prevent and reverse colorectal adenomas and carcinomas in animal 
models and man (Pollard et al, 1980; Kudo et al, 1980; Kune et al, 1988). Since then 
several other studies have been published and nearly all have confirmed the original 
reports. Indeed, the chemopreventive properties of several non-steroidal anti­
inflammatory drugs including aspirin (Giovannucci, 1994), indomethacin (Rubio et al, 
1989), piroxicam (Pollard et al, 1984), and sulindac (Skinner et al, 1991) have been 
confirmed.
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Clinical experience with non-steroidal anti-inflammatory drugs included a series of case 
reports (Waddell and Loughry, 1983; Waddell et al, 1989) and randomised trials 
(Labayle et al, 1991; Giardello et at, 1993), which demonstrated the ability of NSAID 
including sulindac to reduce the size and number of colorectal polyps occurring in 
patients with familial adenomatous polyposis (FAP). These findings have important 
public health implications, as it is likely that the adenoma/carcinoma sequence in 
familial adenomatous polyposis patients is similar to that of the general population. This 
concept is supported by recent epidemiological findings of a 40-50% reduction in 
mortality from colorectal cancer among people regularly taking non-steroidal anti­
inflammatory drugs compared with those not taking these agents (Cotton et al, 1996; 
Smalley et al, 1997; Janne, 2000; Sandler, 2003).
Despite the strong evidence that the use of non-steroidal anti-inflammatory drugs lowers 
the risk of colorectal cancer, many questions remain. Aspirin was the sole or 
predominant non-steroidal anti-inflammatory drug evaluated in most of the 
epidemiologieal studies to date. However, patterns of use (dose and duration) necessary 
to prevent colorectal cancer are still unclear. Giovannucci and colleagues (1995) found 
an increasing protective effect with an increasing duration of regular aspirin use. 
Although this reduction became significant only after 20 years of use, the relative risk 
for colorectal cancer began to steadily decline after 5 to 9 years of regular use. 
Rosenberg and co-workers (1991) found a protective effect when regular use was 
started in the year before diagnosis and found a weak effect of duration of use when any 
regular use was compared with regular use over five or more years. Although these
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independent lines of research all support the link between NSAID use and a reduction in 
colorectal cancer, the pharmacological basis of NSAID protection remains unclear.
It is likely that these mechanisms are related, at least in part, to those underlying the 
anti-inflammatory properties of non-steroidal anti-inflammatory drugs, that is, their 
ability to inhibit the cyclooxygenase enzymes (Smalley et al, 1997), which reduces the 
levels of tissue-specific prostaglandins (PG) (Figure 1.2), the mediators of the 
inflammatory response (Funk, 2001). Cyclo-oxygenase (COX) is an enzyme that is 
responsible for the conversion of arachidonic acid into prostaglandins (PG).
An inducible form of eydo-oxygenase was recognized in early 1990s (Xie et al, 1991; 
Masferrer et al, 1992). This was confirmed and led to the classification of two 
isoenzymes (Table 1.1), COX-1, the constitutive form, is expressed in many tissues to 
regulate and maintain normal cellular function. In contrast, COX-2 is expressed only 
after stimulation via a variety of different growth factors, cytokines and mitogens 
(Smith et al, 2001). Aspirin and other NSAIDs inhibit the activity of both isoforms; the 
therapeutic anti-inflammatory effects are attributed to COX-2 inliibition, whereas the 
side-effects of these drugs (gastrointestinal inflammation, ulceration, prolonged 
bleeding time) seem to be due primarily to the inliibition of COX-1 (FitzGerald et al, 
2001; Chan et al, 2002).
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Figure 1.2 Potential mechanistic pathways that may account for some of the anticancer 
effects of the non-steroidal anti-inflammatory drugs (NSAIDs) and cyclo oxygenase 2 
inhibitors (coxibs) (Adapted from Church, 2003).
Protection is probably multifactorial and could be related to the ability o f  NSAIDs to 
arrest colorectal carcinogenesis at several stages. The specific mechanisms o f action o f  
COX-2 inhibitors as anticancer agents have yet to be established. The inhibition o f  
cyclo-oxygenase and reduction in tissue prostaglandin levels in human subjects have 
been established (FitzGerald, 2001), but the downstream cellular events are not as clear. 
An impact o f  the coxibs on angiogenesis (Jones, 1999) and apoptosis (Richter, 2001) 
has been observed. In addition, there is some evidence to suggest that Cox-2 inhibitors 
have effects on cellular proliferation and adhesion, breakdown o f  the extracellular
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matrix, and modulation of immune surveillance (Dannenberg, 1999; Pan, 
2001;Yamazaki, 2002).
COX-2 inhibitors may prove to be attractive chemopreventive agents because selective 
inhibition may prevent cancer while avoiding the complication of bleeding and gastric 
irritation (FitzGerald, 2001; Chan, 2002). However, to date their efficiency in humans is 
not well defined.
Table 1.2 Cyclo-Oxygenase enzymes (Adapted from Church, 2003).
Cyclo-oxygenase-1 Cyclo-oxygenase-2
Expression Constitutive Constitutively expressed only in brain, lung,
kidney
Found in all tissues Rapidly induced in inflammatory tissue (1-3 h)
induced by cytokines and growth factors (IL- 
2,TNF-a)
inhibited by anti-inflammatory cytokins (IL- 
10)
Functions Housekeeping Inflammatory process in macrophages,
function in platelet, leucocytes, fibroblasts, and endothelium 
stomach, kidneys, 
and endothelium
Inhibition Aspirin and non- Aspirin, non-steroidal anti-inflammatory drugs
steroidal anti- and glucocorticoids
inflammatory drugs
COX = Cyclo-oxygenase, IL-1= Interleukin 1, IL-10 = Interleukin 10, TNFa == Tumour 
necrosis factor alpha.
38
1.3 Host Immune Response and Colorectal Cancer
1.3.1 Basis of immunology
The physiologic function o f  the immune system is to protect individuals from infectious 
pathogens. The mechanisms that are responsible for this protection fall into two broad 
categories (Figure 1.3). Innate immunity (native immunity) refers to defence 
mechanisms that are present even before infection and have evolved to specifically 
recognize microbes and protect multicellular organisms against infections. Adaptive 
immunity (specific, immunity) consists o f  mechanisms that are stimulated by (adapt to) 
microbes and are capable o f  also recognizing nonmicrobial substances, called antigens. 
Innate immunity is the first line o f  defence, because it is always ready to prevent and 
eradicate infections. Adaptive immunity develops later after exposure to microbes and is 
even more powerful in combating infections. By convention, the term "immune 
response" refers to adaptive immunity (Abbas, 2005).
Figure 1.3 Innate and adaptive immunity (Abbas, 2005).
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Innate immunity
The major components of innate immunity are epithelial barriers that block entry of 
environmental microbes, phagocytic cells (mainly neutrophils and macrophages), 
natural killer (NK) cells, and several plasma proteins, including the proteins of the 
complement system. Phagocytes are recruited to sites of infection, resulting in 
inflammation, and here the cells ingest the microbes and are then activated to destroy 
the ingested pathogens. Phagocytes recognize microbes by several membrane receptors 
(Abbas, 2005).
Complement proteins are some of the most important plasma proteins of the innate 
immune system. Recall that in innate immunity, the complement system is activated by 
binding to microbes using the alternative pathways; in adaptive immunity, it is activated 
by binding to antibodies using the classical pathway. Other circulating proteins of innate 
immunity are mannose-binding lectin and C-reactive protein, both of which coat 
microbes for phagocytosis and complement activation (see section 1.3.6). Lung 
surfactant is also a component of innate immunity, providing protection against inhaled 
microbes.
Adaptive immunity
The adaptive immune system consists of lymphocytes and their products, including 
antibodies. The receptors of lymphocytes are much more diverse than those of the 
innate immune system, but lymphocytes are not inherently specific for microbes, and 
they are capable of recognizing a vast array of foreign substances.
40
1.3.2 Humoral and Cell-mediated immunity
There are two main types o f  adaptive immunity— cell-mediated (or cellular) immunity, 
which is responsible for defence against intracellular microbes, and humoral immunity, 
which protects against extracellular microbes and their toxins (Fig. 1.4). Cellular 
immunity is mediated by T (thymus-derived) lymphocytes, and humoral immunity is 
mediated by B (bone marrow-derived) lymphocytes and their secreted products, 
antibodies. Both these mechanisms o f adaptive immunity are capable o f causing injury 
to the host and subsequent disease.
Figure 1.4 Humoral and cell-mediated immunity (Abbas, 2005).
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T Lymphocytes
T lymphocytes are generated from immature precursors in the thymus. Mature, naive T 
lymphocytes are found in the blood, where they constitute 60% to 70% of lymphocytes, 
and in T- lymphocytes zones of peripheral lymphoid organs, such as the paracortical 
areas o f lymph nodes and periarteriolar sheaths of the spleen. The segregation of naive 
T lymphocytes to these anatomic sites is because the cells express receptors for 
chemoattractant cytokines (chemokines) that are produced only in these regions of 
lymphoid organs (Cyster, 1999; Mebius, 2003) Each T lymphocytes is genetically 
programmed to recognize a specific cell-bound antigen by means of an antigen-specific 
T-cell receptor (TCR) (Davis, 1998). In approximately 95% of T lymphocytes, the TCR 
consists of a disulfide-linked heterodimer made up of a and p polypeptide chain (Figure 
1.5), each having a variable (antigen-binding) and a constant region. The a p TCR 
recognizes peptide antigens that are displayed by major histocompatibility soluble 
antigens; therefore, presentation of processed, membrane-bound antigens by antigen- 
presenting cells is required for induction of cell-mediated immunity. T- lymphocytes 
receptors are capable of recognizing a very large number of peptides; each T 
lymphocytes expresses TCR molecules of one structure and specificity.
A minority of mature T lymphocytes express another type of TCR composed of y and ô 
polypeptide chains (Hayday, 1999). The y 8 TCR recognizes peptides, lipids, and small 
molecules, without a requirement for display by MHC proteins. These T cells tend to 
aggregate at epithelial surfaces, such as the mucosa of the respiratory and 
gastrointestinal tracts, suggesting that these cells are sentinels that protect against 
microbes that try to enter tlirough these epithelia. Another small subset of T 
lymphocytes expresses markers that are found on natural killer (NK) cells; these cells
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are called NK-T lymphocytes, NK-T lymphocytes express a very limited diversity of 
TCRs, and they recognize glycolipids that are displayed by the MHC-like molecule 
CDl. The functions of NK-T lymphocytes are also not well defined.
T lymphocytes also express a number of non-polymorphic, function-associated 
molecules, also called accessory molecules, including CD4, CD8, CD2, integrins, and 
CD28. CD4 and CD8 are expressed on two mutually exclusive subsets of a p T 
lymphocytes. CD4 is expressed on approximately 60% of mature CD3+ T lymphocytes, 
whereas CD8 is expressed on about 30% of T lymphocytes. These T- lymphocytes 
membrane-associated glycoproteins serve as co-receptors in T- lymphocytes activation. 
During antigen presentation, CD4 molecules bind to the non-polymorphic portions of 
class II MHC molecules expressed on antigen-presenting cells (Figure 1.5).
In contrast, CD8 molecules bind to class I MHC molecules. CD4 and CD8 are required 
to initiate signals that activate T lymphocytes that recognize antigens. Because of this 
requirement for co-receptors, CD4+ helper T lymphocytes can recognize and respond to 
antigen only in the context of class II MHC molecules, whereas CD8+ cytotoxic T 
lymphocytes recognize cell-bound antigens only in association with class I MHC 
molecules. It is now well established that T lymphocytes need two signals for 
activation. Signal 1 is provided when the TCR is engaged by the appropriate MHC- 
bound antigen, and the co-receptors CD4 and CD8 bind to MHC molecules. Signal 2 is 
delivered by the interaction of the CD28 molecule on T lymphocytes with the co­
stimulatory molecules B7-1 (CD80) and B7-2 (CD86) expressed on antigen-presenting 
cells (Figure 1.5). The importance of co-stimulation by this pathway is attested to by the 
fact that, in the absence of signal 2, the T cells fail to respond, undergo apoptosis, or
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become unreactive (Lenschow et al, 1996). When T lymphocytes are activated by 
antigen and co-stimulators, they secrete locally acting proteins called cytokines 
(described below). Under the influence of a cytokine called interleukin-2 (ÏL-2), the T 
lymphocytes proliferate, thus generating a large number of antigen-specific 
lymphocytes. Some of these cells differentiate into effector cells, which perform the 
function of eliminating the antigen that started the response. Other activated cells 
differentiate into memory cells, which are long-lived and poised to respond rapidly to 
repeat encounters with the antigen.
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Figure 1.5 T-cell receptor (TCR) complex (Abbas, 2005). 
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CD4+ and CD8+ T lymphocytes perform distinct but somewhat overlapping effectors 
functions (von Andrian et al, 2000). The CD4+ T lymphocytes can be viewed as a 
master regulator by secreting cytokines; CD4+ T lymphocytes influence the function of 
virtually all other cells of the immune system, including other T lymphocytes, B 
lymphocytes, macrophages, and NK cells. The central role of CD4+ T lymphocytes is 
tragically illustrated when the human immunodeficiency virus cripples the immune 
system by selective destruction of this T- lymphocytes subset. In recent years, two 
functionally distinct populations of CD4+ helper lymphocytes have been recognized on 
the basis of the different cytokines they produce (Figure 1.6) (Abbas, 1996). The T- 
helper-1 (Th 1) subset synthesizes and secretes IL-2 and interferon-y (IFN-y) but not IL- 
4 or IL-5, whereas Th 2 cells produce IL-4, IL-5 and IL-13 but not IL-2 or IFN-y. This 
distinction is significant because the cytokines secreted by these subsets have different 
effects on other immune cells. The Th 1 subset is involved in facilitating delayed 
hypersensitivity, macrophage activation, and synthesis of opsonizing and complement- 
fixing antibodies. The Th 2 subset aids in the synthesis of other classes of antibodies, 
notably IgE (mediated by IL-4 and IL-13) and in the activation o f eosinophils (mediated 
by IL-5). CD8+ T lymphocytes function mainly as cytotoxic lymphocytes to kill other 
cells but, similar to CD4+ T lymphocytes, they can secrete cytokines, primarily of the 
Th 1 type.
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Figure 1.6 The cytokines produced by Thl and Th2 lymphocyte populations (Abbas, 
1996).
effector effectorfunctions functions
B Lymphocytes
B lymphocytes develop from immature precursors in the bone marrow. Mature B 
lymphocytes constitute 10% to 20% o f  the circulating peripheral lymphocyte population 
and are also present in peripheral lymphoid tissues such as lymph nodes, spleen, or 
tonsils and extralymphatic organs such as the gastrointestinal tract. In lymph nodes, 
they are found in the superficial cortex. In the spleen, they are found in the white pulp. 
At both sites, they are aggregated in the form o f  lymphoid follicles, which on activation
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develop pale-staining germinal centers, B lymphocytes are located in follicles, the B- 
lymphocytes zones of lymphoid organs, because the cells express receptors for a 
chemokine that is produced in follicles (Cyster, 1999; Mebius, 2003).
B lymphocytes recognize antigen via the B~ lymphocytes antigen receptor complex. 
Immunoglobulin M (IgM) and (IgD) D, present on the surface of all naive B cells, 
constitute the antigen-binding component of the B-cell receptor complex. After 
antigenic stimulation, B lymphocytes form plasma cells that secrete immunoglobulins, 
which are the mediators of humoral immunity.
B lymphocytes may be activated by protein and non-protein antigens. The end result of 
B- lymphocytes activation is their differentiation into antibody-secreting cells, called 
plasma cells. Antibody-secreting cells reside in lymphoid organs and mucosal tissues, 
and some plasma cells may migrate to the bone marrow and live for many years in this 
tissue. Secreted antibodies enter mucosal secretions and the blood and are able to find, 
neutralize, and eliminate antigens. B- lymphocytes responses to antigens require help 
from CD4+ T lymphocytes (Clark et al, 1994). Helper T lymphocytes activate B 
lymphocytes by engaging CD40, a member of the tumour necrosis factor (TNF)- 
receptor family, and by secreting cytokines. Activated helper T lymphocytes express 
CD40 ligand, which specifically binds to CD40 expressed on B lymphocytes (Clark et 
al, 1996). This interaction is essential for B- lymphocytes maturation and secretion of 
IgG, IgA, and IgE antibodies.
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Natural Killer Cells
NK cells make up approximately 10% to 15% of the peripheral blood lymphocytes and 
do not bear T- lymphocytes receptors or cell surface immunoglobulins. 
Morphologically, NK cells are somewhat larger than small lymphocytes, and they 
contain abundant azurophilic granules. Hence, they are also ealled large granular 
lymphocytes. NK cells are endowed with an innate ability to kill a variety of tumour 
cells, virally infected eells, and some normal cells, without previous sensitization 
(Cerwenka et al, 2001). These cells are part of the innate immune system, and they may 
be the first line of defenee against viral infections and, perhaps, some tumours. NK cells 
do not rearrange T- lymphocytes receptor genes and are CDS negative. Two cell surface 
molecules, CD16 and CD56, are widely used to identify NK cells. CD16 is the Fc 
receptor for IgG and it endows NK cells with another function, the ability to lyse IgG- 
coated target cells. This phenomenon, known as antibody-dependent cell-mediated 
cytotoxieity.
The functional activity of NK cells is regulated by a balance between signals from 
activating and inhibitory receptors. The activating receptors stimulate NK cell killing by 
recognizing ill-defined molecules on target cells, some of which may be viral products; 
the inhibitory receptors inhibit the activation of NK cells by recognition of self-class I 
MHC molecules. The class I MHC-recognizing inhibitory receptors on NK cells are 
aptly called killer inhibitory receptors. They are biochemically distinct from T-cell 
receptors. It is believed that NK cells are inhibited from killing normal cells because all 
nucleated normal cells express self-class I MHC molecules (Ochsenbein, 2002).
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NK cells also secrete cytokines, such as IFN-y, TNF, and granulocyte macrophage 
colony-stimulating factor (GM-CSF). IFN-y activates macrophages to destroy ingested 
microbes, and thus NK cells provide early defence against intracellular microbial 
infections. IFN-y also promotes the differentiation of naive CD4+ T- lymphocytes into 
Th 1 lymphocyte. Thus, activation of NK cells early in the immune response can favour 
induction of delayed hypersensitivity and secretion of opsonising antibodies by 
promoting the development of Th 1 lymphocytes. The activity of NK cells is regulated 
by many cytokines, ineluding IL-2, IL-15, and IL-12. IL-2 and IL-15 stimulate 
proliferation of NK cells, whereas IL-12 activates killing and secretion of IFN- y 
(Ochsenbein, 2002).
1.3.3 Cytokines: messenger molecules of the immune system
Cytokines are intercellular signalling polypeptides produced by activated cells 
mediating cell-cell communication during inflammatory and immune responses. 
Cytokines term includes the previously designated lymphokines (lymphocyte-derived), 
monokines (monocyte-derived), and several other polypeptides that regulate 
immunologic, inflammatory, and reparative host responses. Molecularly defined 
cytokines are called interleukins, implying that they mediate communieations between 
leukocytes. Most cytokines have a wide spectrum of effects, and some are produced by 
several different cell types.
The cytokines that are produced during and participate in inflammatory processes are 
the chief stimulators of the production of acute-phase proteins. These inflammation- 
associated cytokines include interleukin-1, interleukin-6, tumour necrosis factor (alpha),
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interferon (gamma), transforming growth factor (beta), (Kushner, 1993) and possibly 
interleukin-8 (Wigmore et al, 1997).
Interleukin-1 has a multifunctional role. It stimulate the production of lymphocyte- 
activating factor, endogenous pyrogen, leucocyte endogenous mediator, osteoclast 
activating factor, B-cell stimulating factor, catabolism and proteolysis-inducing factor 
(Dinarello et al, 1988).
Interleukin-2 promotes proliferation and differentiation of helper T lymphocytes, 
cytotoxic T lymphocytes, and B-lymphocytes. Interleukin-2 is in turn produced by 
CD4+ and CD8+ lymphocytes and acts as an immune stimulant. It has also been 
reported to activate lymphocytes and kill tumour cells in vitro and in vivo (Smith, 
1988). Consequently, interleukin-2 participates in both cell-mediated immunity and 
humoral immunity, and is probably necessary for both primary and secondary adaptive 
immune responses. Interleukin-2 may also augment innate or "natural" immunity by 
stimulating natural killer (NK) cells and monocytes. Interleukin-2 can also induce the 
classic signs of delayed-type hypersensitivity, even in the absence of specific antigen. 
(Caligiuri et ai, 1993).
Tumour necrosis factor functions (TNF) as a pyrogen, activates the elotting system and 
stimulates production of the acute phase proteins by the liver. Tumour necrosis factor 
induces expression of the adhesion molecules, which promote adhesion, and migration 
of leucocytes from the blood vessels to the extra-vascular compartment. It also 
activates white blood cells leading to the production by macrophages of various 
cytokines, including interleukin-6 and tumour necrosis itself (Woolf, 1998).
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Interleukin-6 is the chief stimulator of the production of most acute-phase proteins 
(Gauldie et al, 1987), whereas the other implicated cytokines influence subgroups of 
acute-phase proteins. It is released by a number of cells, including monocytes, 
fibroblasts and endothelial cells.
Interleukin-6 is eommonly produced at local tissue sites and released into circulation in 
almost all situations of homeostatic disruption typically including endotoxemia, trauma, 
and acute infections (Kishimoto et al, 1992; Zitnik et al, 1993). In addition to its critical 
participation in the generation of immunity against chronic intracellular infections, 
circulating IL-6, together with other alarm cytokines TNF-a and IL-1, is known to be 
required for the induction of acute phase reactions composed of fever, corticosterone 
release, and hepatic production of acute phase proteins many of which are protease 
inhibitors (Baumann et al, 1994; Xing et al, 1995). Overall, the induction by IL-6 of 
these acute phase reactions has been regarded as part of an attempt to maintain 
homeostasis. However, it still remains unclarified whether during local or systemic 
acute inflammatory responses, IL-6 is also directly involved in the modulation of other 
aspects of inflammation, particularly cytokine responses and tissue inflammatory 
infiltration.
During local or systemic acute inflammatory responses, IL-6 is involved in the 
induction of acute phase reactions and controlling the level of acute inflammatory 
responses by downregulating the expression of proinflammatory cytokines and 
upregulating antiinflammatory molecules including IL-1 receptor antagonist protein 
(IRAP), TNF soluble receptor (TNFsR), and extrahepatic protease inhibitors. During
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chronic diseases, particularly intracellular viral or bacterial infections, IL-6 is involved 
not only in the elicitation of acute phase reactions but the development of specific 
cellular and humoral immune responses including end-stage B cell differentiation, 
immunoglobulin secretion and T cell activation.
General Properties of Cvtokines
Although cytokines have many diverse actions, all of them share some important 
properties. The actions of cytokines are pleiotropic, meaning that any one cytokine may 
act on many cell types and mediate many effects. For example, IL-2, initially discovered 
as a T-cell growth factor, is known to affect the growth and differentiation of B cells 
and NK cells as well. Cytokines are also often redundant, meaning that different 
cytokines may stimulate the same or overlapping biologic responses.
Cytokines induce their effeets in three ways: (1) They act on the same cell that produces 
them (autocrine effect), such as occurs when IL-2 produced by antigen-stimulated T 
eells stimulates the growth of the same cells; (2) they affect other cells in their vicinity 
(paracrine effect), as occurs when IL-7 produced by bone marrow or thymic stromal 
cells promotes the maturation of B-cell progenitors in the marrow or T-cell precursors 
in the thymus, respectively; and (3) they affect many cells systemically (endocrine 
effect), the best examples in this category being IL-1 and TNF, which produce the 
systemic acute-phase response during inflammation (Gabay and Kushner, 1999).
Cytokines mediate their effects by binding to specific high-affinity receptors on their 
target cells. For example, IL-2 activates T cells by binding to high-affinity IL-2 
receptors (IL-2R). Blockade of the IL-2R by specific anti-receptor monoclonal
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antibodies prevents T-cell activation. This observation is the basis for the use of anti-IL- 
2R antibodies to control undesirable T-cell activation, as in transplant rejection. The 
knowledge gained about cytokines has practical therapeutic ramifications. First, by 
inhibiting cytokine production or action, it may be possible to control the harmful 
effects of inflammation or tissue-damaging immune reactions. Patients with rheumatoid 
arthritis often show dramatic responses to TNF antagonists, an elegant example of such 
therapy. Second, recombinant cytokines can be administered to enhance immunity 
against cancer or microbial infections (immunotherapy), (Abbas, 2005).
1.3.4 Tumour Immunity
The biological malignancy of human cancer is determined by the net effects of 
biological malignancy of tumor cells and host factors. The immune and inflammatory 
reactions are representatives of the host factors. In human cancers, however, such 
immune reactions are generally insufficient beeause of weak immunogenicity of caneer 
cells or impaired immunity in cancer-bearing patients (Villunger et al, 1999). The 
presumptive mechanisms of these included absence of tumor-specific antigens, down- 
regulation of MHC elass I molecule expression (Natali et al, 1989), or secretion of 
immunosuppressive cytokines (Barth et al, 1996). Recently, functional inactivation of 
potentially tumor-reactive T cells was analyzed as an important mechanism of immune 
evasion (Lee et al, 1999).
Tumour antigens
For the adaptive immunity against tumours, antigens are needed to trigger a specific 
immune response. Ideal antigens should be able to elicit specific B or T cell responses 
or both, with T cell responses including recognition of HLA class Il-restricted epitopes.
54
Tumour associated antigens (TAA) that can be recognised on tumour cells by T 
lymphocytes form a heterogenous group. They are generally divided into three 
categories (Rosenberg et al, 1996; Boon et al, 1996). The first consists of unique 
antigens that are specific for each single tumour, usually derived from mutated proteins, 
and can be recognised either by HLA elass I or HLA Class II restricted T lymphocytes, 
according to their length and aminoacid sequence (Rosenberg et al, 1996; Boon et al, 
1996; Pardoll and Topalian, 1998). TAA shared with other tumours but predominantly 
expressed by malignaneies form a second category; these are usually transcriptionally 
reactivated genes that are not normally expressed (e.g. genes from the MAGE family in 
various tumours and testicular tissue), previously known as embryonic antigens and 
recently referred to as cancer testis (CT) antigens. A third category is that of 
differentiation antigens derived from the tissue of origin of the tumour (e.g. gplOO, 
Melan-A, and tyrosinase in melanomas). Surprisingly enough, these normal antigens 
turned out to include some of the TAA most frequently recognised by the immune 
system (Rosenberg et al, 1996). Yet other antigens, have been considered for 
immunotherapy of cancer. Examples of these are overexpressed antigens that are also 
present in normal tissues (e.g. CEA) (Bremers et al, 1995). Moreover, oncogene and 
tumour suppressor gene products that play an essential role in the development of 
malignancies, can generate epitopes able to induce immune responses (e.g. mutated 
RAS, p53), (Rosenberg et al, 1996; Boon et al, 1996; Pardoll and Topalian, 1998). 
Since some tumour histotypes, like pancreatic and lung cancers, bear such mutated 
genes with a high frequency, such antigens may represent interesting targets. Finally, 
viral products in virus associated tumours can deliver a potent and effective stimulus to 
the immune system (hepatitis B virus), (Chang et al, 1997), Human papilloma virus 
(Ressing et al, 1996).
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It is of note that only recently HLA class Il-restricted epitopes have been clearly defined 
and that most of them belong to the unique group of antigens that derive by point 
mutation from already known proteins (Toes et al, 1999).
T- Lvmnhocvtes
Most efforts put into the development of tumour immunology have focused on 
cytotoxic T lymphocytes (CTL) mediated immunity, since these cells are regarded as 
the most important effectors cells against tumours. Recognition of tumour antigens by 
eytotoxie T lymphocytes (CTL) is the result of a complex process (Figure 1.7).
In this system an antigen is processed inside the target or antigen presenting cell (AFC) 
into small peptide fragments that are then presented at the cell surface within the groove 
of the Major Histocompatibility Complex (MHC, HLA in humans) Class I molecules. 
This complex is then recognised by a T cell receptor (TCR) present on cytotoxic T 
lymphocyte (CTL). This T cell receptor (TCR) must be fitting to both the HLA allele 
present on the cell, and to the peptide presented (Davis et al, 1998). Though 
underestimated during the last few years, MHC Class II restricted recognition is also 
very important for the induction of antitumour cytotoxic T lymphocyte (CTL) which are 
activated through a (CD4 mediated) T helper response (Pardoll and Topalian, 1998).
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Figure 1.7 Anti tumour immune response. (Adapted by Armstrong, 2001).
The outcome of antigen recognition though, is not necessarily tumour cell killing. 
Inflammation or destruction, occurring during infection, come with cytokine-mediated 
signals (e.g. TNF-a and GM-CSF), resulting in activation of T-lymphocytes. Lack of 
these signals may result in tolerance, as is usually the case for the majority of antigens 
physiologically present in the body.
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1.3.5 Tumour T-lymphocytes infiltration
Several studies clearly support the protective role of a pronounced tumour lymphocytic 
infiltrate in colorectal cancer (Jass,1986; Harrison et al, 1994; Ropponen et al, 1997; 
Naito et al, 1998; Nielsen et al, 1999; Guidoboni et al, 2001). The results from the 
above studies on this issue are difficult to compare because the histological criteria used 
to define intra-tumour lymphocytes infiltrates differ from study to study, both 
qualitatively and quantitatively (Compton et al, 2000). Variations in the pathological 
definition of lymphocytic infiltrate presumably explain variations in study results, 
because lymphocytic infiltrate are biologically heterogeneous and can originate through 
different mechanisms, reflecting diversities in tumour biology and tumour-host 
interaction. To avoid confusion, pathological evaluation of intra-tumour lymphocytic 
infiltrate should take into careful consideration some important parameters, such as 
cellular T-lymphocytes composition and anatomical localisation.
From an immunologist’s point of view, the type of immune effectors that can more 
reliably be considered as a sign of a systemic anti-tumour immune response are 
cytotoxic T lymphocytes (CTLs), classically CDS T-lymphocytes. T- lymphocytes are 
the main effector arm of acquired and antigen-specific cellular immune responses, and 
play a central role both in the control of viral infections and in immunity against cancer 
(Melief et al, 1991; Riddell et al, 1995). Indeed, also in colorectal cancer several studies 
have focused on lymphocytes and have indicated that the presence of lymphocytic 
infiltrates might have a positive prognostic role (Naito et al, 1998; Nielsen et al, 1999; 
Guidoboni et al, 2001). These results are difficult to evaluate and to compare, because 
in many cases, especially in early studies, no functional characterization of infiltrating 
lymphocytes was performed or specific staining for CD4+ and CD8+ T-lymphocytes.
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Distinction among different subsets of lymphocytes is probably important, because the 
lamina propria of normal colorectal mucosa is rich in B cells (Lee et al, 1988). 
Moreover, different studies show substantial differences in other important parameters 
with potential prognostic value, such as the anatomical distribution of lymphocytes 
within the tumour tissue.
When evaluating the presence of lymphocytic infiltrates, authors use different criteria to 
include or exclude them in their analysis, depending on the anatomical localization of 
the immune effectors within the tumour tissue. Different authors have focused on 
different types of lymphocytie infiltrates, including: (a) the presence of a peri-tumoural 
lymphocytic stromal reaction, forming a continuous mantle or cuff at the invasive 
margin of the tumour (Jass, 1986), (b) the presence of so-ealled Crohn’s like lymphoid 
reactions, defined as lymphoid aggregates, often with germinal centres, surrounding the 
periphery of invasive carcinoma (Graham , 1990; Harrison et al, 1994), (c) the presence 
of lymphocytic infiltrates within the tumour stroma (Ropponen et al, 1997; Nielsen et 
al, 1999), (d) the presenee of lymphocytic infiltrates directly infiltrating within the 
tumour epithelium (Naito et al, 1998; Guidoboni et al, 2001).
Prognostic role of intra-enithelial T-lvmnhocvtes infiltrates
A key to understand the prognostie and complex role of lymphocytic infiltrates in 
colorectal cancer could reside in accurate and quantitative classification of 
inflammatory infiltrates, and their anatomical localization within the tumour tissues 
(intra-epithelial vs. stromal or peri-tumoural). Indeed, this approach has recently been 
undertaken by Naito and co-workers (1998) who have evaluated the prognostic role of 
CD8+ T-lymphocytes infiltrates in primary colorectal carcinomas, dividing CD8+ T-
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lymphocytes in three groups: (a) peri-tumoural, when distributed along the invasive 
margin of the tumour; (b) stromal, when infiltrating the tumour stroma; and (c) intra- 
epithelial, when infiltrating within cancer cell nests and taking direct contact with 
tumour cells. In this study on 131 patients, the presence of peri-tumoural and stromal 
CDS T-lymphocytes was not associated with improved prognosis in multivariate 
analysis, while the presence of intra-epithelial CD8+ T-lymphocytes was a strong 
predictor of better survival independently of Duke’s stage. These data have now been 
confirmed by an independent studies on 109 colon cancer patients (Guidoboni et al, 
2001), and show two important features: (a) a clear and objective method to classify 
lymphoid infiltrates, where intra-epithelial CD8+ T-lymphocytes are readily identified 
within epithelial cell nests; (b) compatibility with current theories on anti-tumour 
immunity, since they focus on a specific category of immune effectors that are known to 
play a central role in anti-tumour immune responses (CD8+ T-lymphocytes ) and 
evaluate their actual distribution among neoplastic cells.
A better understanding of the role and nature of intra-epithelial CD8+ T-lymphocytes 
could benefit from their detailed functional characterisation. Functional characterization 
of Tumour infiltrating lymphocytes has proved to be an important feature in renal cell 
carcinoma, where the prognostic role of intra-tumour CD8 T-lymphocytes is dependent 
on a high proliferative activity, as defined by immunohistochemistry for the 
proliferation antigen Ki-67 (Nakano et al, 2001). It has been shown that intra-epithelial 
T-lymphocytes in colorectal carcinoma display a higher Ki-67 labelling index (Naito et 
al, 1998), and higher expression of molecules involved in target cell killing, such as 
perforin and granzyme B (Guidoboni et al, 2001; Dolcetti et al, 1999), when compared
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with those localised in the tumour stroma or the adjacent normal mucosa, suggesting 
that they are actually active effectors.
1.3.6 Systemic Inflammatory Response
A local injury (e.g. infection, necrosis, tumour growth) of sufficient magnitude will lead 
to a series of systemic changes in body haemostasis, involving many organ systems, 
distant from the site of inflammation (Heinrich et al, 1990). Notable among these 
systemic changes is the acute-phase protein response, so-called since the discovery that 
C-reactive protein was increased in the plasma of patients during the acute phase of 
pneumococcal pneumonia (Tillett, 1930). The term, acute phase response, has continued 
to be used despite the realisation that this response accompanies both acute and chronic 
inflammatory disorders. More correctly this response should be termed the systemic 
inflammatory response (Gabay and Kusliner, 1999).
The acute-phase proteins are a family of proteins synthesized solely by the liver. An 
acute-phase protein has been defined as one whose plasma concentration increases 
(positive acute-phase proteins) or decreases (negative acute-phase proteins) by at least 
25 percent during an inflammatory disorder (Morley, 1982). This response is associated 
with characteristic metabolic changes in several other systems that include 
hematological, endocrinological, and immunological dysfunction. These changes are 
believed to be mediated by proinflammatory cytokines, notably the hepatocyte- 
stimulating cytokine, interleukin-6 (Heinrich, 1990). The changes in the concentrations 
of acute-phase proteins are due largely to changes in their production by hepatocytes. 
The magnitude of the inereases varies from about 50 percent in the case of
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ceruloplasmin and several complement components to as much as 1000-fold in the case 
of C-reactive protein and serum amyloid A (Figure 1.8).
Table 1.3 Human Acute-Phase Proteins.
Proteins whose plasma concentrations increase 
Complement system 
C3 
C4 
C9
Factor B 
Cl inhibitor 
Coagulation and fibrinolytic system 
Fibrinogen 
Plasminogen
Tissue plasminogen activator
Urokinase
Protein S
Plasminogen-activator inhibitor 1 
Antiproteases
a-1 Protease inhibitor 
a-1 Antichymotrypsin 
Inter-a-trypsin inhibitors 
Transport proteins
Ceruloplasmin 
Haptoglobin 
Hemopexin 
Participants in inflammatory responses 
Secreted phospholipase A2 
Interleukin-1 -receptor antagonist 
Granulocyte colony-stimulating factor
Others
C-reactive protein 
Serum amyloid A 
a-Acid glycoprotein 
Ferritin
Proteins whose plasma concentrations decrease
Albumin
Transferrin
a-fetoprotein
Thyroxin-binding globulin 
Insulin-like growth factor I 
Factor XII
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Figure 1.8 Characteristic Patterns of Change in Plasma Concentrations of Some Acute- 
Phase Proteins after a Moderate Inflammatory Stimulus (Adapted from Gabay and 
Kushner, 1999).
Although the concentrations of multiple components of acute-phase response commonly 
increase together, not all of them increase uniformly in all patients with the same 
illness. Thus, febrile patients may have normal concentrations of C-reactive protein, and 
discordance between the plasma concentrations of different acute-phase proteins is 
common. These variations, which indicate that the components of the acute-phase 
response are individually regulated, may be explained in part by differences in the 
patterns of production of specific cytokines or their modulators in different 
pathophysiologic states (Gabay and Kushner, 1999).
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Table 1.4 Other Acute-Phase Phenomena.
Neuroendocrine changes
Fever, somnolence, and anorexia
Increased secretion of corticotropin-releasing hormone,
Decreased production of insulin-like growth factor I 
Increased adrenal secretion of catecholamines
Hematopoietic changes
Anemia o f chronic disease
Leukocytosis
Thrombocytosis
Metabolic changes
Loss of muscle and negative nitrogen balance 
Decreased gluconeogenesis 
Increased hepatic Hpogenesis 
Increased lipolysis in adipose tissue
Decraesed lipoprotein lipase activity in muscle and adipose tissue 
Cachexia
Hepatic changes
Increased metallothionein, inducible nitric oxide synthase, 
tissue inhibitor of metalloproteinase-1 
decreased phosphopyruvate carboxykinase activity 
hypozincemia, hypoferremia, and hypercupremia 
increased plasma retinol and glutathione concentrations
In summary acute-phase response includes stereotyped, coordinated adaptations ranging 
from behavioral to physiologic changes (Table 1.4), in an attempt from the body to 
localize and limit the injury and clear tissue debris (Kushner, 1993). Acute phase 
response includes the hepatic synthesis of large quantities of proteins with various 
functions, which include binding proteins (opsonins), protease inhibitors, complement 
factors, apoproteins, fibrinogen, and others.
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1.3.7 C-reactive protein and colorectal cancer
C-reactive protein (GRP) is one of the acute phase proteins and is produced almost 
exclusively by the liver during episodes of acute inflammation. Local inflammation and 
tissue injury if of sufficient magnitude may signal the liver to produce and release C- 
reactive protein into the bloodstream (Pasche and Serhan, 2004). Specifically, C- 
reactive protein is stimulated by pro-inflammatory cytokines, mainly interleukin- 6 (IL- 
6), this response is enhanced in combination with ILl-p and TNF-a (Gabay and 
Kushner, 1999). A major function of C-reactive protein, a component of the innate 
immune system, is its ability to bind phosphocholine and thus recognize some foreign 
pathogens as well as phospholipid constituents of damaged cells (Volanakis, 1997). It 
can activate the complement system when bound to one of its ligands and can also bind 
to phagocytic cells, an observation suggesting that it can initiate the elimination of 
targeted cells by its interaction with both humoral and cellular effector systems of 
inflammation (Volanakis, 1997). Other proinflammatory effects of C-reactive protein 
include the induction of inflammatory cytokines and tissue factor in monocytes (Ballou 
et al, 1992: Germak et al, 1993). However, it would appear that its net effect is anti­
inflammatory (Ahmed et al, 1996: Xia et al, 1997). Such an effect of C-reactive protein 
may be explained by its ability to prevent the adhesion of neutrophils to endothelial 
cells by decreasing the surface expression of L-selectin (Zouki et al, 1997), to inhibit the 
generation of superoxide by neutrophils, and to stimulate the synthesis of interleukin-1- 
receptor antagonist by mononuclear cells. Therefore, it appears that C-reactive protein 
has many patho-physiological roles in the inflammatory process.
The biological malignancy of human cancer in general is determined by the net effects 
of biological malignancy of tumor cells and host factors. Inflammation or presence of
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systemic inflammatory response as evidence by raised C-reactive protein is closely 
related to the host immune responses (Du Clos, 2000). Increased C-reactive protein 
levels may reflect both inflammatory status and an attempt by the host to suppress 
tumor formation or growth. On the other hand C-reactive protein stimulates release of 
more interleukin-6 through activation of complement system (the complement-split 
products stimulates release of more interleukin-6 by macropghages), which in turn 
stimulate the synthesis and secretion of more C-reactive protein in the liver, this a 
completes a positive feedback loop (Kotler, 2000). The release of pro-inflammatory 
cytokines and growth factors in the presence of the tumour, may promote tumour 
growth and differentiation (Abramovitch et al, 1999: Balkwill et al, 2001). They also 
have profound catabolic effects on host metabolism (McMillan et al, 1994: Barber et al, 
2000). Interleukin-6 or interleukin-1 type cytokines produced either by the tumour or 
surrounding cells (Tisdale, 1999) stimulates liver production of acute-phase protein 
(such as C-reactive protein and fibrinogen) in the fasted and fed state (Barber et al, 
2000). The increase in the production of the acute-phase proteins results in an increase 
in the demand for certain amino acids which, if limited in the diet, may be obtained 
from the breakdown of skeletal muscle (Preston et al, 1998: McMillan et al, 1998). In 
these ways the presence and magnitude of a chronic systemic inflammatory response in 
advanced cancer patients may produce a progressive nutritional and functional decline 
ultimately resulting in reduced survival.
Recently, Nozoe and co-workers (2000) in cohort of 155 colorectal cancer patients 
showed that preoperative elevation of serum CRP is related to the reduction of 
lymphocyte percentages in peripheral blood, and it can be an indicator of impaired 
immunity in the patients with colorectal cancer. The clinico-pathological characteristic
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of tumour (tumour size, the proportions of liver métastasés, the lymph node métastasés, 
and the venous invasion) were significantly greater in patients with a preoperative 
elevation of serum C-reactive protein (Nozoe et al, 2003).
C-reactive protein elevation is considered by many authors as a prognostic factor in 
patients with operable colorectal cancer. Preoperative C- reactive protein concentration 
in patients with late-stage colorectal tumours were considerably higher than those in 
patients with early-stage malignant conditions in most studies (Durdey et al, 1984; 
Stamatiadis et al, 1992; Nozoe et al, 1998; Nielsen et al, 2000). Moreover, elevated 
levels of C-reactive protein or interleukin-6, a positive regulatory cytokine for C- 
reactive protein (Gabay and Kushner, 1999), in patients with colorectal cancer were 
associated with advanced tumour stage, recurrence and reduced survival (McMillan et 
al, 1995; Nozoe et al, 1998; Kinoshita et al, 1999; Belluco et al, 2000; Wigmore et al, 
2001; McMillan et al, 2001; Chung and Chang, 2003; McMillan et al; 2003). In 
addition, interleukin-6 levels in colorectal tumor tissue were substantially higher than 
those in normal tissue (Komoda et al, 1998; Kinoshita et al, 1999). Finally, 2 small 
case-control studies reported higher C-reactive protein or interleukin-6 levels in patients 
with colorectal cancer than in controls (Kinoshita et al, 1999; Chung and Chang, 2003). 
However, in the largest study to date of almost 600 patients undergoing elective surgery 
for colorectal cancer, Nielsen and his co-worker (2000) reported that an increased pre 
operative C-reactive protein was a prognostic factor, independent of Dukes’ stage.
Therefore, there is increasing evidence that the presence of a systemic inflammatory 
response, as evidenced by an elevated C-reactive protein concentration, is associated 
with poorer survival in patients undergoing resection for colorectal cancer. It also
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would appear that the systemic inflammatory response promotes tumour growth and 
dissemination. However, it remains to be determined whether an elevated C-reactive 
protein concentration reflects a nonspecific inflammatory response secondary to tumor 
necrosis or local tissue damage or alternatively, whether its development reflects the 
phenotype and metastatic potential of the tumour.
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1.4 Staging for Colorectal Cancer
1.4.1 Dukes’ classification
Lochart-Mummery (1927), noted a relationship between prognosis and extension of 
rectal cancers, suggesting a clinical classification that was later modified to include 
pathological data (Gordon-Watson and Dukes, 1929). Dukes subsequently changed the 
criteria, developing a system for the pathological classification of rectal carcinoma 
(Dukes, 1932). Dukes classified rectal tumours into those not penetrating the bowel wall 
and without lymph node métastasés (A), those penetrating the wall, but still without 
lymph node métastasés (B), and finally tumours with lymph node métastasés, regardless 
of the depth of penetration of the cancer (C). Stage C was modified by Dukes in 1935 
(Gabriel et al, 1935), dividing it in Cl with lymph node métastasés near to the rectal 
wall and C2 with lymph node métastasés near to the ligation of the superior rectal 
artery,
Kirklin and co-worker (1949) extended the use of Dukes' staging to include the colon, 
but it has been shown that prognosis may be different in the colon compared with the 
rectum in patients with the same Dukes' stage (Pihl et al, 1980). Kirklin and co-worker 
(1949) also changed the meaning of Dukes' A, now being limited to the mucosa, 
whereas B1 would mean penetrating into the mucosa, but not through the muscularis
propria, and B2 penetrating the bowel wall, including the serosal surface in colonic%
tumours. This change of definition in Dukes' stage A has caused much confusion, 
because it has been adapted in America but not by Europeans, who still prefer Dukes' A 
to mean cancers which do not penetrate through the muscularis propria. It must be 
emphasised that the definition of colorectal cancer includes penetration of the lamina 
muscularis mucosa, which has not always been pointed out in American literature
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(Enker et al, 1979) presenting tumours confined to the mucosa, not mentioning whether 
penetration of the muscularis mucosae has occurred; it is believed that tumours have to 
penetrate this layer before they are able to spread to lymph nodes. The conclusion has 
resulted in over treatment as well as insufficient treatment; it is strongly recommended 
that tumours not penetrating the lamina muscularis mucosae should be called no more 
than adenomas with severe dysplasia, and words like carcinoma in situ and intramucosal 
carcinoma should be avoided (Jass et al, 1987).
Astler and Coller (1954) subdivided Dukes' C into Cl meaning regional lymph node 
métastasés, but tumour limited to the bowel wall and C2 when the tumour penetrated 
through the bowel wall with lymph node métastasés; however, stage C l only presents a 
small part of all colorectal cancer (Phillips et al, 1984). In this context, it should be 
remembered that degree of invasion may vary in different parts of the tumour making it 
mandatory to look at several sections before deciding whether the muscularis propria 
has been penetrated (Rubio et al, 1977). Unfortunately, the authors did not add anything 
to solving the problem of obtaining a uniform terminology for Dukes' stage A, The 
previous staging was based on examination of resected bowel and adjacent mesentery. 
Turnbull and co-workers (1967) introduced a clinicopathological staging which has 
achieved worldwide use; he adapted the staging by Dukes (1932), but added a stage D 
(Table 1.5), meaning métastasés to distant organs; patients with unresectable tumours 
because of parietal invasion or invasion of neighbouring organs were also placed in 
stage D. Again, most Europeans have not used the last distinction, but usually they 
mention whether Dukes' B or C tumour have invaded the abdominal wall or other 
organs.
70
It must be realised that survival figures may vary, depending upon the thoroughness 
with which the pathologist looks for penetration of the bowel wall and lymph node 
métastasés. Also, 5-year survival is sometimes reported after exclusion of immediate 
postoperative mortality (Whittaker et al, 1976). The large variations in survival figures 
(Whittaker et al, 1976; Nilsson et al, 1984; Ohman, 1985; Kune et al, 1990) suggest that 
Dukes' staging is unreliable; however, it is the simplest method today, and it is 
questionable whether prognostic discrimination will improve by using the TNM system, 
unless clinical and other than pathological variables are included in the staging 
procedure (Wood, 1968; UICC, 1978).
The histological grade of the tumour and the number of involved nodes, which are both 
known to be related to survival (Wolmark et al, 1983; Jass et al, 1987; Quirk et al, 1987; 
Fisher et al, 1989), are not considered in Dukes’ staging. The thoroughness of the 
pathologist in examining the lymph nodes is also important. Blenkinsopp and co­
workers (1981), reviewing pathological assessment of the depth of tumour penetration 
in 2046 patients from several institution, noted that variation between observers ranged 
from 5 to 30 per cent. Differences were also noted between centres in the mean number 
of lymph nodes harvested per specimen and the proportion of cases in which no nodes 
were identified.
Irrespective of these problems, there are deficiencies in the entire Dukes’ classification. 
Analysis based on a few tissue samples may miss break through of the muscularis 
propria, such that some patients who die quite soon are misclassified into the good 
prognosis Dukes’ A group. In series of 2037 rectal cancers, Dukes reported a crude 5-
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year survival rate of 81.2 per cent for patient with Dukes’ A cancer, instead of the near 
100 per cent expected if the staging were perfect (Dukes, 1958).
Despite these problems, Dukes’ classification remains an extremely powerful 
prognostic tool. Major series employing multivariate analysis have identified tumour 
stage as the primary determinant of prognosis in colorectal cancer (Quirke et al, 1987; 
Griffin et al, 1987; Wiggers et al, 1988).
In conclusion, the deficiency of Dukes’ classification is that it fails to take clinical 
factors and number of involved nodes into account. Modifications have resulted only in 
confusion over the interpretation of the various classes, particularly stage A. In spite of 
these problems, the prognostic significance and comparative ease of Dukes’ 
classification ensure that it remains the gold standard against which all other prognostic 
variables in colorectal cancer be tested.
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Table 1.5 Dukes’ classification and its impact on outcome in colorectal cancer (Adapted 
from McArdle and Hole, 2002).
DUKES' STAGE PROPORTION OF PATIENTS 5-YEAR SURVIVAL
Stage A 7 % 85 - 95 %
Stage B 47 % 70 - 75 %
Stage C 30 % 35 - 45 %
Stage D* 15% 0 - 5 %
*Dukes' original classification did not include a stage D
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1.4.2 TNM  Classifîcation;
In an attempt to overcome the problem of Dukes’ Classification, the International Union 
Against Cancer (UICC) proposed a clinical classification in 1966, separating colonic 
and rectal cancer (Wood, 1968). However, the proposition was withdrawn and tumours 
were then classified by extent of primary tumour (T), condition of regional lymph nodes 
(N) and presence or absence of distant métastasés (M) at time of diagnosis, including a 
pretreatment clinical classification (TNM) as well as a post surgical histopathological 
classification (pTNM) (UICC, 1978; Beahrs, 1989),
The TNM system has undergone six revisions and, in the United States, these changes 
have been guided by the American Joint Committee on Cancer (AJCC), which was 
established in 1959 and which has published a succession of revisions of its AJCC 
Cancer Staging Manual. Until the sixth edition (Greene et al, 2002), the TNM stages for 
colon cancer had not changed substantially in 35 years. The stages in the first AJCC 
staging manual, published in 1976 (AJCC, 1976), were virtually identical to those in the 
fifth edition (Fleming et al, 1997), except for T2 having moved from stage II in the first 
edition to stage I by the fifth edition. O’Comiell and co-workers (2004) reported that the 
sixth edition of the AJCC Cancer Staging Manual is substantially different from the 
fifth edition in terms of stages II and III (Figure 1.6&7). In the fifth edition, stage II was 
composed of (T3, NO, MO) and (T4, NO, MO). In the sixth edition, stage II is divided 
into two sub stages: Ila, which is (T3, NO, MO), and lib, which is (T4, NO, MO). This 
change indicates that Ilb patients will, on average, have a worse prognosis than stage Ila 
patients and a better prognosis than stage Ilia (T1-T2, N l, MO) patients. This finding 
appear to violate the rules of the stage model upon which the TNM system is based. The 
use of the colon cancer staging in the sixth edition may result in uncertainty in clinical
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trials and potentially incorrect patient therapy. Therefore, until the advent of the seventh 
edition, clinicians and researchers may not use the sixth edition’s colon cancer staging; 
rather, relying on the previous (fifth) edition.
O’Connell and co-workers (2004) evaluated the new AJCC sixth edition staging system 
for colon cancer. They found that the new AJCC sixth edition staging system for colon 
cancer results in better estimates of survival by providing more sub stages than the fifth 
edition system (Table 1.6). In addition, they demonstrated that other factors may be used 
to improve colon cancer staging, such as tumour grade and additional stratification of 
the number of positive lymph nodes. It is unclear why stage Ilia patients appear to have 
better survival than that of stage lib, but this finding brings up the important and 
debated question of whether patients with stage II colon cancer should receive adjuvant 
therapy. Further studies to determine whether stage lib patients would benefit from 
receiving chemotherapy routinely may be indicated.
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Table 1.6 Stages as defined by the American Joint Committee on Cancer (AJCC) fifth and 
sixth edition staging systems (Adapted from O’Connell, 2004).
Staging system T stage N stage M stage
AJCC fiftli edition
I T1 or T2 NO MOÎI 13 or 14 NO MOm Any T Nl MOw Any T Any N M l
AJCC sixtli edition
I T1 or T2 NO MO
Ila T3 NO MO
lib T4 NO MO
lEa T i or T2 N l MOmb T3 or T4 N l MGme Any T N2 MOw Any T Any N M l
T1 = tumor invades submucosa; T2 -  tumor invades muscularis propria; T3 = tumor invades 
through the muscularis propria into the subserosa or into nonperitonealized pericolic tissues; T4 
= tumor directly invades other organs or structures and/or perforates visceral peritoneum; NO = 
no regional lymph node metastasis; N l -  metastasis to one to three regional lymph nodes; N2 = 
metastasis to four or more regional lymph nodes; MO = no distant metastasis; Ml = distant 
metastasis.
Table 1.7 Five-year survival by American Joint Committee on Cancer fifth edition system 
stages I-IV (Adapted from O’Connell, 2004).
Stage 3-Y ears Survival (%) 5-Years Survival (%)
I 96.1 93.2
II 89.2 82,5
III 72.7 59.5
IV 17.3 8.1
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In summary; the future utility of the TNM staging system depends on its ability to deal 
with the increase in population screening for cancer, the discovery of new therapies, and 
the use of the new molecular biomarkers. First, the predictive accuracy of the TNM 
system depends on patients presenting across the entire chronological range of the 
disease. Because the system depends on the sequential progression of tumors for its 
predictive accuracy, anything that reduces the time of disease progression will reduces 
its accuracy. The early detection of disease because of screening results in a shift in 
populating the stages to earlier disease so that the majority of patients are in stage I or at 
most stages I and II. This stage compression reduces the accuracy of the TNM staging 
system. Adding to the stage compression problem are the trends of very small surgical 
specimens and to neo-adjuvant therapy. Both these changes in the clinical approach to 
disease further reduce the size of tumors, the detection of nodal métastasés, and the 
accurate grading of tumors due to changes in histology.
Furthermore, the viability of the temporal model of TNM staging has been questioned 
by observational studies of breast cancer; for example, some patients with small tumors 
and no evidence of lymph node involvement die of their disease earlier than patients 
who present with more advanced disease (Fisher et al, 1978), Second, the TNM staging 
system does not take into account neo-adjuvant therapy, anti-hormonal therapy, 
chemotherapy, or the new, targeted, monoclonal molecular therapies. Thus, changes in 
survival related to these therapies are not reflected in the TNM stages. For the TNM 
system to incorporate new therapies into its stages, it must stratify by therapy (Burke et 
al, 1998). If staging does not incorporate new therapies, it will not be useful in 
predicting patient outcomes beyond what is predicted to happen if the patient undergoes 
only surgery. Third, the TNM staging system has difficulty dealing with continuous
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biomarkers and adding new biomarkers. It has been reported that a computer-based 
statistical program that allows the T and N variables to remain continuous appear to 
give more accurate prediction of 5- and 10-year disease-specific survival for breast and 
colon cancer than the TNM staging system (Burke et al, 1997). Carcinogenesis is not 
defined by what stage the patient is in at detection but rather by the molecular 
(genomic) characteristics of the tumor and the host reaction. Biological determinism 
takes the view that the anatomic location of the disease at detection is more related to 
our methods of detection than to the tumor itself. Thus, all patients are at risk of 
metastatic disease; some are further along a biological metastatic pathway at detection 
than others. In this light, treatment should be driven by the molecular biology of the 
tumor or host and not the tumor’s location at detection.
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1.4.3 Jass’s classification
Although Dukes’ classification was extremely helpful and easy to use, it failed to 
employ potentially important clinicopathological variables, while the TNM system, 
containing some of these variables, was too complex for routine use. The advent of 
multivariate survival analysis allowed Jass and co-workers (1986) to develop a system 
based on tumour stage and series of pathological variables related to histological grade. 
Jass and co-workers (1987) identified four independent variables, which have an 
influence on clinical outcome. These factors were selected by means of multivariate 
regression analysis of 379 specimens of patients who underwent curative surgery for 
rectal cancer. These factors are: the character of invasive margin, the presence of 
lymphocytic infiltration, local tumour spread and the number of lymph nodes with 
metastatic tumour (Figure 1.9). Flistopathological variables include:
Invasive margin
Cancers were described as expanding when invasive margin was pushing or reasonably 
well circumscribed, and infiltrating when the tumour invaded in a diffuse manner with 
widespread penetration of normal tissues.
Lvmphocvtic infiltration
This was regarded as conspicuous when there was a distinctive mantle or cap at the 
invasive margin of the growth, consisting of lymphocytes and other inflammatory cells.
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Local tumour spread
This was described as none (limited to the rectal wall), slight to moderate (spread 
beyond the rectal wall), and extensive. Extent of spread beyond the bowel wall was 
based on a subjective assessment made at the time of the original dissection.
Lymph node metastasis
This was grouped as none, 1-4 nodes and more than 4 nodes involved.
Then these divided into groups, as following (adapted from Jass, 1986):
GROUP TOTAL SCORE PROGNOSIS (5 YEARS SURVIVAL)
I 0 -1 96%
II 2 85%
III 3 67%
IV 4 - 5 27%
This classification was claimed to be superior to that of Dukes’ classification (Jass et al, 
1986; Jass et al, 1987; Jass et al, 1990). Although all of the grade-related variables 
investigated by Jass and co-workers (1986) correlated with survival on univariate 
analysis, only three remained important after Cox’s regression analysis. After correction 
for Dukes’ classification, the degree of lymphocytic infiltration was the only grade- 
related variable that remained significantly related to survival.
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Figure 1.9 Scoring system for pathological variables (adapted from Jass, 1987).
Limitation of growth 
to bowel wall
YES SCORE
0
No. of lymph n o d e s  
with m e ta s ta s is
O SCORE0
1 - 4
>4 ..
Invasive margin
.EXPANDING SCORE
INFILTRATING
Conspicuous peritumbural 
lymphocytic infiltrate
YES SCORE
0
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The new prognostic classification was superior to that of Dukes because it placed twice 
as many patients into groups that provided a confident predication of clinical outcome. 
As well as offering prognostic guidance it was suggested that the system would be of 
value in selecting patients (group IV) who might receive the most benefit from adjuvant 
therapy aimed at eradicating occult disease (Jass, 1987).
The success of any system of classification depends upon the care devoted to the 
collection of the data upon which it is based. Four pathological variables are used in the 
present Jass system. Two of these are subjective (character of the invasive margin and 
presence of a peritumoural lymphocytic infiltration), but can be assessed rapidly and 
with high levels intra-observer agreement (Jass, 1986). Spread within or beyond the 
bowel wall can be evaluated readily. The subjective division of extramural spread 
(defined as spread beyond the muscularis propria irrespective of the presence or absence 
of peritoneum) into slight or moderate versus extensive did not improve the model 
(Jass, 1987). The most important variable is lymph node metastasis, but unfortunately 
the systematic removal and examination of lymph nodes is the most time-consuming 
aspect of pathological examination.
Other variables (tumour type, grade of differentiation, venous invasion, and 
involvement of the apical lymph node) provide no clinically important improvement to 
Jass prognostic model. However, to be of clinical relevance a system must be 
reproducible as well as of prognostic significance. Jass’s classification relies on the 
pathologist interpreting visual images into verbal categories and is potentially 
subjective. Jass and co-worker (1987) initially assessed intra-observer variation by one 
specialist pathologist and subsequently reported fair to excellent level of inter-observer
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agreement for tumour type, differentiation, growth pattern and lymphocytic infiltration 
(Shepherd et al, 1989)
These assessments were performed by specialist pathologists from a centre dealing 
almost entirely with colorectal cancer. Reporting using non-specialist general 
pathologists, which may be more relevant to the majority of pathology departments 
nationwide, has suggested that observer consistency of many of the components of 
Jass’s classification is poor (Dundas et al, 1988; Deans, 1991). In particular, the intra­
observer and inter-observer variation of lymphocytic infiltration in some series was 
little better than chance (Dundas et al, 1988; Deans, 1991).
Invasive growth pattern and lymphocytic infiltration are the most subjective element of 
the Jass classification and their usefulness has been the subject of debate (Fisher et al, 
1989; Harrison et al, 1994; Deans et al, 1994). For example, other workers have found 
that lymphocytic infiltration failed to be an independent prognostic variable because of 
the degree of subjectivity involved in its assessment (Dundas et al, 1988; Shepherd et al, 
1989; Fisher et al, 1989). Secco and co-workers (1990) found that there was a 
significant relation between lymphocytic infiltration and survival in colorectal cancer. 
However, they failed to demonstrate a significant difference in survival between Jass’s 
grades II and III.
On the other hand, several multivariate studies have shown that peritumoral 
lymphocytic infiltration (Jass, 1987; Halvorsen, 1989; Secco et al, 1990; Jass, 1990; 
Kubota et al, 1992; Di Giorgio, 1992; Deans et al, 1994) and/or tumour growth pattern 
(Jass, 1987; Quirke, 1987; Halvorsen, 1989; Shepherd, 1989; Jass, 1990; Kubota et al,
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1992; Gagliardi et al, 1995) serve as independent prognostic factors in large bowel 
cancer.
Reports employing both Dukes and Jass classifications have suggested that the former 
was more significantly related to survival on multivariate analysis (Deans, 1991; Fisher 
et al, 1989). For example, Fisher and co-workers (1989) compared the prognostic values 
of the Dukes and Jass’s systems in 722 patients with rectal cancer. The Jass system 
allowed for only two major prognostic groups, whereas five were noted by Dukes’ 
method. Both Fisher (1989) and Deans (1994) and their co-workers reached the same 
conclusion; that is that Dukes’ classification is of greater prognostic value and more 
reproducible than the components of Jass’ classification.
Recently De Quay et al (1999) in a cohort observational study of 108 consecutive 
patients undergoing potentially curative surgery for Dukes’ B colorectal carcinoma, 
found the nature of the invasive margin of the tumour (as a component of Jass’s 
classification) allowed these patients to be separated into different prognostic groups. 
This means that a group of patients with a Dukes’ B tumours whose prognosis is similar 
to that of those with a Dukes’ C tumour can be identified, the nature of the margin of 
invasion being used to classify a greater proportion of patients.
Because the Jass’s classification is not reproducible, not simple and requires a certain 
degree of pathological experience as compared to Dukes’ and TNM classifications, it is 
not routine in hospital laboratories. However, an interesting feature of the Jass 
classification is that it is the only pathological system that includes a host-response i.e.
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lymphocytic infiltration, which may be an important factor in the defence against 
tumours.
As none of the above systems used in the classification of colorectal cancers are able to 
identify precisely those patients, who at the time of curative resection have occult 
métastasés and who in turn would benefit most from adjuvant chemotherapy, the search 
will continue to avoid giving toxic treatment to patients who may or may not develop a 
recurrence and to cut unnecessary costs of follow up.
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1.5 Management of Colorectal Cancer
1.5.1 Clinical Features
The mode of presentation of a colorectal cancer depends on several factors. Broadly 
speaking there are two categories of presentation, emergency or elective. In general, the 
more distal the lesion, the more obstructive are the symptoms. The reason is that the left 
colon has a narrower calibre than the right and its content tends to be less fluid 
(Aldridge et al, 1986). Usually patients present with clinical features of the primary 
tumour, but occasionally they may present with symptoms related to métastasés.
Change in bowel habit is probably the most common symptom, particularly with left 
sided lesions (Aldridge et al, 1986). Central or lower abdominal colic is a frequent 
complaint. Bleeding may be obvious or occult; the blood may vary in hue from bright 
red to black. The more proximal the lesion, the more altered will the blood become.
Bleeding is the most common symptom of rectal lesion, and is frequently ignored by the 
patient; the blood is often red, but not bright red. It may be mixed in with the stool or 
passed separately (Goulston, 1986). The passage of mucus is common; it may be 
separated from the stool or mixed with it. The patient often describes the symptoms as 
'passing slime'. A patient with a rectal lesion frequently has the urge to defecate but on 
going to the lavatory passes only blood and mucus. Such 'tenesmus' is often most acute 
in early morning and occurs soon after the patient rises from bed (Morris, & Wood, 
2000)
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1.5.2 Diagnosis of colorectal cancer
Physical Examination
A full clinical examination is essential in all cases of suspected colorectal carcinoma. 
The tumour itself may be palpable; right-sided lesions are stated to be more often 
palpable than left-sided ones (Goligher, 1984).
After general and abdominal examination it is necessary to proceed with digital 
examination of the rectum. Approximately 75% of carcinomas of the lower two-thirds 
of the rectum (0— 12 cm from anal verge) should be palpable per rectum (Williams et 
al, 1985).
Proctoscopy and sigmoidoscopy
All patients who on rectal examination have a palpable reetal carcinoma need further 
evaluation to obtain histology to confirm the diagnosis and to establish whether other 
lesions in colon are present.
Flexible sigmoidoscopy has the important advantages that it can be passed to a higher 
level in the colon and the view is far superior to the rigid instrument. For example, 
McCallum and co-workers (1984) examined 1015 symptomatic patients, ages 20-89 
years, using flexible sigmoidoscopy. Eighty five neoplastic lesions were identified in 78 
patients. Among patients over the age of 60 years, 3.3% had carcinoma compared with
0.8% of patients younger than 60 years. Of more importance, over 50% of the 
neoplastic lesions were detected more than 20 cm from the anal verge and were unlikely 
to have been detected using a rigid instrument. Similar results were reported by 
Reynolds and co-workers (1983).
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It must be stressed that neither barium enema nor colonoscopy alone are adequate 
investigations to rule out rectal carcinoma and therefore digital rectal examination and 
sigmoidoscopy must also be undertaken (Keighley & Williams, 1999)
Barium enema examination & Colonoscopv
Double contrast barium enema is used routinely in investigation of colorectal cancer 
patients. The tumour may cause a stricture either of a 'string' or 'napkin ring' type. The 
string type is quite short, usually about 2 cm in length, whereas the napkin ring is up to 
8 cm. There is 'shouldering' o f the growth giving the appearance of an 'apple core’ 
deformity, the latter term being sometimes used describe this type of stricture (Keighley 
& Williams, 1999).
In many units it is still the policy to perform a double-contrast barium enema if digital 
examination and proctosigmoidoscopy are normal. However, even in the most expert 
hands it is recognized that radiology can be misleading (Brady et al, 1994).
The errors are usually due to lesions within the caecum or sigmoid colon. For example, 
Boulos and co-workers (1984) reported a series of 65 patients who all had a barium 
enema followed by colonoseopy. Of the 46 patients in whom the radiograph showed 
apparently straightforward diverticular disease, eight (17%) had polyps and three (6%) 
were found to have a carcinoma. These findings have also been confirmed to some 
extent by Farrands et al (1983) who, although not using full colonoscopy, found that in 
84 patients with polyps or cancer submitted to both flexible sigmoidoscopy and double-
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contrast barium enema, there was a miss rate of 25% in the sigmoid colon on barium 
enema alone, mainly due to coexisting diverticular disease.
Durdey et al (1987) suggested that full colonoscopy should be the first investigation 
following proctosigmoidoscopy. However, many clinicians believe that is unwise since 
they consider that colonoscopy carries significantly more risk than barium enema 
(William et al, 1985). Air leaks are sometimes reported, presumably owing to the high 
pressure that may be generated by endoscopy, particularly when the tip impinges on the 
mucosa in a closed loop (Ehrlich et al, 1984; Humphreys et al, 1984). Furthermore a full 
colonoscopy is not always possible even with modern instrumentation. Even the most 
skilled operators fail in approximately 10% of patients and the less experienced will 
naturally be less successful (MacCarty, 1992). More recently, with increasing 
subspecialisation colonoscopy has became safer and there is a view that it might be used 
as part of the sereening programme for colorectal cancer.
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1.5.3 Surgical Treatment of Colorectal Cancer
Principles of Surgery for colorectal cancer
Surgery remains the mainstay of treatment for colorectal cancer. The principles of 
surgery depend to some extent on whether the operation is being performed in the belief 
that cure is possible (radical) or whether it is considered a palliative procedure. A 
radical procedure requires that the tumour be removed with an adequate margin of 
normal colon together with the associated vascular pedicle and as many of the 
corresponding lymph nodes as possible. A palliative procedure can be a limited excision 
of the tumour, a bypass or a defunctioning procedure, each of which is designed to 
alleviate the patient’s symptoms (Keighley & Williams, 1999). Following excision of 
the tumour-bearing segment of bowel, gastrointestinal continuity is normally restored 
by anastomosis between the proximal and distal bowel; the exact technique varies 
according to the individual surgeon’s preference. No matter which procedure is 
performed it should, if possible, be carried out on a well-prepared bowel and with the 
minimum amount of spillage. Tissues should be handled with care, haemostasis must be 
absolute and apposition of tissue must be accurate. There is no room for complacency in 
this type of surgery since leakage from a bowel anastomosis is a potentially lethal 
complication. (Keighley and Williams, 1999).
For tumours of the right colon, that is, the caecum, ascending colon, hepatic flexure and 
proximal half of the transverse colon—the ileocolic artery, right colic and the right 
branch of the middle colic artery are usually divided, and resection of the distal 10 cm 
of ileum, the caecum, ascending colon and proximal one-third of the transverse colon is 
carried out. This is the standard right hemicolectomy.
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For all tumours of the left colon, which includes those of the distal half of the transverse 
colon, the splenic flexure and the descending and sigmoid colon, the inferior mesenteric 
artery should be divided as close to the aorta as possible and the proximal colon 
anastomosed to the rectum (Williams et al, 1985). Such anastomoses depend on an 
adequate blood supply from the middle colic artery via an intact marginal artery. In 
infirm patients a more limited resection may be appropriate.
There are three requirements regarding the elective surgical treatment of rectal cancer: 
(1) adequate locoregional clearance, (2) minimal complications and (3) satisfactory 
function. Of these, the first is by far the most important, since local recurrence 
inevitably results in death in almost all these patients (Welch, 1974).
Abdominoperineal resection (APR) is generally indicated for lesion of the lower one 
third of the rectum or for higher lesion in the presence of an incompetent anal sphincter. 
It may also be indicated in morbidly obese patients, particularly males with a narrow 
pelvis, in patients with significant anal sphincter weakness, and with bulky or poorly 
differentiated lesions located less than 2 cm from the dentate line (Pricolo, 2001). APR 
includes complete removal of the distal sigmoid, rectum, and anal sphincteric complex 
through combined abdominal and perineal approaches, with creation of a permanent 
colostomy. Until recently, this operation was considered the standard for rectal cancers 
located less than 5 cm from the dentate line (Kirwan et al, 1989).
Nowadays, a sphincter-saving procedure is possible in the majority of rectal cancers. 
Many studies have shown that if a margin of 2.5 cm of normal rectum below the distal 
border of the tumour is achieved by anterior resection, there is no compromise of
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survival or local clearance compared with those of abdominoperineal excision (Pollet et 
al, 1983; Williams et al, 1984; Phillips et al, 1984). This means that most tumours 6 cm 
or more from the anal verge, and therefore within 2 or 3 cm above the anorectal 
junction, are suitable for restorative resection. Also the availability of endoluminal 
circular stapling devices and the often significant reduction of size in bulky distal rectal 
cancer with preoperative radiation therapy have made sphincter preservation the rule 
rather than the exception for cancer of the distal one third of the rectum (Pricolo, 2001).
The concept of total mesorectal excision (TME) has also had a significant impact on 
treatment of distal rectal cancer over the past two decades. Heald and co-workers (1982) 
deserve credit for attracting the attention of the surgical community to the need for 
complete excision of the mesorectum in all pelvic resection for rectal cancer. Heald and 
co-workers (1982) observed microscopic deposits in a lymphatic vessel 4 cm below the 
edge of a rectal cancer with no nodal involvement, and further studies of the distal 
mesorectum suggest that these deposits are by no means rare.
The technique of mesorectal excision involves the development of an avascular plane 
between visceral structures (rectum and mesorectum) and the autonomic nerve plexuses 
by sharp dissection, thereby protecting the pelvic wall, genito-urinary structures, 
presacal nerves, and parasympathetic roots. Heald (1988) described this avascular plane 
as “Holy plane”. Macfarlane (1993) independently, analysed the data produced by 
Heald and his co-workers (1986) with prospective follow-up extended over a 10 years 
interval. The local recurrence rate in the curative resection subgroup was less than 4%. 
Indeed, most series from Europe and the United States have reported local recurrence 
rates less than 10% and satisfactory long-term survival with total mesorectal excision
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alone (Arbman et al, 1996; Aitken, 1996; Arenas et al, 1998; Martling et al, 2000). 
These results are better than that in the surgery-alone arm in most adjuvant therapy trials 
(Fisher et al, 1988; Gerard et al, 1988; Krook et al, 1991). More recent studies have 
confirmed that nodal métastasés may be present in the mesorectum distal to the primary 
tumour, in approximately 20% of patients (Scott et al, 1995; Reynolds et al, 1996; Hida 
et al, 1997).
In summary, surgical technique remains an extremely important factor in determining 
long term survival of patients with colorectal cancer. With increasing sub-specialisation 
of colorectal surgery it is likely that there will further improvements in outcome 
following potentially curative resection for colorectal cancer.
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CHAPTER TWO
2.1 Hypothesis
There is now good evidence that the presence of a systemic inflammatory response 
plays a pivotal role in defining outcome in variety of sold tumours, including colorectal 
cancer. For example, the presence of a systemic inflammatory response is associated 
with increased recurrence and decreased survival independent of Dukes stage, in 
patients undergoing surgery for colorectal cancer.
The interrelationship between tumour and host factors and disease progression in 
patients with colorectal cancer is not clear. The presence of the tumour cells will 
activate the imiate immune system as part of the host reaction to the presence of tumour. 
The attraction and activation of various inflammatory cells at or near the tumour site 
will lead to the release of various cytokines. Some will act locally on other 
inflammatory cells while others will find their way in to the circulation and activate the 
systemic inflammatory response. The release of IL-6 into the circulation will activate 
the release of the aeute phase proteins in the liver. The adaptive immune system will be 
activated due to the presence of antigens in the tumour. These tumour specific antigens 
will activate the humoral immune system and add to the inflammatory response.
It is recognised that the systemic inflammatory response is primarily driven by the local 
and systemic release of the pro-inflammatory cytokines, in particular interleukin-6. 
However, the source of increased circulating interleukin-6 is not clear. Clearly, the 
increase in circulating interleukin-6 could be due to increased production by the tumour 
or secondary to the release of tumour products which stimulate host production of 
interleukin-6. Recently, the source of interleukin-6 has been localised to the tumour and
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this would be consistent with the observation that circulating concentrations of 
interleukin-6 and C-reactive protein are related to tumour size and that concentrations 
fall after resection of the primary tumour. However, it is not clear whether the increased 
production of interleukin-6 by the tumour arises from the tumour cells or the associated 
inflammatory infiltrate.
It has been hypothesized that in patients with cancer, either the tumour cells or the host 
cells or a combination of the two are responsible for the production of the pro- 
inflammatory cytokines that induce the systemic inflammatory response. These 
cytokines will trigger the change in protein metabolism, characterised by increased rates 
of synthesis of acute phase proteins using amino acids from skeletal muscle, which may 
contribute to the muscle wasting seen in cancer cachexia.
The pro-inflammatory cytokines mainly IL-6 trigger the release of C-reactive protein 
which is a part of the acute phase proteins. Rising acute phase reaction proteins are 
usually a sign of disturbance of the host-tumour relationship with the survival 
probability tending to decrease as the levels of acute phase reaction proteins rise. Such 
an intense reaction, will promote the tumour growth locally and affect the patient in 
general through cachexia.
The aim of the proposed study was to examine the relationship between the systemic 
inflammatory response, tumour inflammatory infiltrate and tumour proliferative index 
in patients with primary operable colorectal cancer. These factors will also be related to 
survival.
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2.2 Aims
The aims of this project were to:
1. Examine the prognostic value of elevated circulating C-reactive protein 
concentrations and its combination with Dukes stage to form a new prognostic score in 
patients undergoing apparently curative resection for colorectal cancer,
2. Examine the relationships between the systemic inflammatory response, tumour 
lymphocytic infiltration, tumour proliferative activity and cancer survival in patients 
with primary operable colorectal cancer.
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CHAPTER THREE
3.1 Patients
Patients with histologically proven colorectal cancer who, on the basis of pre-operative 
imaging and the surgeons’ assessment at operation, were considered to have undergone 
potentially curative resection for Dukes B and C colorectal cancer between January 
1997 and August 2001 in a single surgical unit at Glasgow Royal Infirmary were 
included in the study. Those patients who underwent emergency surgery or had pre­
operative radiotherapy or subsequently died within 30 days of surgery. Also those 
patients who showed clinical evidence of infection or other inflammatory conditions 
were excluded from the study. The tumours were staged using conventional Dukes’ 
classification (Dukes and Bussey, 1958). All patients were followed-up at a colorectal 
cancer clinic.
The study was approved by the ethics committee of the Royal Infirmary, Glasgow.
3.2 C-reactive protein concentration
Prior to surgery, blood was obtained for routine laboratory measurement of C-reactive 
protein. Based on work both in apparently healthy elderly individuals (O’Reilly et al, 
2006) and in intestinal cancer patients (O’Gorman et al., 2000) an elevated C-reactive 
protein concentration (>10mg/l) was considered to indicate a significant systemic 
inflammatory response since less than 1% of apparently healthy elderly individuals and 
only a proportion of cancer patient have a C-reactive protein concentration in this range. 
Previously, a variety of cut-offs for C-reactive protein has been used in cancer, for 
example greater than 5 mg/1 in advanced renal cancer (Blay et al., 1992) or 5mg/l in 
primary operable colorectal cancer (Nozoe et ah, 1998). It has been shown that a cut­
off of greater than 10 mg/1 is superior to either of these cut-offs (Bromwich et ah, 2004;
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O’Gorman et a l, 2000). Clearly, standardizing this cut-off will enable comparison of 
results between studies and substantiate the importance of the measurement of C- 
reactive protein in patients with cancer.
C-reactive protein was measured by fluorescence polarization immunoassay using a 
TDX analyzer and reagents obtained from Abbott Laboratories (Abbott Park, IL). The 
limit of deteetion of the assay is a C-reactive protein concentration of >5 mg/1.
3.3 Immunohistochemical staining of CD4+ and CD8+ lymphocytes
The slides for this study were cut from the blocks of the primary tumour taken at the 
time of the surgical resection. All tissues were fixed in 10% buffered formalin and 
embedded in paraffin wax. One representative block of tumour was selected for each 
patient. Sections (4pm) were cut and mounted on slides coated with 
aminopropyltriethoxysilane.
Sections were then immunostained using a streptavidin biotin technique. The primary 
antibody for CD4 was mouse monoclonal (Vector, Peterborough, UK) and that for CDS 
was mouse monoclonal (Dako, Cambridgeshire, UK). Sections were dewaxed and 
rehydrated.
Endogenous peroxidase was blocked by incubation in 0.3% hydrogen peroxide for 10 
minutes. Antigen retrieval for CDS was performed by microwaving in 1 niM EDTA 
buffer, pH 8, for 5 minutes at full pressure in a plastic pressure cooker in a microwave 
oven. Antigen retrieval for CD4 was achieved by immersing the sections in high pH
buffer (9.9) from Dako for 75 minutes at 99 °C.
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The sections were then incubated with the primary antibodies at dilutions of 1/50 (CD4) 
and 1/100 (CDS) for 30 minutes at room temperature. The Detection system was 
Vector laboratories ABC “ELITE” kit (Vector laboratories LTD, Peterborough, UK), 
and was used as per kit instructions.
Sections were then incubated in 3’3’diaminobenzidine for 10 minutes at room 
temperature and then in 0.5% copper sulphate in normal saline. Nuclei were then 
counterstained with haematoxylin, dehydrated, cleared and mounted with synthetic 
resin.
3.4 Morphometry of CD4+ and CD8+ lymphocytes
The method selected for quantitative analysis of the lymphoid infiltrates was point 
counting (Anderson and Dunnill, 1965) using a random sampling technique. With this 
method, the volume occupied by any given component - volume density (Vy) is
expressed as a percentage of the total volume of the tissue. In the main study, the 
volumes of CD4 and CDS immunopositive cells were calculated as percentage of the 
total tumour volume. A 100 point ocular grid was used at x 400 magnification and 30 
fields were counted per case for each antibody. Only fields containing tumour tissues 
were counted (Figure 2.1 & Figure 2.2). Any normal tissue on the slide was excluded 
from the analysis. The final method was designed on the basis of a pilot study.
The volume density (Vy) of CD4 and CDS positive lymphocytes was calculated for
each tumour including tumour nest. A summation average graph was plotted for both 
CD4 and CDS. The volume density of CD4 and CDS reached a plateau after 25 to 30
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fields. These findings formed the basis for the method of the main study, thirty fields 
being selected as appropriate for counting. It was also shown that CD4 plus CDS 
counts approximately equalled CD3 (Ali et al, 2004). In the full study, therefore, only 
CD4 and CDS figures were calculated. All cases were counted by the author. For the 
purpose of assessing inter-observer reproducibility, a second observer (P McArdle) 
independently measured CD4+ and CD8+ volume density in a large subgroup of cases. 
The observers were blinded to the clinical outcome of the patient.
As shown in Table 3.1 and Figures 3.5 and 3.6, there was close agreement between the 
two observers for measurements of the volume density of both CD4+ and CDS+ 
lymphocytes. Both the conventional (Pearson) and the intra-class correlation 
coefficients were greater than 0.90. Differences between observers were statistically 
significant for CD4+, but the mean difference between observers was less than 0.1% 
volume density. Differences for CD8+ were statistically insignificant. As shown by the 
limits of agreement in the Bland-Altman plots, more than 95% of independent 
measurements of the volume density of either type of lymphocyte would be expected to 
lie within less than one percentage point of each other.
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Figure 3.1 Immunohistochemical staining of CD8+ antigen in the tumour tissue.
101
mk
Figure 3.2 Immunohistochemical staining of CD4+ antigen in tumour tissue.
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3.5 Immunohistochemical staining of Ki-67 antigen
Sections were immunostained using the ChemMate Dako Envision method (Dako, 
Cambridgeshire, UK). The primary antibody for Ki-67 was mouse monoclonal 
antibody (Dako). Sections were dewaxed and rehydrated. Antigen retrieval for Ki-67 
was performed by a pressure cooker microwave technique using 1 mM EDTA buffer, 
pH 8, for 5 minutes.
After antigen retrieval the sections were placed on the Dako Autostainer. In the 
autostainer the sections were incubated with blocking serum (5% normal goat serum in 
Tris Buffered Saline (TBS) pH 7.6) for 20 minutes then primary antibodiy at a dilution 
of 1/200 for 30 minutes at room temperature. Sections were then rinsed in TBS and 
endogenous peroxidase was blocked by incubation in ChemMate Dako Peroxidase 
blocking solution for 5 minutes. ChemMate Dako Envision was applied for 30 minutes, 
sections were again rinsed in TSB. Sections were then incubated in 
3’3’diaminobenzidine for 10 minutes at room temperature. Sections were then removed 
from the machine and the nuclei were then counterstained with haematoxylin. Copper 
enhancement was done for 5 minutes then the sections were dehydrated, cleared and 
mounted with synthetic resin.
3.6 Morphometry Ki-67 antigen
The percentages of Ki-67-reactive tumour cells (Figure 3.3) were evaluated with a light 
microscope (x400 magnification) by scoring a minimum of 1000 tumour cells in 
randomly selected fields (Ki-67 labelling index). Assessment of Ki-67-reactive tumour 
cells was carried out blindly by two independent observers (K Canna & M Hilmy) for
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sixty cases, counting every case twice. All cases were counted by K Canna and these 
Ki-67 labelling indexes were taken into the final analysis.
As shown in Figure 3.7, there was reasonable agreement between the two observers for 
measurement of the Ki-67 labelling index. The mean labelling index was 69% and 64% 
for the first and second observers respectively, and the difference between observers 
was statistically significant (mean 5%, 95% confidence interval 3% - 8%, p<0.001). As 
shown by the limits of agreement in the Bland-Altman plot, individual differences 
between observers could range up to 25%. However, the intra-class correlation 
coefficient was 0.84, which is within the range conventionally classed as excellent.
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Figure 3. 3 Immunohistochemical staining of Ki-67 antigen in tumour tissue.
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3.7 Immunohistochemical staining of interleukin-6
Sections were immunostained using the ChemMate Dako Envision method (Dako, 
Cambridgeshire, UK). The primary antibody raised against interleukin-6 was a rabbit 
polyclonal antibody (Abeam, Cambridgeshire, UK) was evaluated as previously 
described (Kinoshita et al., 1999).
The sections were dewaxed and rehydrated. Antigen retrieval for 11-6 was performed by 
microwaving with a citrate solution (pH 6) for 5 minutes in a plastic pressure cooker in 
a microwave oven.
After antigen retrieval the sections were placed on the Dako Autostainer. In the 
Autostainer the sections were incubated with blocking serum (5 % normal goat serum in 
Tris Buffered Saline (TBS; pH 7.6). The sections were drained of normal goat serum 
which was replaced with IL-6 antibody at various dilutions (1:10 - 1:1000) for 30 
minutes or overnight at room temperature. Sections were then rinsed in TSB and 
endogenous peroxidase was blocked by incubation in ChemMate Dako Peroxidase 
blocking solution for 5 minutes.
ChemMate Dako Envision was applied for 30 minutes; sections were again rinsed in 
TSB. Section were then incubated in 3 3 diaminobenzidine for 10 minutes at room 
temperature. Sections were then removed from the machine and nuclei were then 
counterstained with haematoxylin. Copper enhancement was carried out for 5 minutes 
and the sections were dehydrated, cleared and mounted with synthetic resin.
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The same method was used again with the same rabbit polyclonal IL-6 antibody but 
different methods of antigen retrieval (EDTA buffer, PH 8 in a plastic pressure cooker 
in a microwave oven) and various dilutions of the IL-6 antibody. There was however 
deep background staining with all variations of technique using the rabbit polyclonal 
IL-6 antibody, which precluded accurate counting and scoring of IL-6 positive cells 
(Figure 3.4a & b).
The sections were also immunostained using Vector laboratories ABC “ELITE” kit 
(Vector laboratories LTD, Peterborough, UK), which was used as per kit instructions. 
The primary antibody raised against interleukin-6 was a goat polyclonal antibody (R&D 
system, Mimieapolis, MN), also using different dilution of the goat polyclonal IL-6 
antibody, incubated for 30 minutes and also overnight at room temperature and different 
methods of antigen retrieval (EDTA buffer, pH 8, or citrate solution, pH 6 in a plastic 
pressure cooker in a microwave oven). Suitable negative and positive control material 
were used. The same problem of deep background staining was encountered again 
(Figure 3.4c & d).
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Figure 3.4 (a) Immunohistochemical staining of IL-6 antigen in tumour tissue, 
deep background staining. (Rabbit IL-6 polyclonal antibody (citrate)).
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mFigure 3.4 (b) Immunobistocbemical staining of IL-6 antigen in tumour tissue 
(Rabbit IL-6 polyclonal antibody (EDTA)).
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rFigure 3.4 (c) Immunohistochemical staining of IL-6 antigen in tumour tissue 
(Goat IL-6 polyclonal antibody (EDTA)).
110
/ - A -  -■
Figure 3.4 (d) Immunohistochemical staining of IL-6 antigen in tumour tissue 
(Goat IL-6 polyclonal antibody (citrate)).
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Table 3.1 Inter-observer comparison of CD4+ and CD8+ lymphocyte volume density 
in 128 patients.
O bserver 1 
M ean
Observer 2 
M ean
Difference M ean  
(95% C l)
P Ri
CD4+ % 1.12 1.20 -0.08 (-0.14, -0.03) 0.003 0.92
CD8+ % 1,44 1.38 0.06 (-0 .01,0.14) 0.11 0.92
95% Cl = 95% confidence interval, P = P-value, paired t-test, Rj = intra-class 
correlation coefficient.
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Figure 3.5
A. Relationship between independent measurements o f  CD4+ lymphocyte volume 
density by two observers. The equation o f  the least-squares linear regression line is 
shown together with the Pearson correlation coefficient. B. Bland-Altman plot o f the 
difference between measurements o f  CD4+ lymphocyte volume density by two 
observers. The mean difference (solid line), its 95% confidence interval (fine dotted 
lines) and the limits o f  agreement within which 95% o f  individual differences would be 
expected to lie (coarse dotted lines) are also shown.
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Figure 3.6
A. Relationship between independent measurements o f  CD8+ lymphocyte volume 
density by two observers. The equation o f  the least-squares linear regression line is 
shown together with the Pearson correlation coefficient. B. Bland-Altman plot o f  the 
difference between measurements o f  CD 8+ lymphocyte volume density by two 
observers. The mean difference (solid line), its 95% confidence interval (fine dotted 
lines) and the limits o f  agreement within which 95% o f  individual differences would be 
expected to lie (coarse dotted lines) are also shown
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Figure 3.7
A. Relationship between independent measurements of Ki-67 labelling index by two 
observers. The equation of the least-squares linear regression line is shown together 
with the Pearson correlation coefficient. B. Bland-Altman plot of the difference between 
measurements of Ki-67 labelling index by two observers. The mean difference (solid 
line), its 95% confidence interval (fine dotted lines) and the limits of agreement within 
which 95% of individual differences would be expected to lie (coarse dotted lines) are 
also shown.
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CHAPTER FOUR
4.0 Evaluation of a simple prognostic score based on pathological stage and the 
system ic inflam m atory response for patients with prim ary operable colorectal 
cancer
4.1 Introduction
Colorectal cancer is the second commonest cause of death from cancer in the United 
Kingdom. Each year in the UK, there are approximately 27,000 new cases and 
approximately 18,000 deaths attributable to the disease. Overall survival is poor, even 
in those who undergo potentially curative resection approximately 50% die within five 
years (McArdle and Hole, 2002).
The ideal prognostic score for patients undergoing potentially curative resection of a 
primary colorectal cancer should clearly distinguish those who will eventually succumb 
to the disease from those who are cured. Whilst Dukes' stage has been widely used, it 
fails to provide clear separation between these groups. Alternative factors which would 
provide additional information to that of Dukes' staging are therefore required.
Tumour progression is a complex process, which depends not only the intrinsic 
properties of the tumour*, but also the tumour environment (Balkwill and Mantovani, 
2001). One aspect of the host response, the non-specific systemic inflammatory 
response, is recognised to be an impoi*tant factor in the progressive nutritional and 
functional decline of cancer patients (Kotler, 2000). Furthermore, there is accumulating 
evidence that the presence of a systemic inflammatory response (as evidenced by C- 
reactive protein) has prognostic significance in patients with colorectal cancer 
(McMillan et al., 1995; Nozoe et al., 1998; Nielsen et al., 2000; Wigmore et al., 2001;
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Chung and Chang, 2003). However, some of these studies have questioned whether C~ 
reactive protein has prognostic value independent of conventional pathological criteria 
including Dukes stage (Wigmore et al., 2001; Chung and Chang, 2003). Moreover, 
since in the above studies C-reactive protein was a significant prognostic factor, 
independent of Dukes stage, it may be that Dukes stage and C-reactive protein could be 
used to construct a new prognostic score.
The aim of the present study was to assess the value of combining Dukes stage and C- 
reactive protein to form a new prognostic score in patients undergoing apparently 
curative resection for colorectal cancer.
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4.2 Patients and m ethods
Patients with Dukes B and C colorectal cancer, who, on the basis of laparotomy 
findings and pre-operative computed tomography, underwent curative resection 
between January 1997 and September 2001 in a single surgical unit at Glasgow Royal 
Infirmary, were included in the study. The tumours were staged using conventional 
Dukes’ classification (Dukes and Bussey, 1958). Pre-operatively a blood sample was 
taken for the routine measurement of C-reactive protein. At this time no patient showed 
clinical evidence of tumour recurrence, infection, or other inflammatory conditions. 
Based on previous work a C-reactive protein concentration of greater than lOmg/1 was 
considered to indicate the presence of a systemic inflammatory response (see section 
3,2, chapter 3).
4.3 Statistical analysis
Data are presented as median and range. Comparisons between groups of patients were 
carried out using contingency table analysis (X^), Grouping of the variables age and C- 
reactive protein was carried out using standard thresholds as shown in Table 4.1 
(McArdle et al., 2003; Forrest et al., 2003; O’Gorman et al, 2000),
Survival analysis was performed using the Cox proportional hazard model. Deaths up 
to 3 December 2004 have been included in the analysis. Multivariate survival analysis 
was performed using a stepwise backward procedure to derive a final model of the 
variables that had a significant independent relationship with survival. To remove a 
variable from the model, the comesponding p-value had to be greater than 0.10. The 
survival curves in Figure 4.1 and survival rates in Table 4.2 were calculated using the
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Kaplan-Meier technique. Analysis was performed using SPSS software (SPSS Inc., 
Chicago, Illinois, U.S.A.).
4.4 Results
The baseline clinicopathological characteristics of the patients (n=147) who underwent 
potentially curative surgery for colorectal cancer are shown in Table 4.1. 
Approximately one third of patients were aged 75 or over. The majority had colonic 
tumours, were Dukes stage B and had moderately differentiated tumours. Fifty four 
(36%) patients had an elevated C-reactive protein concentration prior to surgery.
The minimum follow-up was 40 months; the median follow-up of the survivors was 71 
months. During this period 59 patients died 40 patients o f their cancer and 19 of 
intercurrent disease.
On univariate analysis, increased age (p<0.001), Dukes stage C (p<0.0001), elevated 
circulating C-reactive protein concentrations (p<0.0001) and venous invasion (p<0.01) 
were associated with poor cancer specific survival.
On multivariate analysis, including the above variables, age (Hazard Ratio 1.96, 95%CI 
1.26-3.04, p=0.0026), Dukes stage (HR 4.09, 95%CI 2.04-8.24, p=0.0001) and C- 
reactive protein (HR 4.38, 95%CI 2.11-9.09, p=0.0001) were significantly associated 
with cancer specific survival.
Since the magnitude of hazard ratios of Dukes stage (1.41) and C-reactive protein (1.48) 
were similar, this indicates that either an elevated CRP or the presence of a systemic
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inflammatory response had approximately the same relative risk as an increase in 
pathological stage from Dukes B to Dukes C, and that they could be simply combined 
to form a prognostic score. Such a cumulative prognostic score was therefore 
constructed by assigning one point for each of the following criteria: Dukes stage C and 
C-reaetive protein >10mg/l.
The relationship between stage, C-reactive protein concentration, the cumulative 
prognostic score and mortality are shown in Table 4.2. The relationship between the 
cumulative prognostic score and cancer specific survival is shown in Figure 4.1. The 
cancer specific smwival rates at 3 years for patients with a cumulative prognostic score 
of 0, 1, 2 were 100%, 78% and 34% respectively (HR 5.02, 95%CI 3.09-8.17,
p<0.0001).
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4.5 Discussion
The ideal prognostic index for patients undergoing potentially curative resection of the 
primary colorectal cancer should clearly distinguish those who will eventually succumb 
to the disease from those who are cured. Whilst Dukes' stage has been widely used, it 
fails to provide clear separation between these groups. Alternative techniques, which 
would provide additional information to that of Dukes’ staging, are therefore required.
There is a complex relationship between the primary tumour and the host response, 
which determines the likelihood of tumour recurrence (Balkwill and Mantovani, 2001). 
Clearly, in defining optimal prognostic factors both these aspects should be taken into 
account.
Several studies have shown that elevated circulating C-reactive protein concentrations 
are associated with poor survival in patients with colorectal cancer (McMillan et al., 
1995; Nozoe et al., 1998; Nielsen et al., 2000; Wigmore et al., 2001; Chung and Chang, 
2003). However, the relationship between C-reactive protein concentrations and 
conventional clinicopathological criteria is not clear since some of the above studies 
have included patients with Dukes A tumours who were unlikely to progress and 
patients with Dukes D tumours who had already progressed (Wigmore et al., 2001; 
Chung and Chang, 2003). This is likely to have confounded the assessment of the 
prognostic value of an elevated circulating C-reactive protein concentration.
Clinicians have long recognised that some high-risk Dukes B patients behave more like 
patients with Dukes C tumours. Not only has this implication for the prediction of 
survival but may also have implications for treatment. For example, there is evidence
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that adjuvant chemotherapy is of benefit, at least in Dukes C colorectal cancer 
(IMPACT investigators, 1995, O’Connell et ah, 1997). A third of these patients 
however, will survive 5 years without treatment, and would therefore receive potentially 
toxic therapy without benefit. In contrast, many patients with Dukes B tumours, almost 
one third of whom will die of their disease within 5 years, may fail to receive 
chemotherapy (McArdle and Hole, 2002).
In the present study, both Dukes stage and C-reactive protein concentrations were 
independently associated with cancer specific survival. These results are consistent 
with those of Nielsen and co-workers (2000) who, in a cohort of almost 400 patients 
undergoing resection for Dukes B and C tumours, also demonstrated that C-reactive 
protein was a Dukes stage independent prognostic factor. The mechanism by which a 
systemic inflammatory response might influence cancer survival is not clear. However, 
it is known that as part of the systemic inflammatory response, there is a release of pro- 
inflammatory cytokines and growth factors which may promote tumour growth 
(Abramovitch et al, 1999) and compromise immune function (Coussens and Werb, 
2002).
In the present study, when C-reactive protein concentrations were combined with Dukes 
stage to form a new prognostic score, the combined score improved the prediction of 
cancer specific survival. The addition of C-reactive protein differentiated between low 
and high risk Dukes B and low and high risk Dukes C patients. Cancer related mortality 
ranged from 0% in patients with Dukes B tumours and a normal C-reactive protein 
concentration to 66% in patients with Dukes C tumours and an elevated C-reactive 
protein concentration. Cancer related mortality in patients with Dukes B tumours and
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an elevated C-reactive protein concentration ’was similar to that of patients with Dukes 
C tumours and a normal C-reactive protein concentration. Therefore, this cumulative 
prognostic score may be useful in identifying high risk Dukes B patients for adjuvant 
therapy.
It is generally recognised that tumour stage, as reflected for example in the Dukes 
classification, is one of the most powerful predictors of final outcome in colorectal 
cancer patients (Deans et al, 1992). The overall 5-year survival rate of patients with 
colorectal cancer is approximately 60%. However, this differs greatly for the different 
stages (Table 1.5). For stage A (approximately 9 % of patients) 5-year survival exceeds 
90% and, conversely, for Dukes D (approximately 15% of patients) this figure is 
between 2 and 5 % (McArdle and Hole, 2002). For stage B, however, which constitutes 
approximately 47 % of patients, 5-year survival is 70 % and for Dukes C (about 30 % of 
patients) this is approximately 45 %. The lack of prognostic precision in stages B and C 
hampers stratification of patients into subgroups which might benefit from additional 
adjuvant therapy. Pathologists have responded to this problem by introducing new 
parameters which might have independent prognostic significance. More detailed 
histologieal evaluation of the pattern of invasion into the bowel wall or into veins has 
been advocated.
For example, Hase and co-workers (1993) reported that irregular tumour cell budding at 
the invasive front of the tumour indicates more aggressive behaviour than a straight 
“pushing” tumour margin. Also, Yamazoe and eo-workers (1992) investigated the 
depth of venous invasion as a predictor for liver metastasis. This parameter appeared to 
predict the occurrence of liver metastasis with high probability, especially in
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combination with desmoplastic reaction, lymphocytic infiltration and depth of invasion. 
The extent of lymphocytic infiltration was also taken into account in the classification 
proposed by Shepherd and co-workers (1989). The latter classification has gained some 
popularity, but has not become generally accepted. An important limitation of 
classifications based upon detailed histopathological criteria to date is their lack of 
standardization and thus reproducibility. More recently, pathological TNM staging for 
colorectal cancer has been introduced and provides further discrimination in predicting 
cancer specific survival. However, in the time period of the present study TNM staging 
was not routinely carried out and therefore it remains to be determined whether the 
systemic inflammatory response, as evidenced by an elevated C-reactive protein 
concentration, will offer prognostic value in addition to TNM stage.
The results of the present study indicate that the combination of Dukes stage and the 
systemic inflammatory response, as evidenced by an elevated C-reactive protein 
concentration, which reflects both the contribution of the tumour and the host response, 
differentiates between low risk and high risk Dukes B and C tumours in patients 
undergoing potentially curative resection for colorectal cancer. This combined score of 
pathological stage and C-reactive protein has the advantage that of being simple to 
measure, routinely available and well standardised.
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Table 4.1 Clinicopathological characteristics in patients with colorectal cancer; 
univariate survival analysis.
Patients Hazard ratio p-value
(n= 147) (95% Cl)
Age group (<65/ 65-74/ >75) 46/ 44/ 57 2.13 (1.39-3.25) 0.0005
Sex (male/ female) 78/ 69 1.77 (0.94-3.31) 0.0749
Site (colon/ rectum) 105/42 1.39 (0.66-2.89) 0.3960
Dukes stage (B/ C) 91/56 4.34 (2.24-8.43) <0.0001
C-reactive protein (<10/ >10mg/l) 93/54 6.05 (3.05-12.01) <0,0001
Tumour characteristics
Diameter (mm) 49/ 49/ 49 0.90 (0.62-1.31) 0.5985
Tertile (range) 10-35
Tertile (range) 35-50
Tertile (range) 50-130
Ulceration (no/ yes) 72/ 75 1.07 (0.58-2.00) 0.8212
Differentiation (well/ moderate/ poor) 18/116/13 1.45 (0.72-2.92) 0.2925
Lymphatic invasion (negative/ positive) 124/22 1.29 (0.57-2.91) 0.5469
Venous invasion (negative/ positive) 118/28 2.79(1.46-5.35) 0.0020
Adjuvant therapy (no/ yes) 116/31 1,09 (0.52-2.30) 0.8108
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Table 4.2 Prognostic score following curative resection for colorectal cancer.
Dukes stage C-reactive protein Cumulative Patients 3 yr survival rate
Score (mg/1) Score Score (n) (%)
B 0 <10 0 0 62 100
>10 1 1 29 75
C 1 <10 0 1 31 81
>10 1 2 25 34
Cumulative score obtained by adding scores for Dukes stage and C-reactive protein.
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Figure 4.1 The relationship between the cumulative prognostic score ( 0 ......   , _  1, _____
2) and cancer specific survival following potentially curative surgery for colorectal cancer.
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CHAPTER FIVE
5.0 An investigation of the inter-relationships between the systemic 
inflammatory response, tumour lymphocytic infiltration, tumour proliferative 
activity and cancer survival in patients with primary operable colorectal cancer
5.1 Introduction
It has long been recognised that disease progression in cancer patients is not solely 
determined by the characteristics of the tumour but also by the host response. Indeed, 
there is increasing evidence that both local and systemic inflammatory responses play 
an important role in the progression of a variety of common solid tumours (O'Byme and 
Dalgleish, 2001; Vakkila and Lotze, 2004; Pages et al., 2005).
In the previous chapter, we showed that the systemic inflammatory response, as 
evidenced by elevated circulating concentrations of C-reactive protein, was associated 
with poorer cancer specific survival, independent of Dukes stage. Circulating 
concentrations C-reactive protein appear to be primarily determined by concentrations 
of interleukin-6 (Gabay and Kushner, 1999). It is of interest therefore, that circulating 
IL-6 concentrations in patients with colorectal cancer are related to its production by the 
tumour (Komoda H et al., 1998; Piancatelli et al., 1999; Kinoshita et al., 1999). 
However, it remains unclear whether this interleukin-6 originates from the tumour cells 
themselves or from the inflammatory infiltrate. Nevertheless, there is some evidence 
that IL-6 acts as a proliferative factor In patients with colorectal cancer (Kinoshita et al., 
1999).
From immunological point of view, the types of immune effectors that can reliably be 
considered as a sign of a systemic anti-tumour immune response are cytotoxic T
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lymphocytes (CTLs), classically CD8+ T-lymphocytes. T-lymphocytes are the main 
effector arm of acquired and antigen-specific cellular immune responses, and play a 
central role both in the control of viral infections and in immunity against cancer 
(Melief et al, 1991; Riddell et al, 1995). In patients with colorectal cancer, there is good 
evidence that, on simple staining of tumour sections, the presence of a pronounced 
lymphocytic infiltration within the tumour is associated with improved survival (Jass et 
al., 1987; Ropponen et a l, 1997; Nielsen et a l, 1999). More recently, the ability to 
identify lymphocyte subsets reliably by immunohistochemistry has led to renewed 
interest in the relationship between the tumour inflammatory infiltrate and outcome. 
Indeed, increased infiltration of the tumour by CD8+ (Naito et a l, 1998; Prall et a l, 
2004; Chiba et a l, 2004) and CD4+ T-lymphocytes (Ali et a l, 2004) has been shown to 
be associated with increased survival in patients with colorectal cancer.
In the studies to date, patients who were unlikely to progress (Dukes A) and patients 
who had already progressed (Dukes D) were included in the analysis. Therefore, the 
value of total and subset lymphocytic counts in patients with Dukes B and C tumour, in 
whom it is difficult to predict disease progression, remains uncertain.
One factor which may determine the pattern and extent of the tumour T-lymphocytic 
infiltration is the proliferative activity of the tumour. It has long been recognised that a 
high tumour proliferation rate is associated with aggressive malignant disease 
(Rosenwald, 2004). Indeed, it has been shown that increased expression of the protein 
Ki-67, a high molecular weight nuclear protein associated with cell division, is 
associated with an increased proliferation rate and poorer survival in a variety of 
common solid tumours including breast and lung cancer (Brown and Gatter, 2002).
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However, the relationship between the expression of Ki-67 in the tumour and survival 
in colorectal cancer is less clear.
For example, in a recent review of those studies which examined the relationship 
between tumour expression of Ki-67 and outcome in colorectal cancer, only two out of 
12 reported a significant association with survival (Brown and Gatter, 2002). However, 
many of these studies were based on small numbers, some included both primary 
operable and advanced disease and most used semi-quantitative techniques for the 
measurement of Ki-67.
To date, the inter-relationships between the systemic inflammatory response, tumour 
lymphocytic infiltration, tumour proliferative activity and cancer survival in patients 
with primary operable colorectal cancer do not appear to have been examined. 
Therefore, the aim of the present study was to examine the relationship between 
systemic inflammatory response, tumour lymphocytic infiltration, tumour proliferative 
activity and cancer specific survival in patients undergoing potentially curative resection 
for colorectal cancer
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5.2 Patients & Methods.
Patients with Dukes B and C colorectal cancer, who, on the basis of laparotomy 
findings and pre-operative computed tomography, underwent curative resection 
between January 1997 and September 2001 in a single surgical unit at Glasgow Royal 
Infirmary were included in the study. The tumours were staged using conventional 
Dukes’ classification (Dukes and Bussey, 1958). Pre-operatively a blood sample was 
taken for the routine measurement of C-reactive protein. At this time no patient showed 
clinical evidence of tumour recurrence, infection, or other inflammatory conditions. 
Based on previous work a C-reactive protein concentration o f greater than lOmg/1 was 
considered to indicate the presence of a systemic inflammatory response. Patients who 
had non-elective surgery or pre-operative radiotherapy or died within 30 days of surgery 
or showed clinical evidence of infection or other inflammatory conditions were 
excluded from the study (see section 3.1, Chapter 3).
Blocks from the primary tumour were fixed in 10% buffered formalin and embedded in 
paraffin wax. One representative block of tumour was selected for each patient. Serial 
sections (4 mm) were cut and mounted on slides coated with 
aminopropyltriethoxysilane.
CD4+ and CD+ T-lymphocytes (Figure 3.1& 3.2)
Sections were immunostained using the peroxidase-based Envision (Dako, 
Cambridgeshire, UK) technique as previously described (Section 3.3, Chapter 3). The 
primary antibody for CD4 was mouse monoclonal (Vector, Peterborough, UK) and that 
for CD8 was mouse monoclonal (Dako, Cambridgeshire, UK).
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Ki-67 (Figure 3.31:
Sections were immunostained using the ChemMate Dako Envision method (Dako, 
Cambridgeshire, UK). The technique as previously described (Section 3.5, Chapter 3), 
The primary antibody for Ki-67 was mouse monoclonal antibody (Dako).
Momhometrv
Quantitative analysis of the lymphoid infiltrate was performed using point counting 
(Anderson and Dunnill, 1965) with a random sampling technique (Section 3.4, Chapter
3). The Ki-67 labelling indexes were assessed using same method as previously 
described (Section 3.6, Chapter 3).
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5.3 Statistical analysis
For the purpose of analysis, T-lymphocyte subsets and Ki-67 labelling index were 
grouped by tertiles. Relationships between T-lymphocyte counts and other variables 
were analysed using the Mantel-Haenszel chi squared test for trend and Spearman rank 
correlation analysis as appropriate. Survival analysis was performed using the Cox 
proportional hazard model.
The degree of agreement between observers in the measurement of CD4+ and CD8+ 
lymphocyte volume density was expressed by the intra-class correlation coefficient 
(Bartko and Carpenter 1976). A high value for the conventional correlation coefficient, 
which is a measure of linear association, does not necessarily imply close agreement: 
for example, there may be a consistent additive or multiplicative bias between the 
observers. By contrast, the intra-class correlation coefficient (R;) is a measure of true 
agreement. The conventional interpretation of Rj is as follows: Rj<0.40, poor agreement; 
Ri=0.40-0.59, fair agreement; RrO.60-0.74, good agreement; Ri>0.75, excellent 
agreement. . In the present study the intra-class coefficient for measurement of CD4+, 
CD8+ and Ki-67 labelling index were greater thdn 0.84 (see sections 3.4 & 3.6, chapter 
3)
Bias between observers was assessed using the paired t-test, a p-value of 0.05 or less 
being considered statistically significant. Bland-Altman plots of the inter-observer 
difference against the mean of the two observers' measurements were also constructed 
(see sections 3.4 & 3.6, chapter 3).
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Survival (cancer-specific) analysis was performed using the Cox proportional hazard 
model. Deaths up to 31®^ December 2004 have been included in the analysis. 
Multivariate survival analysis was performed using a stepwise backward procedure to 
derive a final model of the variables that had a significant independent relationship with 
survival. To remove a variable from the model, the corresponding P-value had to be 
greater than 0.10. Analysis was performed using SPSS software (SPSS Inc., Chicago, 
IL, USA).
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5.4 Results
The baseline clinicopathological characteristics of the patients (n=147) who underwent 
potentially curative surgery for colorectal cancer are shown in Table 5.1. 
Approximately one third of patients were aged 75 or over. The majority had colonic 
tumours, were Dukes stage B and 54 (36%) patients had an elevated C-reactive protein 
concentration prior to surgery. The majority of patients had haemoglobin, white cell, 
lymphocyte and platelet counts were in the normal range.
The minimum follow-up was 40 months; the median follow-up of the suiwivors was 71 
months. During this period 59 patients died 40 patients of their cancer and 19 of 
intercurrent disease. On univariate analysis, increased age (p<0.001), sex (p<0.10), 
Dukes’ stage (p<0.0001), elevated circulating C-reactive protein concentrations 
(p<0.0001), venous invasion (p<0.01), increased Ki-67 labelling index (p<0.01), 
decreased percentage tumour volume of CD+4 (p<0.05) and CD8+ (p<0.10) T- 
lymphocytes were associated with poor cancer-specific survival.
Patients were grouped according to absence or presence of a systemic inflammatory 
response (C-reactive protein <10/ >10mg/l respectively) are shown in Table 5.2. The 
groups were similar in terms of sex, tumour site, stage, haemoglobin, lymphocyte, 
platelet counts and tumour characteristics. Those patients with evidence of a systemic 
inflammatory response were older (p<0.01), had higher white cell counts (p<0.10), 
larger tumour diameter (p<0.001), more ulcerative tumours (p<0.10), more moderate 
and poor tumour differentiation (p<0.10), a higher Ki-67 labelling index (p<0.05), a 
lower tumoui CD4+ lymphocytic infiltration (p<0.001). There was a significant 
correlation between the percentage tumour CD4+ and CD8+ T-lymphocytes (rs= 0.44,
135
p<0.001). There was an inverse relationship between percentage tumour CD4+ T- 
lymphocytes and C-reactive protein (rg= -0.26, p=0.003, Figure 5.1). There was no 
significant relationship between percentage tumour CD8+ T-lymphocyte and C-reactive 
protein (rs= -0.09, p=0.273, Figure 5.2).
Patients were grouped according to tertiles of the percentage tumour volume of CD4+ 
T-lymphocytes are shown in Table 5.3. The groups were similar in terms tumour site, 
stage, white cell, lymphocyte and platelet counts and tumour characteristics. Those 
patients with a high tumour CD4+ lymphocytic infiltration were older (p<0.10), more 
likely to be male (p<0.05), had a normal C-reactive protein (p<0.001) and haemoglobin 
(p<0.05) concentrations, a smaller tumour diameter (p<0.05) and a higher tumour CD8+ 
lymphocytic infiltration (p<0.001).
Patients were grouped according to tertiles of the Ki-67 labelling index are shown in 
Table 5.4. The groups were similar in terms age, tumour site, stage, haemoglobin, 
white cell, lymphocyte and platelet counts and tumour characteristics. Those patients 
with a high tumour Ki-67 labelling index, more likely to be female (p<0.05), had an 
elevated C-reactive protein (p<0.05. Figure 5.3) and a larger tumour diameter (p<0.01).
sexOn multivariate analysis of the significant covariates (Table 5.5), only age (p<0.01), 
(p<0.05), stage (p<0.001), C-reactive protein (p<0.001) and tumour CD8T lymphocytic 
infiltration (p<0.01) retained independent significance.
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5.5 Discussion
In the present study, confined to patients with Dukes B and C colorectal cancer 
undergoing potentially curative resection, a number of factors were associated with poor 
cancer specific survival. In particular, a poor tumour CD4+ and CD8+ T-lymphocyte 
infiltrate and increased Ki-67 labelling index were associated with poorer cancer 
specific survival. Poor tumour CD4+ T-lymphocyte infiltrate was associated with an 
elevated circulating C-reactive protein and haemoglobin concentration but not tumour 
characteristics. Similarly, increased Ki-67 labelling index was associated with an 
elevated circulating C-reactive protein, tumour diameter but not other tumour 
characteristics. An elevated C-reactive protein, in addition to being associated with 
poor tumour CD4+ T-lymphocyte infiltrate and increased Ki-67 labelling index was 
also associated with tumour diameter. Taken together these results would suggest that 
local and systemic inflammatory responses are linked to tumour proliferation in patients 
with colorectal cancer and these responses are in turn linked to cancer specific survival, 
independent of tumour stage.
In order to examine the relative importance of these factors we carried out multivariate 
survival analysis. This showed that both local (tumour CD8+ T-lymphocyte infiltrate) 
and systemic (C-reactive protein) inflammatory responses, but not tumour proliferation 
(Ki-67 labelling index), were significantly associated with cancer specific survival. The 
reasons that, compared with the inflammatory responses, tumour proliferation is a 
relatively poor predictor of survival possibly relates to the fact that tumour 
dissemination, rather than tumour proliferation, is the primary determinant of survival in 
patients with colorectal cancer.
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With respect to the relationship between the Ki-67 labelling index and survival the 
results of the present study appear to be in contrast with those of previous studies. For 
example, Brown and Gatter (2002) in their recent review of those studies, only three out 
of 12 studies reported a significant association with survival (Palmqvist et al, 1999; 
Saleh et al, 1999; Kimura et al, 2000). Indeed, the result of above studies which did 
show a correlation were also contradictory; for example, Palmqvist and co-workers 
(1999) concluded that colorectal carcinomas with low Ki-67 protein expression at the 
invasive margin had a poor prognosis, whilst Saleh and co-workers (1999) and Kimura 
and co-workers (2000) showed that a high Ki-67 protein expression at the site of 
invasive margin had a worse prognosis. These apparently contradictory findings may 
be the result of the marked heterogeneity of Ki-67 protein expression in colorectal 
carcinomas (Ofner et al, 1996), However, many of these studies were based on small 
numbers; some included both primary operable and advanced disease and most used 
semi-quantitative techniques for the measurement of Ki-67. Indeed, some of the largest 
studies included both patients with primary operable and advanced disease (Jansson and 
Sun, 1997; Buglioni et al., 1999).
In the present study, a minimum of 1000 tumour cells in randomly selected fields were 
counted in order to assess the percentage of Ki-67 positively staining nuclei. In 
contrast, most of the largest studies to date have used semi-quantitative methods to 
assess Ki-67 expression (Jansson and Sun, 1997; Bhatavbekar et al., 2001; Allegra et 
al., 2002). Therefore, it is likely that the method used in the present study offers a more 
accurate assessment of Ki-67 expression. Recently, Valera and co-workers (2005) 
reported that, using a double immunohistochemical staining procedure and a 
quantitative technique in a cohort of 106 patients who underwent curative resection for
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colorectal cancer, an increased Ki-67 proliferation index was associated with poorer 
survival and it maintained significance as an independent predictor of long-term 
outcome m a multivariate analysis that included other prognostic factors. This study 
also showed a significant correlation between proliferative index and several 
pathological characteristics of colorectal carcinomas, such as tumour differentiation, 
metastatic disease and local invasiveness in keeping with earlier studies (Porschen et al, 
1991; Kubota et al, 1992; Diebold et al, 1994; Kyzer et al, 1997).
These results would confirm that although Ki-67 expression reflects the proliferation
rate of the tumour, it does not reflect the ability of the tumour to disseminate. These
results are consistent with the concept that tumour proliferation alone does not
determine outcome in the cancer patient (Balkwill and Mantovani, 2001; Vakkila et al, 
2004).
In the present study there was a direct relationship between the Ki-67 labelling index 
and C-reactive protein concentrations. These results are consistent with the concept that 
C-reactive protein produetion is primarily determined by interleukin-6 which in turn 
stimulates tumour cell proliferation in colorectal cancer (Kinoshita et al, 1999). In the 
present study, we were unable to reliably identify regions o f 11-6 expression in the 
colorectal tumours due to deep background staining which precluded accurate scoring 
of IL-6 positive cells in the tumour tissue. This was despite using different methods of 
antigen retrieval and staining and the use of negative and positive controls. The reasons 
for the poor quality of immuno-staining are unclear. However, on inspection of the 
equivalent 11-6 staining by Kinoshita and co-workers (1999) it would appear likely that 
non-specific binding by the primary antibody was a problem.
139
Like most epithelial solid tumours, colorectal carcinoma has long been considered 
poorly immunogenic and substantially refractory to immunotherapy. This opinion was 
based on indirect data from: (a) epidemiological studies on lack of spontaneous 
regression of cancer; (b) in vitro studies on tumour infiltrating lymphocytes (TIL); (c) a 
first generation of clinical trials of immunotherapy in colorectal cancer patients; (d) in 
colorectal carcinoma spontaneous regression is only exceptionally observed, and does 
not appear to be associated with an immune response (Papac et al, 1996; Francis et al, 
1997).
During the last decade, however, continuous progress in the molecular characterisation 
of T cell-defined tumour associated antigens (TAA) and in methods allowing detection 
of antigen-specific T cell responses have slowly modified the scientific community’s 
perspective. One classical way to evaluate if anti-tumour immune responses are taking 
place in vivo in cancer patients, and can influence the natural history of the disease, is to 
perform histopathological evaluation of surgically resected tumour lesions looking for 
immune effectors within tumour tissue, and trying to correlate their presence with 
patient prognosis. To avoid confusion, pathological evaluation of intra-tumour 
inflammatory infiltrates should take into careful consideration some important 
parameters, such as cellular composition and anatomical localisation.
A key to understand the complex local inflammatory response in colorectal cancer could 
reside in accurate and qualitative classification of inflammatory infiltrates, taking into 
careful consideration both the type of recruited immune effectors and their anatomical 
localization within the tumour tissues (intra-epithelial vs. stromal or peri-tumoural). 
The results of the present study are consistent with those of Nielsen and co-workers
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(1999) who showed, on simple staining of tumour sections, that a poor inflammatory 
infiltrate including lymphocytes was associated with poorer survival. Also, they appear 
to be consistent with previous work by Naito and co-workers (1998) who showed that, 
in 131 tumours, tumour CD8+ T-lymphocyte infiltrate had prognostic value in patients 
with colorectal cancer. They divided CD8+ T-lymphocytes into three groups: (a) peri- 
tumoural, when distributed along the invasive margin of the tumour; (b) stromal, when 
infiltrating the tumour stroma; and (c) intra-epithelial, when infiltrating within cancer 
cell nests and taking direct contact with tumour cells. They reported that the presence 
of peri-tumoural and stromal CD8+ T lymphocytes was not associated with improved 
prognosis in multivariate analysis, while the presence of intra-epithelial CD8+ T 
lymphocytes was a strong predictor of better survival independently of Duke’s stage. In 
the present study tumour T-lymphocyte subset density was assessed using a point 
counting technique. This approach provided an objective assessment of lymphocytic 
infiltration and circumvents the problem of variation in distribution of lymphocytes 
within an individual tumour. Furthermore, the study of Naito and colleagues (1998) 
included patients with Dukes A tumours who were unlikely to progress and patients 
with Dukes D tumours who had already progressed.
The relationship between tumour CD4+T-lymphocytic infiltration and cancer specific 
survival is the opposite of that previously reported for both renal and prostate cancer 
(Bromwich et ah, 2003; McArdle et al., 2004a). The reasons for this are as yet unclear. 
However, given that tumour lymphocytic infiltration parallels that of other 
inflammatory cells (Nielsen et al., 1999; Lin and Pollard, 2004) and that an elevated C- 
reactive protein is associated with poor outcome in all three tumours (Blay et al., 1992; 
Lewenhaupt et al, 1990; McMillan et al, 2003) it appears likely that the source of 
interleukin-6, the primary stimulus to C-reactive protein, (Gabay and Kushner, 1999) is
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different in different tumours. Indeed, McArdle and coworkers (2004b) have recently 
reported that the relationship between interleukin-6 and C-reactive protein was similar 
in benign prostatic hyperplasia and prostate cancer and that there was no relationship 
between interleukin-6 and PSA concentrations. This would suggest that interIeukin-6 
was coming from inflammatory cells. In colorectal cancer, however, it has been 
reported that interleukin-6 concentrations increase with tumour stage and correlate with 
CEA concentrations and this might, therefore suggest that interleukin-6 is coming from 
tumour cells (Kinoshita et al., 1999; Belluco et a l, 2000; Miki et a l, 2004). If this were 
to prove to be the case it would have important implications for the treatment of the 
systemic inflammatory response in patients with different cancers.
It was also of interest that C-reactive protein (a marker of the systemic inflammatory 
response) was also independently associated with cancer specific survival. Clearly, C- 
reactive protein can be measured with greater accuracy and precision than tumour T- 
lymphocytic infiltration. Nevertheless, it would appear from the present results that the 
systemic inflammatory response is also important in determining survival in these 
patients. The reasons for the importance of the systemic inflammatory response, 
independent of the local inflammatory response, are not clear. There are a number of 
possible explanations. Firstly, that C-reactive protein plays a more pivotal role in the 
tumour-host relationship. An elevated C-reactive protein concentration may identify 
those patients with a proangiogenic environment, since increased angiogenesis is 
associated with poor outcome in patients with colorectal cancer (Salmon et al, 2005) 
and circulating concentrations of vascular endothelial growth factor are directly 
associated with C-reaetive protein (Xavier et al, 2006). Secondly, that C-reactive 
protein is recognised to be an activator of innate immunity and a modulator of adaptive
142
immunity (Du Clos and Mold, 2004) and its elevation is a precursor to progressive 
involuntary loss of weight and lean tissue which are key factors in determining cancer 
survival (McMillan et a l, 1999, Kotler, 2000, Van Cutsem and Arends, 2005). Clearly, 
both local and systemic inflammatory mechanisms may be related and promote 
unrestrained tumour growth and the dissemination required for the greater malignant 
potential associated with these inflammatory response.
In summary, the results of the present study show that both an increased tumour Ki-67 
labelling index and a low CD8+ T-lymphocyte count are independently associated with 
poorer outcome in patients undergoing curative resection for colorectal cancer. C- 
reactive protein, a mediator of the inate immune response, also had prognostic value 
independent of Dukes stage. Taken together these results may suggest that upregulation 
of the innate immune response and down regulation of cell mediated immunity is 
important in determining poorer survival in colorectal cancer
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Table 5.1 The relationship between clinicopathological characteristics and cancer
specific survival in patients undergoing potentially curative resection for colorectal
cancer: Univariate survival analysis.
Age group (<65/ 65-74/ >75)
Sex (male/ female)
Site (colon/ rectum)
Dukes stage (B/ C)
C-reactive protein (<10/ >10mg/l) 
Haemoglobin (>12/ <12g/dl)
White cell count
(<8.5/8.5-11.0/>11.0x10®)
Lymphocyte percentage
(20-40/ 12-19.9/0-11.9)
Platelets (<400/ >400 xlO^)
Tumour characteristics
Diameter (tertiles 1, 2, 3)
Ulceration (no/ yes)
Differentiation (well/ moderate/ poor) 
Lymphatic invasion (negative/ 
positive)
Venous invasion (negative/ positive) 
Ki-67 labelling index (tertiles 1, 2, 3) 
CD4+ T-lymphocytes (tertiles 1, 2, 3) 
CD8+ T-lymphocytes (tertiles 1, 2, 3) 
CD4+plus CD 8+ T-lymphocytes 
(tertiles 1, 2, 3)
Adjuvant therapy (no/ yes)
Alive/ dead
Cancer specific/ intercurrent disease 
* Median (range)
Patients 
(n= 147)
46/ 44/ 57 
78/ 69 
105/42 
91/56 
93/ 54 
69/ 78
93/ 30/ 24
73/35/39
126/21
40(10-130)*
72/ 75
18/116/13
124/22
118/28
0.72 (0.32-0.96)* 
0.90 (0.03-3.57)*
1.13 (0.23-6.30)*
2.17(0.50-8.27)*
116/31
88/59
40/19
Hazard ratio p-value
(95% Cl)
2.13 (1.39-3.25) 0.0005
1.77 (0.94-3.31) 0.0749
1.39 (0.66-2.89) 0.3960
4.34 (2.24-8.43) 0.0001
6.05 (3.05-12.01) 0.0001
1.16(0.62-2.16) 0.6438
0.80 (0.52-1.25) 0.3310
1.06 (0.74-1.53) 0.7466
0.83 (0.33-2.13) 0.7050
0.90 (0.62-1.31) 0.5985
1.07 (0.58-2.00) 0.8212
1.45 (0.72-2.92) 0.2925
1.29 (0.57-2.91) 0.5469
2.79(1.46-5.35) 0.0020
1.79(1.20-2.69) 0.0047
0.64 (0.43-0.95) 0.0272
0.68 (0.46-1.01) 0.0541
0.67 (0.45-0.99) 0.0426
1.09 (0.52-2.30) 0.8108
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Table 5.2 The relationship between an elevated C-reactive protein concentration and
clinicopathological characteristics in patients undergoing potentially curative resection for
colorectal cancer.
C-reactive protein C-reactive protein p-value
Age group (<65/ 65-74/ >75)
Sex (male/ female)
Site (colon/ rectum)
Dukes stage (B/ C)
Haemoglobin (>12/ <12g/dl)
White cell count
(<8.5/8.5-11.0/>11.0xl0®)
Lymphocyte percentage 
(20-40/12-19.9/0-11.9)
Platelets (<400/ >400 xlO^)
Tumour characteristics
Diameter (tertiles 1, 2, 3)
Ulceration (no/ yes)
Differentiation (well/ moderate/ poor) 
Lymphatic invasion (negative/ positive) 
Venous invasion (negative/ positive) 
Ki-67 labelling index (tertiles 1, 2, 3) 
CD4+ T-lymphocytes (tertiles 1, 2, 3) 
CD8+ T-lymphocytes (tertiles 1, 2, 3) 
CD4+plus CD8+ T-lymphocytes 
(tertiles 1,2, 3)
Adjuvant therapy (no/ yes)
<10mg/l
(n= 93)
33/34/26
52/41
30/63
62/31
46/47
65/14/14
51/19/23
81/12
41/29/23
51/42
14/73/6
80/12
77/15
37/31/25
22/32/39
30/29/34
26/29/38
73/20
>10mg/l 
(n= 54) 
13/10/31 
26/28 
12/42 
29/25 
23/31 
28/16/10
22/16/16
45/9
8/20/26
21/33
4/43/7
44/10
41/13
12/18/24
27/17/10
19/20/15
23/20/11
43/20
0.004
0.365
0.196
0.120
0.423
0.099
0.189
0.531
0.0001
0.063
0.072
0.374
0.251
0.012
0.0001
0.404
0.871
0.871
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Table 5.3 The relationship between CD+ T-lymphocyte tumour infiltration and
clinicopathological characteristics in patients undergoing potentially curative resection for
colorectal cancer.
CD4+ CD4+ CD4+ p-value
(Tertile 1) (Tertile 2) (Tertile 3)
Age group (<65/ 65-74/ >75) 12/13/24 18/11/20 16/20/13 0.070
Sex (male/ female) 22/27 23/26 33/16 0.026
Site (colon/ rectum) 14/35 13/36 15/34 0.824
Dukes stage (B/ C) 30/19 33/16 28/21 0.678
C-reactive protein (<10/ >10mg/l) 22/27 32/17 39/10 0.0001
Haemoglobin (>12/ <12g/dl) 18/31 21/28 30/19 0.015
White cell count 32/8/9 30/13/6 31/9/9 0.894
(<8.5/8.5-11.0/>11.0xl0®)
Lymphocyte percentage 
(20-40/12-19.9/0-11.9)
21/12/16 25/12/12 27/11/11 0.188
Platelets (<400/ >400 xlO^) 44/5 43/6 39/10 0.150
Tum our characteristics
Diameter (tertiles 1, 2, 3) 12/19/18 15/14/20 22/16/11 0.036
Ulceration (no/ yes) 21/28 22/27 29/20 0.107
Differentiation (well/ moderate/ poor) 6/38/5 7/37/5 5/41/3 0.826
Lymphatic invasion (negative/ positive) 40/8 43/6 41/8 0.966
Venous invasion (negative/ positive) 38/10 42/7 38/11 0.835
Ki-67 labelling index (tertiles 1, 2, 3) 16/15/18 15/17/17 18/17/14 0.549
CD8+ T-lymphocytes (tertiles 1, 2, 3) 30/12/7 11/22/16 8/15/26 0.0001
Adjuvant therapy (no/ yes) 43/6 40/9 33/16 0.014
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Table 5.4 The relationship between increasing Ki-67 labelling index and tumour
characteristics in patients undergoing potentially curative resection for colorectal cancer.
Ki-67 Ki-67 Ki-67 p-value
(Tertile 1) (Tertile 2) (Tertile 3)
Age group (<65/ 65-74/ >75) 18/14/17 14/20/15 14/10/25 0.147
Sex (male/ female) 26/23 35/14 17/32 0.069
Site (colon/ rectum) 14/35 13/36 15/34 0.824
Dukes stage (B/ C) 30/19 33/16 28/21 0.678
C-reactive protein (<10/ >10mg/l) 37/12 31/18 25/24 0,012
Haemoglobin (>12/ <12g/dl) 23/26 23/26 23/26 1.000
White cell count 32/9/9 32/6/11 29/15/5 1.000
(<8.5/8.5-11.0/>n.0xl0®)
Lymphocyte percentage 
(20-40/12-19.9/0-1L9)
27/10/12 23/13/13 23/12/14 0.473
Platelets (<400/ >400 xlO^) 39/10 43/6 44/5 0.150
Tumour characteristics
Diameter (tertiles 1, 2, 3) 25/16/8 11/15/23 13/18/18 0.007
Ulceration (no/ yes) 25/24 25/24 22/27 0.546
Differentiation (well/ moderate/ poor) 5/41/3 7/38/4 6/37/6 0.660
Lymphatic invasion (negative/ positive) 39/9 45/4 40/9 0.966
Venous invasion (negative/ positive) 38/10 41/8 39/10 0.961
CD4+ T-lymphocytes (tertiles 1, 2, 3) 16/15/18 15/17/17 18/17/17 0.459
CD8+ T-lymphocytes (tertiles 1, 2, 3) 17/17/15 16/16/17 16/16/17 0.711
CD4+plus CD8+ T-lymphocytes 16/16/17 18/13/18 15/20/14 0.805
(tertiles 1, 2, 3)
Adjuvant therapy (no/ yes) 39/10 37/12 40/9 0.805
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Table 5.5 The relationship between clinicopathological characteristics and cancer
specific survival in patients undergoing potentially curative resection for colorectal
cancer: Multivariate survival analysis.
Patients Hazard ratio p-value
(n= 147) (95% Cl)
Age group (<65/ 65-74/ >75) 46/ 44/57 2.10(1.34-3.29) 0.0013
Sex (male/ female) 78/ 69 2.13 (1.06-4.28) 0.0329
Dukes stage (B/ C) 91/56 4.28 (2.11-8.68) 0.0001
C-reactive protein (<10/ >10mg/l) 93/ 54 4.39 (2.11-9.10) 0.0001
Tumour characteristics
Venous invasion (negative/ positive) 118/28 1.97 (0.98-3.94) 0.0569
Ki-67 labelling index (tertiles 1, 2, 3) 0.72 (0.32-0.96)* 1.27 (0.84-1.92) 0.2628
CD4+ T-lymphocytes (tertiles 1, 2, 3) 0.90 (0.03-3.57)* 1.00 (0.63-1.89) 0.9902
CD8+ T-lymphocytes (tertiles 1, 2, 3) 1.13 (0.23-6.30)* 0.56 (0.36-0.85) 0.0075
* Median (range)
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Figure 5.1 Relationship between percentage tumour CD4+ T-lymphocyte infiltration 
and preoperative C-reactive protein in patients undergoing potentially curative resection 
for colorectal cancer.
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Figure 5.2 Relationship between percentage tumour CD8+ T-lymphocyte infiltration 
and preoperative C-reactive protein in patients undergoing potentially curative resection 
for colorectal cancer.
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C-reactive protein in patients undergoing potentially curative resection for colorectal 
cancer.
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CH APTER SIX
6.0 CO NCLUSION
Systemic inflammatory response and colorectal cancer:
The field of cancer research has largely been guided by a reductionist focus on cancer 
cells and the genes within them. This focus has produced an extraordinary body of 
knowledge but with little clinical impact. Howeyer, some workers haye proposed that 
in the future important new deyelopments in the treatment of cancer will come 
regarding tumours as complex tissues. Indeed, Hanahan and Weinberg (2000) haye 
proposed that “important new inroads will come from regarding tumors as complex 
tissues in which mutant cancer cells haye conscripted and subyerted normal cell types to 
serye as actiye collaborators in their neoplastic agenda. The interactions between the 
genetically altered malignant cells and these supporting coconspirators will proye 
critical to understanding cancer pathogenesis and to the deyelopment of noyel, effectiye 
therapies.”
The present study examined, for the first time, the relationship between the pre- 
operatiye systemic inflammatory response and tumour based factors and suggests that 
the systemic inflammatory response is more closely related to outcome in patients 
undergoing potentially euratiye resection for colorectal cancer. One possible 
explanation is that C-reactiye protein can be measured with greater accuracy and 
precision than tumour based factors.
Alternatiyely, it may be that C-reactiye protein plays a more piyotal role in the tumour- 
host relationship. C-reactiye protein is recognised to be an actiyator of innate immunity 
and a modulator of adaptiye immunity (Du Clos and Mold, 2004). Its eleyation is a
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precursor to progressive involuntary loss of weight and lean tissue through an increase 
in the demand for certain amino acids, which if limited in the diet, may be obtained 
from the breakdown of skeletal muscle. In these ways the presence and magnitude of a 
chronic systemic inflammatory response may produce a progressive nutritional and 
functional decline ultimately resulting in reduced survival in the cancer (McMillan et 
ah, 1998, Kotler, 2000).
The results of the present study do not exclude non-malignant causes of an elevated C- 
reactive protein in patients with colorectal cancer. However, it is of interest that C- 
reactive protein concentrations above the threshold used in the present study (>10mg/l) 
are rare (<5%) in the general elderly population in the West of Scotland (O’Reilly et ah, 
2006). However, it was of interest that, in the present study, an elevated C-reactive 
protein concentration prior to surgery, was associated with older age but not Dukes 
stage. This raises the question of whether those patients with an elevated C-reactive 
protein, prior to surgery had worse nutritional status or increased co-morbidity. 
Although we did not record nutritional status or co-morbidity in the present study it 
would be important to examine their relationship with the systemic inflammatory 
response in future studies since it may shed light on whether a poorer health state results 
in the tumour behaving more aggressively since this would be an important 
consideration in the administration o f adjuvant chemotherapy.
The results of the present study are consistent with recent work which has shown that an 
elevated C-reactive protein concentration has prognostic value, independent of TNM 
stage, following resection, in variety of sold tumours (Ikeda et al., 2003; Jamieson et al., 
2005; Lamb et al., 2006; Crumley et al., 2006). In the present study, when C-reactive
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protein concentrations were combined with Dukes stage to form a new prognostic score, 
the combined score improved the prediction of cancer specific survival. The addition of 
C-reactive protein differentiated between low and high risk Dukes B and low and high 
risk Dukes C patients. Cancer related mortality ranged from 5% in patients with Dukes 
B tumours and a normal C-reactive protein concentration to 65% in patients with Dukes 
C tumours and an elevated C-reactive protein concentration. Cancer related mortality in 
patients with Dukes B tumours and an elevated C-reactive protein concentration was 
similar to that of patients with Dukes C tumours and a normal C-reactive protein 
concentration. However, the tumours in the present thesis were not pathologically 
staged according to TNM classification. Therefore it would be important to carry out 
further work in patients whose tumours were TNM staged. In particular, since surgery 
alone is the recommended treatment modality for TNM stage 1/ II disease it would be 
important to confirm the prognostic value of a pre-operative C-reactive protein 
concentration in this node negative group.
Cellular Immunitv and Colorectal Cancer
Cellular immunity is initiated by specifically sensitised T lymphocytes. It includes the 
classic delayed-type hypersensitivity reactions initiated by CD4+ T lymphocytes and 
direct cell cytotoxicity mediated by CD8+ T lymphocytes. The latter immune 
mechanism is important for the elimination of virally infected cells and tumour cells 
that express neoantigens.
In the present study, confined to patients with Dukes B and C colorectal cancer 
undergoing potentially curative resection, a number of factors were associated with poor 
cancer specific survival. In particular, a poor tumour CD4+ and CD8+ T-lymphocyte
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infiltrate, an increased Ki-67 labelling index were associated with poorer cancer specific 
survival. Poor tumour CD4+ T-lymphocyte infiltrate was associated with an elevated 
circulating C-reactive protein and haemoglobin concentration but not tumour 
characteristics. Similarly, increased Ki-67 labelling index was associated with an 
elevated circulating C-reactive protein, tumour diameter but not other tumour 
characteristics. An elevated C-reactive protein, in addition to being associated with 
poor tumour CD4+ T-lymphocyte infiltrate and increased Ki-67 labelling index was 
also associated with tumour diameter. Taken together these results would suggest that 
local and systemic inflammatory responses are linked to tumour proliferation in patients 
with colorectal cancer and these responses are in turn linked to cancer specific survival, 
independent of tumour stage.
However, there are other aspects of the local inflammatory response that may be 
important and worthy of future study. In particular, the inter-relationships between 
tumour T-lymphocyte subsets infiltration, macrophage infiltration, microvessel density 
and COX-2 expression would also be of considerable interest since these are central to 
tumour dissemination and the local inflammatory process in the tumour respectively. 
Finally, it would be important to establish reliable methodology for the staining of 
interleukin-6 in paraffin-embedded colorectal tumours.
In summary, the results of the present thesis show that both an increased tumour Ki-67 
labelling index and a low CD8+ T-lymphocyte count are independently associated with 
poorer outcome in patients undergoing curative resection for colorectal cancer. Given 
that C-reactive protein, a mediator of the innate immune response, had significant
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prognostic value. These results may suggest that innate rather than cell mediated 
immunity is important in determining survival in colorectal cancer
Future work
The work in the present thesis suggest a number of avenues for research.
These include;
Confirming the prognostic value of a pre-operative C-reactive protein concentration in 
other centres, evaluating its value within the context of randomised adjuvant trials, 
comparing its prognostic value with other blood markers such as CEA and with more 
rigourous pathological criteria such as the proportion of positive lymph nodes.
Establishing the underlying basis of an elevated C-reactive protein concentration. It 
will be important to examine the relationship between C-reactive protein and tumour 
infiltration of inflammatory cells, other than T-lymphocytes of acquired immunity. 
These include macrophages, of the innate immune system, since they are known to 
release cytokines such as interleukin-6, interleukin-10 and vascular endothelial growth 
factor which are now recognised to stimulate tumour cell growth, inhibit T-lymphocytic 
function and promote angiogenesis respectively.
With such knowledge we will be in a position to devise rational strategies to moderate 
the systemic inflammatory response prior to surgery. If on reduction of the systemic 
inflammatory i espouse, as evidenced by C-reactive protein, prior to surgery we are able 
to reduce tumour recurrence and prolong disease free survival in patients undergoing 
potentially curative resection for colorectal cancer, this would a major step forward in 
the treatment of primary colorectal cancer.
156
7.0 REFERENCE
Abbas, A. K. (1996) Functional diversity of helper T lymphocytes. Nature. 383, 787- 
793.
Abbas, A.K. (2005) Diseases of Immunity, In: Robbins and Cotran Pathologie Basis o f  
Disease, ed. Kumar, V. Abbas, A. & Fausto, N. Ch 6, pp 193-203. Philadelphia: 
Elsevier Saunders.
Abramovitch, R. Marikovsky, M. Meir, G. & Neeman, M. (1999) Stimulation of tumour 
growth by wound-derived growth factors. British Journal o f  Cancer. 79, 1392-1398,
Ahmed, N. Thorley, R. Xia, D. Samols, D. & Webster R O (1996) Transgenic mice 
expressing rabbit C-reactive protein exhibit diminished chemotactie factor-induced 
alveolitis. American Journal o f  Resviratorv Medicine. 153, 1141- 1147.
Aldridge, M. C. Phillips, R. K. Hittinger, R. Fry, J. S. & Fielding, L. P. (1986) Influence 
of tumour site on presentation, management and subsequent outcome in large bowel 
cancer. British Journal o f  Surserv. 73,663-670.
All, A. A. McMillan, D. C, Matalka, I.I. McNicol, A.M. & McArdle CS (2004) Tumour 
T-lymphocyte subset infiltration and tumour recurrence following curative resection for 
colorectal cancer. European Journal ofSursical Oncolosv. 30, 292-295.
Allegra, C.J. Paik, S. Colangelo, I.H. Parr, A.L. Kirsch, I. Kim, G. Klein, P. Johnston, 
P.G. Wolmark, N. & Wieand, H.S. (2003) Prognostic value of thymidylate synthase, 
Ki-67, and p53 in patients with Dukes’B and C colon cancer: a National Cancer 
Institute-National Surgical Adjuvant breast and bowel project collaborative study. 
Journal o f  Clinical Oncolosv. 21, 241-250.
Allegra, C.J. Parr, A.I. Woldle, Mahoney, M. Sargent, D.J. Johnston, P. Klein, P. 
Behan, K. O'Connell, M.J. Levitt, R. Kugler, J.W. Tria Tirona, M. & Goldberg, R.M. 
(2002) Investigation of the prognostic and predictive value of thymidylate synthase, 
p53, and Ki-67 in patients with locally advanced colon cancer. Journal o f  Clinical 
Oncolosv. 20, 1735-1743,
157
Anderson, J. A. & Dunnill, M. S. (1965) Observations on the estimation of the quantity 
of emphysema in the lungs by the point-sampling method. Thorax, 20,462-466.
Arbam, G. Nilsson, E. Hallbook, O. Sjodahl, R. (1996) Local recurrence following total 
mesorectal excision for rectal cancer. British Journal o f  Surserv. 83, 375-379.
Arenas, R.B. Fischera, A. Mhoon, D. & Michelassi, K. (1998) Total mesenteric excision 
in the surgical treatment of rectal cancer: a Prospective study. Archives o f  Surserv, 133, 
608-611.
Armstrong, A. C. Eaton, D. & Ewing, J. C. (2001) Cellular immunotherapy for cancer. 
British Medical Journal, 323, 1289-1293.
Armstrong, B. & Doll, R. (1975) Environmental factors and incidence and mortality in 
different countries, with special reference to dietary practice. International Journal o f  
Cancer, 15,617-631.
Astler, V. B. & Coller, F. A. (1954) The prognostic significance of direct extension of 
carcinoma of the colon and rectum. Annals o f  Surserv, 139, 846-852.
Atiken, R. J. (1996) Mesorectal excision for rectal cancer. British Journal o f Surserv, 
83,214-216.
Balkwill, F. & Maiitonvani, A. (2001) Inflammation and cancer: back to Virchow? 
Lnacet. 357, 539-545.
Ballou, S. P. & Lozanski, G. (1992) Induction of inflammatory cytokine release from 
cultured human monocytes by C-reactive protein. Cvtokine, 4, 361-368.
Barber, M. D, Fearon, K. C. McMillan, D. C. Slater, C. Ross, J. A. & Preston, T. (2000) 
Liver export protein synthetic rates are increased by oral meal feeding in weight-losing 
cancer patients. Am JPhvsiol Endocrinol Metab 279, E707-E714.
Barth, R. J. Jr. Camp, B. J. Martuscello, T. A. Dain, B. J. & Memoli, V. A. (1996) The 
cytokine microenvironment of human colon carcinoma: lymphocyte expression of 
tumor necrosis factor- and interleukin-4 predicts improved survival. Cancer, 78, 1168- 
1178.
158
Bartko, J J . & Carpenter, W.T. (1976) On the methods and theory of reliability. Journal 
o f Nerve and Mental Diseases, 163, 307-317.
Baumann, H. & Gauldie, J. (1994) The acute phase response. Immunolosv Todav, 15, 
74-80.
Beahrs, O. H. (1989) Pretreatment staging of cancer. Cancer, 64,275-278.
Beck, T, Weller, E.E. Weikel, W. Brumm, C. Wilkens, C. Knapstein, P. G. (1995) 
Usefulness of immunohistochemical staining for p53 in the prognosis of breast 
carcinomas; correlations with established prognosis parameters and with the 
proliferation marker, MIB-1. Gvnecolosic Oncolosv, 57, 96-104.
Belluco, C. Nitti, D. Frantz, M. Toppan, P. Basso, D. Plebani, M. Lise, M. & Jessup, J. 
M. (2000) Interleukin-6 blood level is associated with circulating carcinoembryonic 
antigen and prognosis in patients with colorectal cancer. Annals o f  Sursical Oncolosv, 
7, 133-138.
Bennett, A. Del. Tacca, M. Stamford, I. F. & Zebro, T. (1977) Prostaglandins from 
tumours of human large bowel. British Journal o f  Surserv, 35, 882-884.
Bernstein, C. N. Eaden, J. Steinhart, A. H. Munkholm, P. & Gordon, P. H. (2002) 
Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential 
of 5-aminosalicylic acid. Inflammatorv Bowel Diseases, 8, 356-361.
Bhatavdekar, J.M. Patel, D.D. Chikhlikar, P.R. Shah, N.G. & Vora, H.H. (2001) 
Molecular markers are predictors of recurrence and survival in patients with Dukes B 
and Dukes C colorectal adenocarcinoma. Disease o f Colon and Rectum, 44, 523-533
Bland, M.J. & Altman, D.G. (1986) Statistical methods for assessing agreement 
between two methods of clinical measurement. Lancet, I, 307-310.
Blay, J.Y. Negrier, S. Combaret, V. Attali, S. Goillot, E. & Merrouche, Y. (1992) 
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. 
Cancer Research, 52, 3317-3322.
159
Blenkinsopp, W.K. Stewart-Brown, S. Blesovsky, L. Kearney, G, & Fielding, L.P. 
(1981) Histopathology reporting in large bowel cancer. Journal o f  Clinical Patholosv, 
34,509-513.
Boon, Thierry. & van der Bruggen, Pierre. (1996) Human Tumor Antigens Recognized 
by T Lymphocytes. Journal Experimental Medicine, 183, 725-729.
Boulos, P.B. Karamanolis, D.G, Salmon, P.R. & Clarke, C.G. (1984) Is colonoscopy 
necessary in diverticular disease? Lancet, I, 95-96.
Boyle, P. & Langman, J.S. (2000) Clinical review: ABC of colorectal cancer. 
Epidemiology. British Medical Journal 321, 805-808.
Brady, A.P. Stevenson, G.W. & Stevenson, I. (1994) Colorectal cancer overlooked at 
barium enema examination and colonoscopy: a continuing perceptual problem. 
Radiolosv, 92, 373-378.
Bremers, A.J. van der Burg, S.H. Kuppen, P.J. Kast, W.M. van de Velde, C.J. & Melief, 
C.J. (1995) The use of Epstein-Barr virus-transformed b lymphocyte cell lines in a 
peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted 
potential cytotoxic T-lymphocyte epitopes. Journal of immunotheranv with emphasis on 
tumor immunolosv Immunother. 18, 77-85.
Brentnall, T.A. Haggitt, R.C. & Rabinovitch, P.S. (1996) Risk and natural history of 
colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative 
colitis.Gastroenterolosv, 110, 331-338.
Bromwich, E. McMillan, D. C. Lamb, G.W. Vasey, P.A. & Aitcliison, M. (2004) The 
systemic inflammatory response, performance status and survival in patients undergoing 
alpha-interferon treatment for advanced renal cancer. British Journal o f  Cancer, 91, 
1236-1238.
Bromwich, E.J. McArdle, P.A. Canna, K. McMillan, D.C. McNicol, A-M. Brown, M. & 
Aitchison, M. (2003) The relationship between T-lymphocyte infiltration, stage, tumour 
grade and survival in patients undergoing curative surgery for renal cell cancer. British 
Journal o f  Cancer, 89, 1906-1908.
160
Brown, D.C. & Gatter, K.C. (2002) Ki67 protein: the immaculate deception? 
Histopatholosv. 40, 2-11.
Bufill, J.A. (1995) Colorectal cancer genetics. Closing the gap between genotype and 
phenotype. Cancer, 76, 2389-2392.
Buglioni, S. D'Agnano, I. Cosimelli, M. Vasselli, S. D'Angelo, C. Tedesco, M. Zupi, G. 
& Mottolese, M. (1999) Evaluation of multiple bio-pathological factors in colorectal 
adenocarcinomas: independent prognostic role of p53 and bcl-2. International journal 
o f cancer, 84, 545-552.
Bukliolm, I. K. & Nesland, J. M. (2000) Protein expression of p53, p21 (WAFl/CIPl), 
bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 436, 224- 
228.
Burke, H.B. Goodman, P.H. Rosen, D.B. Henson, D.E. Weinstein, J.N. & Harrell, 
F.E.Jr. (1997) Artificial neural networks improve the accuracy of cancer survival 
prediction. Cancer, 79, 857-862.
Burke, H.B. Hoang, A. Iglehart, J.D. & Marks, J.R. (1998) Predicting response to 
adjuvant and radiation therapy in early stage breast cancer. Cancer, 82, 874-877.
Burkitt, D.P. (1971) Epidemiology of cancer of colon and rectum. Cancer, 28, 3-13.
Caligiuri, M.A. Murray, C. Robertson, M.J. Wang, E. & Cochran, K. (1993) Selective 
modulation of human natural killer cells in vivo after prolonged infusion of low dose 
recombinant interleukin 2. Journal o f  Clinical Invesisation, 91,123-132
Cattoretti, G. Becker, M.H., Key, G. Duchrow, M. Schluter, C. Galle, J. & Gerdes, J.
(1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 
and MIB 3) detect proliferating cells in microwave- processed formalin-fixed paraffin 
sections. Journal o f  Patholosv, 168, 357-363.
Cerwenka, A. & Lanier, L.L. (2001) Natural killer cells, viruses and cancer. Nature 
reviews. Immunolosv, 1, 41-49.
161
Chan, F.K. Hung, L.C. Suen, B.Y. Wu, J.C. Lee, K.C. & Leung, V.K. (2002) Celecoxib 
versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in 
patients with artliritis. The New Eneland Journal o f  Medicine, 347,2104-2110.
Chang M.H, Chen C.J, Lai M.S. Hsu, H.M. Wu, T.C. Kong, M.S. Liang, D.C. Shau, 
W.Y. & Chen, D.S. (1997) Universal hepatitis B vaccination in Taiwan and the 
incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study 
Group. New Ensland Journal o f  Medicine, 336, 1855-1859.
Chang, J. Powles, T.J. Allred, D.C. Ashley, S.E. Clark, G.M. Makris, A. Assersohn, L. 
Gregory, R.K. Osborne, C.K. & Dowsett, M. (1999) Biologic markers as predictors of 
clinical outcome from systemic therapy for primary operable breast cancer. Journal o f  
Clinical Oncolosv, 17, 3058-3063.
Chiba, T. Ohtani, H. Mizoi, T. Naito, Y. Sato, E. Sato, E. Nagura, H. Ohuchi, A. 
Ghuchi, K. Shiiba, K. Kurokawa, Y. & Satomi, S. (2004) Intraepithélial CD8+ T-cell- 
count becomes a prognostic factor after a longer follow-up period in human colorectal 
carcinoma: possible association with suppression of micrometastasis. British Journal o f  
Cancer. 91. 1711-1717.
Chung, Y C. & Chang, Y.F. (2003) Serum C-reactive protein correlates with survival in 
colorectal cancer patients but is not an independent prognostic indicator. European 
Journal o f  Gastroenterolosv and Hepatolosv. 15, 369-373.
Chung, Y.C. & Chang, Y.F. (2003) Serum interleukin-6 levels reflect the disease status 
of colorectal cancer. Journal o f  Clinical Oncolosv. 83,222-226.
Church, R.D. Fleshman, J.W. & McLeod, H.L. (2003) Cyclo-oxygenase 2 inhibition in 
colorectal cancer therapy. British Journal o f  Surserv, 90, 1055-1067
Clark, E.A. & Ledbetter, J.A. (1994) How B and T cells talk to each other. Nature, 367, 
425-428.
Coleman, MP, Babb, P, & Damiecki, P (1999) Cancer survival trends in England and 
Wales, 1971-1995: Deprivation and NHS region London, The Stationery Office.
162
Committees and Task Forces of the American Joint Committee for Cancer Staging and 
End Results Reporting. (1976) Classification and staging of cancer by site: a 
preliminary handbook. Chicago (IL): American Joint Committee on Cancer.
Compton, C. Fenoglio-Preiser, C.M. Pettigrew, N. Fielding, L.P. (2000) American Joint 
Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working 
Group. Cancer, 88, 739- 1757.
Cotton, S. Sharp, L. & Little, J. (1996) The adenoma-carcinoma sequence and prospects 
for the prevention of colorectal neoplasia. Critical Reviews in oncosenesis, 7,293-342.
Coussens, L.M. & Verb, Z. (2002) Inflammation and cancer. Nature. 420, 860-867.
Cyster, J.G. (1999) Chemokines and cell migration in secondary lymphoid organs. 
Science, 286, 2098.
Dannenberg, A.J. & Zakim, D. (1999) Chemoprevention of colorectal cancer through 
inhibition of cyclooxygenase-2. Seminars in Oncolosv, 26,499-504.
Davis, M.M. Boniface, J.J. Reich, Z. Lyons, D. Hampl, J. Arden, B. & Chien, Y. (1998) 
Ligand recognition by alpha beta T eell receptors. Annual Review o f  Immunology. 16, 
523-544.
De Quay, N. Cerottini, J.P. Albe, X. Saraga, E. Givel, J.C. & Caplin, S. (1999) 
Prognosis in Duke’s B colorectal carcinoma: the Jass classification revisited. European 
Journal o f  Surserv, 165, 588-592.
Deans, G.T. (1991) The role of flow cytometry and image analysis in colorectal cancer. 
MD Thesis. The Queen’s University of Belfast.
Deans, G.T. Heatley, M. & Anderson, N. (1994) Jass’ classification revisited. Journal 
o f the American Collese ofSurseons, 179. 11-17.
Deans, G.T. Heatley, M. Anderson, N. Patterson, C.C. Rowlands, B.J. Parks, T.G. & 
Spence, R.A. (1995) Comments: Jass’ classification revisited. Journal o f  the American 
College ofSurseons, 180, 252-253.
163
Deans, G.T. Parks, T.G. Rowlands, B. & Spence, R.A.J. (1992) Prognostic factors in 
colorectal cancer. British Journal o f  Surserv. 79, 608-613.
DeVita, V.T. Heilman, S. & Rosenberg, S.A. (2001) Cancer of the Colon. In Cancer: 
Principles & Practice o f Oncology, 6^ '^  ed. Vol. 2. ch 33. Lippincott Williams & 
Wilkins.
Di Giorgio, A. Botti, C. Tocchi, A. Mingazzini, P. & Flammia, M. (1992) The influence 
of tumour lymphocytic infiltration of long term survival of surgically treated colorectal 
cancer patients. International Journal o f  Surserv, 77, 256-260.
Diebold, J. Dopfer, K. Lai, M. & Lohrs, U. (1994) Comparison of different monoclonal 
antibodies for the immunohistochemical assessment of cell proliferation in routine 
colorectal biopsy specimens. Scandinavian Journal o f  Gastroenterolosv, 29,47-53.
Dinarello, C.A. (1988) Biology of interleukins-1. FASEB Journal. 2,108-115.
Dolcetti, R. Viel, A. Doglioni, C. Russo, A. Guidoboni, M. Capozzi, E. Vecchiato, N. 
Maori, E. Fornasarig, M. & Boiocchi M. (1999) High prevalence of activated 
intraepithélial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in 
colorectal carcinomas with microsatellite instability. American Journal o f  Pathology, 
154, 1805-1813.
Du Clos, T.W. & Mold, C. (2004) C-reactive protein: an activator of innate immunity 
and a modulator of adaptive immunity. Immunolosic research. 30, 261-277.
Du Clos, T.W. (2000) Function of C-reactive protein. Annals o f  Medicine, 32, 274-278.
Dukes, C.E. & Bussey, H.J.R. (1958) The spread of rectal cancer and its effect on 
prognosis. British Journal o f  Cancer, 12, 309-320.
Dukes, C.E. (1930) The spread of cancer of the rectum. British Journal o f  Surserv, 17, 
643-648.
Dukes, C.E. (1932) The classification of cancer of the rectum. Journal o f  Patholosv. 35, 
323-332.
164
Dundas, S.A. Laing, R.W. O'Cathain, A. Seddon, I. Slater, D.N. Stephenson, T.J. & 
Underwood, J.C. (1988) Feasibility of new prognostic classification for rectal cancer. 
Journal o f  Clinical Patholosv, 41, 1273-1276.
Durdey, P. Weston, P. & Williams, N.S. (1987) Barium enema or colonoscopy as the 
initial investigation for colonic disease. Lancet, ii, 549-551.
Durdey, P. Williams, N.S. & Brown, D.A. (1984) Serum carcinoembryonic antigen and 
acute phase reactant proteins in the pre-operative detection of fixation of colorectal 
tumours. British Journal o f  Surserv. 71, 881-884.
Eaden, J.A. & Mayberry, J.F. (2000) Colorectal cancer complicating ulcerative colitis; a 
review. American Journal o f  Gastroenterolosv. 95,2710-2719
Eaden, J.A. Abrams, K.R. & Mayberry, J.F. (2001) The risk of colorectal cancer in 
ulcerative colitis: a meta-analysis. Gut. 48, 526-535
Ehrlich, C.P. Hall, F.M. & Joffe, N. (1984) Post endoscopic perforation of normal colon 
in an area remote from instrumentation with secondary tension pneumoperitoneum. 
Gastrointestinal Endoscopv, 30,190-191.
Ekbom, A. Helmick, C. Zack, M. & Adami, H.O. (1990) Ulcerative colitis and 
colorectal cancer: A population-based study. New Ensland Journal o f  Medicine, 
323,1228-1233.
Enker, W.E. Laffer, U.T. & Block, G.E. (1979) Enhanced survival of patients with 
colon and rectal cancer is based upon wide anatomic resection. Annals o f Surserv, 190, 
350-360.
Erlinger, T. P. Platz, E.A. Rifai, N. & Helzlsouer, K.J. (2004) C-reactive protein and the 
risk of incident colorectal cancer. Journal o f  the American Medical Association, 291, 
585-590.
Evertsson, S. Bartik, Z. Zhang, H., Jansson, A. & Sun, X.F. (1999) Apoptosis in relation 
to proliferating cell nuclear antigen and Dukes’ stage in colorectal adenocarcinoma. 
International Journal o f  Oncolosv, 15, 53-58.
165
Farrands, P.A. Vellacott, J.D. Amar, S.S. Balfour, T.W. & Hardcastle, J.D. (1983) 
Flexible fibreoptic sigmoidoscopy and double contrast barium enema examination in 
the identification of adenomas and carcinoma of the colon. Disease o f  Colon & Rectum, 
26, 725-727.
Fearon, E.R. & Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. 
Cell 61, 759-767.
Fearon, E.R. Cho, K.R. Nigro, J.M. Kern, S.E. Simons, J.W. Ruppert, J.M.. Hamilton, 
S.R. Preisinger, A.C. Thomas, G. & Kinzler, K.W. (1990) Identification of a 
chromosome 18q gene that is altered in colorectal cancers. Science, 247, 49-56.
Fischer, B. Wolmark, N. Rockette, H. Redmond, C. Deutsch, M. & Wickerham, D.L. 
(1988) Post operative adjuvant chemotherapy or radiotherapy for rectal cancer: result 
from NSABP protocol K-Ol. Journal o f  National Cancer Institute, 80, 21-29.
Fisher, B. & Gebhardt, M.C, (1978) The evolution of breast cancer surgery: Past, 
present, and future. Seminars in Sursical Oncolosy, 5, 385-394.
Fisher, E.R. Robinsky, B. Sass, R. & Fisher, B. (1989) Relative prognostic value of the 
Dukes and Jass system in rectal cancer: findings from the National Surgical Adjuvant 
Breast and Bowel Projects. Diseases o f  the Colon & Rectum, 32, 944-949.
FitzGerald, G.A. & Patrono, C. (2001) The coxibs, selective inhibitors of 
cyclooxygenase-2. New Ensland Journal o f  Medicine, 345,433-442.
Fleming, I.D. Cooper, J.S. Henson, D.E. Hutter, R.V. Kennedy, B.J. & Murphy, G.P.
(1997) AJCC cancer stasins manual. 5th ed. New York (NY): Springer.
Forrest, L.M. McMillan, D.C. McArdle, C.S. Angerson, W.J. & Dunlop, D.J. (2003) 
Evaluation of cumulative prognostic scores based on the systemic inflammatory 
response in patients with inoperable non-small-cell lung cancer. British Journal o f  
Cancer, 89, 1028-1030.
Frayling, I. M. (1999) Microsatellite instability. Gut, 45, 1-4.
166
Fuchs, C.S. Giovannucci, E.L. & Colditz, G.A. (1999) Dietary fiber and the risk of 
colorectal cancer and adenoma in women. New Ensland Journal o f  Medicine, 340, 169- 
176.
Funk, C.D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. 
Science, 294, 1871-1875.
Gabay, C. & Kushner, I. (1999) Mechanism of Disease: Acute-phase proteins and other 
systemic response to inflammation. New Ensland Journal o f Medicine, 340,448-454.
Gabriel, W.B. Dukes, C. & Bussey, H.J.R. (1935) Lymphatic spread in cancer of the 
rectum. British Journal o f  Surserv, 23, 395-413.
Gagliardi, G. Stepniewska, K.A. Hershman, M.J. Hawley, P.R. & Talbot, I.C. (1995) 
New grade-related prognostie variable for rectal cancer. British Journal o f  Surserv, 82, 
599-602.
Garrity, M.M. Burgart, L.J. Mahoney, M.R. Windschitl, H.E. Salim, M. et al. (2004) 
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 
overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central 
Cancer Treatment Group Study. Journal o f  clinical oncolosv, 22, 1572-1582.
Gauldie, J. Richards, C. Harnish, D. Lansdorp, P. & Baumann, H. (1987) Interferon 
(beta) 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived 
hepatocyte-stimulating factor and regulates the major acute phase protein response in 
liver cells. Proceedinss o f the National Academv o f  Sciences, 84, 7251-7255.
Gerard, A. Buyse, M. Nordlinger, B. Loygue, J. Pene, F. Kempf, P. Bosset, J.F. 
Gignoux, M. Arnaud, J.P. Desaive, C. (1988) Pre-operative radiotherapy as adjuvant 
treatment in rectal cancer. Final results of a randomised study of the European 
Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer 
Cooperative Group. Annals o f  Surserv, 208, 606-614.
Germak, J. Key, N.S. Bach, P.R. Balia, J. Jacob, H.S. & Vercellotti, G.M. (1993) C- 
reactive protein induces human peripheral blood monocytes to synthesize tissue factor. 
Blood, 82,513-520.
167
Giardiello, F.M. Hamilton, S. Krush, A.J. Piantadosi, S. Hylind, L.M. & Celano, P.
(1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous 
polyposis. New Ensland Journal o f  Medicine, 328, 1313-1316.
Giovannucci, E. (2001) An updated review of the epidemiological evidence that cigrate 
smoking increase risk of colorectal cancer. Cancer Epidemiolosv, Biomarker & 
Prevention, 10,725-731.
Giovannucci, E. Egan, K.M. Hunter, D.J. Stampfer, M.J. Colditz, G.A. Willett, W.C. & 
Speizer, F.E. (1995) Aspirin and the risk of colorectal cancer in women. New Ensland 
Journal o f  Medicine, 333, 609-614.
Giovannucci, E. Rim, E.B. Stampfer, M.J. Colditz, G.A. Ascherio, A. & Willett, W.C. 
(1994a) Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer 
Research, 54,2390-2397.
Giovannucci, E. Rimm, E.B. Stampfer, M.J. Colditz, G.A. Ascherio, A. & Willett, W.C. 
(1994b) Aspirin use and the risk for colorectal cancer and adenoma in male health 
professionals. Annals o f  internal medicine, 121, 241-246.
Goloigher J C. (1984) Surgery of the Anus, Rectum and Colon. P 468. London: 
Baillie re Tindall.
Goulston, K.J. Cook, I. & Dent, O.F. (1986) How important is rectal bleeding in the 
dignosis of bowel cancer and polyp? Lancent, 2,261-265.
Graham, D.M. & Appelman, H.D. (1990) Crohn’s-like lymphoid reaction and colorectal 
carcinoma: a potential histologic prognosticator. Modern patholosv, 3: 332-335.
Graham, S. Marshall, J. Haughey, B. Mittelman, A. & Swanson, M. (1988) Dietary 
epidemiology of cancer of the colon in western New York. American journal o f  
Eoidemiolosv, 128, 490-503.
Greenblatt, M.S. Bennett, W.P. Hollstein, M. & Harris, C.C. (1994) Mutations in the 
p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. 
Cancer Research, 54, 4855-4878.
168
Greene, F.L. Page, D.L. Fleming, I.D. Fritz, A.G. Balch, C.M. & Haller, D.G. (2002) 
AJCC cancer staging manual. 6th ed. New York (NY): Springer, 2002.
Griffin, M.R. Bergstrahl, E.J. Coffey, R.J. Beart, R.W. & Melton, J.J. (1987) Predictors 
of survival after curative resection of carcinoma of the colon and rectum. Cancer, 60, 
2318-2324.
Guidoboni, M. Gafa, R. Viel, A. Doglioni, C. Russo, A. Santini, A. Del Tin, L. Maori, 
E. Lanza, G. Boiocchi, M. Dolcetti, R. (2001) Microsatellite instability and high content 
of activated cytotoxic lymphocytes identify colon cancer patients with a favorable 
prognosis. American Journal o f  Patholosv, 159,297- 304.
Gunter, M.J. Stolzenberg-Solomon, R. Cross, A.J. Leitzmann, M.F. Weinstein, S. 
Wood, R.J. Vhtamo, J. Taylor, P.R. Albanes, D. & Sinha R. (2006) A prospective study 
of serum C-reactive protein and colorectal cancer risk in men. Cancer Research, 66, 
2483-2487.
Halvorsen, T.B. & Sein, E. (1989) Association between invasiveness, inflammatory 
reaction, desmoplasia and survival in colorectal cancer. Journal o f  clinical patholosv^ 
42, 162-166.
Hanahan, D & Weinberg, RA (2000). The Hallmarks of Cancer Review. Cell, 100, 57- 
70.
Harrison, J.C. Deans, P.J. El-zeky, F. & Vander Zwaag, R (1994) From Dukes through 
Jass: Pathological prognostic indicators in rectal cancer. Human patholosv, 25,498-505.
Hase, K. Shatney, C. Johnson, D. Trollope, M. Vierra, M. (1993) Prognostic value of 
tumor “budding” in pnatients with colorectal cancer. Disease o f  Colon & Rectum. 36, 
627-635.
Hashimoto, S. Koji, T. Kohara, N. Kanematsu, T. & Nakane, P.K. (1997) Frequency of 
apoptosis relates inversely to invasiveness and metastatic activity in human colorectal 
cancer. Virchows Archiv, 431, 241-248.
169
Hawkins, N. Lees, J. Hargrave, R. O’Connor, T. Meagher, A. & Ward R. (1997) 
Pathological and genetic correlates of apoptosis in the progression of colorectal 
neoplasia. Tumour Biolosv, 18, 146-156.
Llayday, A.C. (2000) [gamma] [delta] cells: a right time and a right place for a 
conserved third way of protection. Annual Review o f Immunolosv, 18, 975-1026.
Heald, R.J. & Karanjie, N.D. (1992) Result of radical surgery for rectal cancer. World 
Journal o f Surserv. 16: 848-857.
Heald, R.J. (1988) The ‘Holy Plane’ of rectal surgery. Journal o f  the Roval Society o f  
Medicine, 81: 503-508.
Heald, R.J. Husband, E.M. & Rayall, R.D. (1982) The mesorectum and rectal cancer- 
the clue to pelvic recuirence? British Journal o f  Surserv. 69, 613-616.
Heinrich, P.C. Castell, J.V. & Andus, T. (1990) Interleukin-6 and acute phase response. 
Biochemical Journal 265, 621-636.
Hida J, Yasutomi M, Maruyama T. Fujimoto, K. Uchida, T. Okuno, K. (1997) Lymph 
node métastasés detected in the mesorectum distal to carcinoma of the rectum by the 
clearing method: Justification of total mesorectal excision. Journal o f  the American 
Collese ofSurseons, 184, 584-588.
House, A. K. & Watt, A.G. (1979) Survival and the immune response in patients with 
carcinoma of the colorectum. Gut, 20, 868-874.
Howe, G.R. Aronson, K.J. Benito, E. Castelleto, R. Cornee, J. Duffy, S. Gallagher, R.P. 
Iscovich, J.M. Deng-ao, J. Kaaks, R. Kune, G.A. Kune, S. Lee, H.P. Lee, M. Miller, 
A.B. Peters, R.K. Potter, J.D. Riboli, E. Slatteiy, M.L. Trichopoulos, D. Tuyns, A. 
Tzonou, A. Watson, L.F. Whittemore, A.S. & Shu, Z. (1997) The relationship between 
dietary fat and risk of colorectal cancer. Cancer causes & control, 8, 215-228.
Howe, G.R. Benito, E. Casteletto, R. Cornee, J. Esteve, J. Gallagher, R. P. (1992) 
Dietary intake of fibers and decreased risk of cancer of the colon and rectum: Evidence
170
from combined analysis of 13 case-control studies. Journal o f  the Natural Canr.P.r 
Institute. 84, 1887-1896.
Humphreys, F. Hewetson, K.A. & Dellpiani, A.W. (1984) Massive subcutaneous 
emphysema following colonoscopy. Endoscopy. 16,160-161.
Iliyasu Y, Ladipo JK, Akang EE (1997) A twenty-year review of malignant colorectal 
neoplasm at university college Hospital, Ibadan, Nigeria. Disease o f  colon & Rectum. 
39:536-540.
IMPACT Trial 1995. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. 
Lancet. 345, 939-944.
Jacquemier, J.D. Penault-Llorca, F.M. Bertucci, F. Sun, Z.Z. Houvenaeghel, G.F. 
Geneix, J.A. Puig, B.D. Bardou, V.J. Hassoun, J.A. Birnbaum, D. & Viens, P.J. (1998) 
et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional 
adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. Journal 
ofPatholosv, 184, 130-135.
Janne, P.A. & Mayer, R.J. (2000) Chemoprevention of colorectal cancer. New Ensland 
journal o f  medicine. 342, 1960-1968.
Jansson, A. & Sun, X.F. (1997) Ki-67 expression in relation to clinicopathological 
variables and prognosis in colorectal adenocarcinomas. APMIS. 105, 730-734.
Jarvmen, R. Kenkt, P. Hakulinen, T. Rissanen, H. & Heliovaara, M. (2001) Dietary fat, 
cholesterol and colorectal cancer in a prospective study. British Journal o f  Cancer. 85, 
357-361.
Jass J R. Piognostic factors in colorectal cancer (1990) In: Current topics in pathology. 
Williams G T ed. Vol. 81. pp 195-322. Berlin Heidelberg: Springer-Verlag.
Jass, J.R. & Morrson, B.C. (1987) Reporting colorectal cancer. Journal o f clinical 
patholosv, 40. 1016-1023.
171
Jass, J.R. (1986) Lymphocytic infiltration and survival in rectal cancer. Journal o f  
clinical patholosv. 39, 585-589.
Jass, J.R. (1989) Prognostic variables in large bowel cancer, Journal o f Clinical 
Patholosv. 42,1006-1007.
Jass, J.R. Atkin, W.S. & Cuzick, J, (1986) The grading of rectal cancer: historical 
perspectives and a multivariate analysis of 447 cases. Histopatholosv, 10, 437-459.
Jass, J.R. Love, S.B. & Northover, J.M.A. (1987) A new prognostic classification of 
rectal cancer. Lancet 6, 1303-1306.
Jones, M.K. Wang, H. Peskar, B.M. Levin, E. Itani, R.M. Sarfeh, I.J. Tarnawski AS.
(1999) Inliibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into 
mechanisms and implications for cancer growth and ulcer healing. Nature Medicine. 5, 
1418-1423.
Kawasaki, H. Altieri, D.C. Lu, C.D. Toyoda, M. Tenjo, T. & Tanigawa, N. (1998) 
Inliibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. 
Cancer Research. 58, 5071-5074.
Keighley, M.R.B. & Williams, N.S. (1999) Surgical Management of Carcinoma of the 
Colon and Rectum. In: Surserv o f The Anus. Rectum & Colon, 2nd. Ed, Vol.l, Ch.. 31, 
pp 1076. London: Bailliere Tindall.
Keighley, M.R.B. & Williams, N.S. (1999). Colorectal cancer: Epidemiology, 
Aetiology, Pathology, Staging, Clinical Feature, Dignosis and Screening. In: Surserv o f  
The Anus. Rectum and Colon. 2"  ^ ed. Vol. 1. Ch. 30, pp 1030-1033. London: Bailliere 
Tindall.
Kikuchi-Yanoshita, R. Konishi, M. Ito, S. Seki, M. Tanaka, K. Maeda, Y. lino, H. 
Fukayama, M. Koike, M. & Mori, T. (1992) Genetic changes of both p53 alleles 
associated with the conversion from colorectal adenoma to early carcinoma in familial 
adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer 
Research. 52, 3965-3971.
172
...
Kimura, T. Tanaka, S. Haruma, K. Sumii, K. Kajiyama, G. Shimamoto, F. & Kohno, N.
(2000) Clinical significance of MUCl and E-cadherin expression, cellular proliferation, 
and angiogenesis at the deepest invasive portion o f colorectal cancer. International 
journal o f  oncolosv. 16, 55-64.
Kinoshita, T. Ito, H. & Miki, C. (1999) Serum interleukin-6 level reflects the tumour 
proliferative activity in patients with colorectal carcinoma. Cancer, 85,2526-2531.
Kirklin, J.W. Dockerty, M.B. & Waugh, J.M. (1949) The role of peritoneal reflection in 
the prognosis of carcinoma of the rectum and sigmoid colon. Surserv, svnecolosv & 
obstetrics. 88, 326.
Kirwan, W. O’Riordan, M. & Waldron, R (1989) Declining indications for 
abdominoperineal resection. British Journal o f  Surserv. 76, 1061-1063.
Kishimoto, T. Akira, S. & Taga, T. (1992) Interleukin-6 and its receptor: a paradigm for 
cytokines. Science. 258, 593-597.
Komoda, H. Tanaka, Y. Honda, M. Matsuo, Y. Hazama, K. & Takao, T. (1998) 
Interleukin-6 levels in colorectal cancer tissues. World Journal o f  Surserv, 22, 895- 
898.
Kono, S. (2001) All epidemiological evidence is important in colorectal cancer. British 
Medical Journal, 322, 611.
Kornfeld, D. Ekbom, A. & Ihre, T. (1997) Is there an excess risk for colorectal cancer in 
patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A 
population-based study. Gut. 41, 522-525.
Kotler, D.P. (2000) Cachexia. Annals o f  internal medicine. 133, 622-634.
Krook, J.E. Moertel, C.G. Gunderson, L.L. Wieand, H.S. Collins, R.T. & Beart, R.W. 
(1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Ensland 
Journal o f Medicine. 324, 709-715.
173
Kubota, Y. Petras, R.E. Easley, K.A. Bauer, T.W. Tubbs, R.R. & Fazio, V.W. (1992) 
Ki-67-determined growth fraction versus standard staging and grading parameters in 
colorectal carcinoma. A multivariate analysis. Cancer, 70, 2602-2609.
Kudo, T. Narisawa, T. & Abo, S. (1980) Antitumour activity of indomethacin on 
methylazomethanol-induced large bowel tumours in rats. Gann, 71. 260-264.
Kune, A.G. Kune, S. Field, B. White, R. Brough, W. Schellenberger, R. Watson, L.F.
(1990) Survival in patients with large bowel cancer. Diseases o f  the Colon & Rectum, 
33, 938-946.
Kune, G.A. Kune, S. & Watson, L.F. (1988) Colorectal cancer risk, chronic illnesses, 
operations and medications: case control results from Melbourne Colorectal Cancer 
Study. Cancer Research, 48, 4399-4404.
Kune, G.A. Kune, S. Vitetta, L. & Watson, L.F. (1992) Smoking and colorectal cancer 
risk: data from Melbourne Colorectal cancer study and brief review of literature. 
International journal o f  Cancer, 50, 369-372.
Kushner, I. (1993) Regulation of the acute phase response by cytokines. Perspectives in 
biolosv and medicine, 36, 611-622.
Kyzer, S. Gordon, P.H. (1997) Determination of proliferative activity in colorectal 
carcinoma using monoclonal antibody Ki67. Diseases o f  the Colon & Rectum, 40, 322- 
325.
Labayle, D. Fischer, D. Viehl, P. Drouhin, F. Pariente, A. & Bories, C. (1991) Sulindac 
causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterolosv, 
101, 635-639.
Langlois, N.E. Lamb, J. Eremin, O. & Heys, S.D. (1997) Apoptosis in colorectal 
carcinoma occurring in patients aged, 45 years and under: relationship to prognosis, 
mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein 
product. Journal o f  vatholosv, 82, 392-397.
174
Lee, E. Schiller, L.R. & Fordtran, J.S. (1988) Quantification of colonie lamina propria 
cells by means of a morphometric point-counting method. Gastroenterolosv, 94, 409- 
418.
Lee, P.P. Yee, C, Savage, P.A. Fong, L. Brockstedt, D. Weber, J.S. Johnson, D. 
Swetter, S. Thompson, J. Greenberg, P.D. Roederer, M. & Davis, M.M. (1999) 
Characterization of circulating T cells specific for tumor-associated antigens in 
melanoma patients. Nature medicine, 5, 677-685.
Lenschow, D.J. Walunas, T.L. & Bluestone, J.A. (1996) CD28/B7 system of T cell 
costimulation. Annual review o f  immunolos^v, 14, 233-258.
Lewenhaupt, A. Ekman, P. Eneroth, P. & Nilsson, B. (1990) Tumour markers as 
prognostic aids in prostatic carcinoma. British journal o f  urolosy, 66, 182 -187
Lin, E.Y. & Pollard, J.W. (2004) Role of infiltrated leucocytes in tumour growth and 
spread. British Journal o f  Cancer, 90, 2053-2058.
Lipkin, M. Reddy, B. & Newmark, H. (1999) Dietary Factors in Human Colorectal 
Cancer. Annual Review o f  Nutrition, 19, 545-86.
Locker, A.P, Birrell, K. Bell, J.A. Nicholson, R.I. Elston, C.W. Blarney, R.W. & Ellis, 
I.e . (1992) K167 immunoreactivity in breast carcinoma: relationships to prognostic 
variables and short term survival. European Journal ofSursical Oncolosy, 18,224-229.
MacCarty, R.L. (1992) Colorectal cancer: the case for barium enema (review). Mayo 
Clinic Proceedings, 67, 253-257.
MacFarlane, J.K. Ryall, R.D.H. & Heald, R.J. (1993) Mesorectal excision for rectal 
cancer. Lancet, 341, 457-460.
Martling, A.L. Holm, T. Rutqvist, L.E. Moran, B.J. Heald, R.J. & Cedermark, B. (2000) 
Effect of a surgical training programme on outcome of rectal cancer in the County of 
Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer 
Reseai’ch Project. Lancet, 356, 93-96.
175
Masferrer, J.L. Seibert, K. Zweifel, B. & Needleman, P. (1992) Endogenous 
glucocorticoids regulate an inducible cyclooxygenase enzyme. Proceedings o f  the 
National Academy o f Sciences U S A , 89, 3917-3921.
McArdle, C.S. & Hole, D.J. (2002) Outcome following surgery for colorectal cancer: 
analysis by hospital after adjustment for case-mix and deprivation. British Journal o f  
Cancer, 86,331-335.
McArdle, C.S. McMillan, D.C. & Hole, D.J. (2003) Male gender adversely affects 
survival following surgery for colorectal cancer. British Journal o f  Sursery, 90, 711- 
715.
McArdle, P.A. Canna, K. McMillan, D.C. McNicol, A.M. Campbell, R. & Underwood, 
M.A. (2004a) The relationship between T-lymphocyte subset infiltration and survival in 
patients with prostate cancer. British Journal o f  Cancer, 91, 541-543.
McArdle, P.A. McMillan, D.C. Sattar, N. Wallace, A.M. & Underwood, M.A. (2004b) 
The relationship between interleukin-6 and C-reactive protein in patients with benign 
and malignant prostate disease. British Journal o f  Cancer, 91, 1755-1757.
McCallum, R.W. Meyer, C.T. Marignani, P. & Cane Contino, C. (1984) Flexible 
sigmoidoscopy diagnostic yield in 1015 patients. American Journal o f  
Gastroenterolosv, 179, 433- 437.
McDermott, F.T. Hughes, P.S.R. Pihl, E. Milne, B.J. & Price, A.B. (1981) Comparative 
results of surgical management of single carcinoma of the colon and rectum: a series of 
1939 patients managed by one surgeon. British Journal o f  Sursery, 68, 850-855.
McKeown-Eyssen, G. & Bright-See, E. (1985) Dietary factors in colon cancer: 
international relationships. An update. Nutrition and cancer, 7, 251-253.
McMichael, A. & Giles, G. (1994) Colorectal cancer. In: Trends in Cancer Incidence 
and Mortality, Ed. Doll, R. Frumeni, J. & Muir, C. pp 77-98. Cold Spring Harber: 
Laboratory press.
176
McMillan, D.C. Canna, K. & McArdle, C.S. (2003) Systemic inflammatory response 
predicts survival following curative resection of colorectal cancer. British Journal o f  
Sursery, 90,215-219.
McMillan, D.C. Elahi, M. Sattar, N. Angerson, W.J. Johnstone, J. & McArdle, C.S.
(2001) Measurement of the systemic inflammatory response predicts cancer specific and 
non-cancer survival in patients with cancer. Nutrition and cancer, 41, 64-69.
McMillan, D.C. Fyffe, G.D. Wotherspoon, H.A. Cooke, T.G. & McArdle, C.S. (1997) 
Prospective study of circulating T-lymphocyte subpopulations and disease progression 
in colorectal cancer. Disease o f Colon & Rectum, 40,1068-1071.
McMillan, D.C. Preston, T. Fearon, K.C. Burns, H.J. Slater, C. & Shenkin, A. (1994) 
Protein synthesis in cancer patients with inflammatory response; investigations with 
[15N] glycine. Nutrition, 10, 232-240.
McMillan, D.C. Scott, H.R. Watson, W.S. Preston, T. Milroy, R. & McArdle, C.S.
(1998) Longitudinal study of body cell mass depletion arid the inflammatory response in 
cancer patients. Nutrition and cancer, 31, 101-105.
McMillan, D.C. Wotherspoon, H.A. Fearon, K.C. Sturgeon, C. Cooke, T.G. & 
McArdle, C.S. (1995) A prospective study of tumor recurrence and the acute-phase 
response after apparently curative colorectal cancer surgery. American Journal o f  
Sursery, 170, 319- 322.
McMillan, D.C. Wotherspoon, H.A. Fearon, K.C.H. Smith, J. Graham, A.F. & McArdle 
C.S. (1994) Interleukin-6, neutrophilia and the acute phase protein response in 
colorectal cancer patients. European Journal ofSursical Oncolosy, 20,151-154.
177
Mebius, R.E. (2003) Organogenesis of lymphoid tissues. Nature Reviews Immunology,
3, 292-303.
Melief, C.J. & Kast, W.M. (1991) Cytotoxic T lymphocyte therapy of cancer and tumor 
escape mechanisms. Seminars in Cancer Biolosv, 2, 347-354.
Miki, C, Konishi, N. Ojima, E. Hatada, T. Inoue, Y. & Kusunoki, M. (2004) C-reactive 
protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-l-IL-6 
network system in colorectal caicinoma. Disestive diseases and sciences. 49, 970-976.
Miller, A.B. Howe, G.R. Jain, M. Craib, K.J. Harrison, L. et al (1983) Foods items and 
food groups as risk factors in a case-control study of diet and colorectal cancer. 
International Journal o f Cancer, 32, 155-161.
Moldawer, L.E. & Copeland, E.M. (1997) Proinflammatory cytokines, nutritional 
support, and the cachexia syndrome: interactions and therapeutic options. Cancer, 79, 
1828-1839.
Moretta, A. Bottino, C. Vitale M. Pende, D. Biassoni, R. Mingari, M.C. Moretta, L. 
(1996) Receptors for HLA class-I molecules in human natural killer cells. Annual 
Review ofImmunolosv, 14, 619-648.
Morley, J.J. & Kushner, I. (1982) Serum C-reactive protein levels in disease. Annals o f  
the New York Academy o f  Sciences, 389,406-418.
Morris, P.J. & Wood, W.C. (2000) Colorectal tumours; clinical presentations. In: 
Oxford Textbook o f Sursery, Ch. 26, pp 1480.Oxford: University Press.
Munkholm, P. (2003) Review article: the incidence and prevalence of colorectal cancer 
in inflammatory bowel disease. Alimentary pharmacolosv & therapeutics, 18, Suppl 
2:1-5.
Naito, Y. Saito, K. Shiiba, K. Ghuchi, A. Saiqenji, K. Naqura, H. & Ohtani, H. (1998) 
CD8+ T cells infiltrated within cancer cell nests as prognostic factor in human 
colorectal cancer. Cancer Research, 58, 3491-3494.
178
Nakano, O. Sato, M. Naito, Y. Suzuki, K. Orikasa, S. Aizawa, M. Suzuki, Y. Shintaku, 
I. Nagura, H. & Ohtani H. (2001) Proliferative Activity of Intratumoral CD81 T- 
Lymphocytes As a Prognostic Factor in Human Renal Cell Carcinoma: 
Clinicopathologic Demonstration of Antitumor Immunity, Cancer research, 61, 5132- 
5136.
Narisawa, T. Satoh, M. Sano, M. Takahashi, T. (1983) Inhibition of initiation and 
promotion by N-metylnitrosourea-induced colon carcinogenesis in rats by non-steroid 
anti-inflammatory agent indomethacin. Carcinosenesis. 4, 1225-1227.
Natali, P.O. Nicotra, M.R. Bigotti, A. Venturo, I. Mai'cenaro, L. Giacomini, P. & Russo, 
C. (1989) Selective changes in expression of HLA class I polymorphic determinants in 
human solid tumors. Proceedinss o f  the National Academy o f Sciences U S A , 86, 6719- 
6723.
Nielsen, H.J. Cliristensen, I.J. Sorensen, S. Moesgaard, F. & Brunner N. (2000) 
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive 
protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study 
Group. Annals ofSursical Oncolosy, 7, 617-623.
Nielsen, H.J. Hansen, U. Christensen, I.J. Reimert, C.M. Brunner, N. Moesgaard, F.
(1999) Independent prognostic value of eosinophil and mast cell infiltration in 
colorectal cancer tissue. Journal o f  Patholosv, 189, 487-495.
Nilsson, B, Gregersen, N.P. Hartvig, B. & Sjodahl, R. (1984) Carcinoma of the colon 
and rectum. Results of treatment in 284 cases. Acta Chirursica Scandinavica, 150, 177- 
182.
Nozoe T. Matsumata T. Sugimachi K. (2000) Preoperative elevation of serum C- 
reactive protein is related to impaired immunity in patients with colorectal cancer. 
American Journal o f  Clinical Oncolosv, 23, 263-266.
Nozoe, T. Matsumata, T. Kitamura, M. & Sugimachi, K. (1998) Significance of 
preoperative elevation of serum C-reactive protein as an indicator for prognosis in 
colorectal cancer. American Journal o f Sursery, 176, 335-338.
179
Nugent, K.P. Farmer, K.C.R, Spigelman, A,D. Williams, C.B. & Philips, R.K.S. (1992) 
Randomised controlled clinical trial of sulindac on intestinal polyposis in FAP. Gul, 33, 
S33.
Nyren, O. Bergstrom, R. Nystrom, L. Engholm, G. Ekbom, A. Adami, H.O. Knutsson, 
A. & Stjernberg, N, (1996) Smoking and colorectal cancer. Journal o f  national cancer 
institute, 88, 1302-1307.
O'Comiell, M.J. Maillard, J. Kaha, M.J. Macdonald, J.S. Haller, D.G. Mayer, R.J. & 
Wieand, H.S. (1997) Controlled trial of fluorouracil and low dose leucovorin given for 
6 months as post-operative adjuvant therapy for colon cancer. Journal o f Clinical 
Oncolosv, 15, 246-250.
O’Connell, J.B. Maggard, M.E. & Ko, C.Y. (2004) Colon cancer survival rates with the 
new American Joint Committee on Cancer sixth edition staging. Journal o f  the National 
Cancer Institute, 96, 1420-1425.
O'Byrne, K.J. & Dalgleish, A.G. (2001) Chronic immune activation and inflammation 
as the cause of malignancy. British Journal o f  Cancer, 85,473-483.
Ochsenbein, A. F. (2002) Principles of tumor immunosurveillance and implications for 
immunotherapy. Cancer Gene Therapy, 9, 1043-1055.
Other, D. Grothaus, A, Riedmann, B. Larcher, P. Maier, FI. Bankfalvi, A. & Schmid, 
K.W. (1996) MIBl in colorectal carcinomas: its evaluation by three different methods 
reveals lack of prognostic signifcance. Analytical Cellular Patholosv, 12, 61-70.
G'Gorman, P. McMillan, D.C. & McArdle, C.S. (2000) Prognostic factors in advanced 
gastrointestinal cancer patients with weight loss. Nutrition and cancer, 37, 36-40.
Ohman, U. (1982) Prognosis in patients with obstructing colorectal carcinoma. 
American Journal o f  Sursery, 143, 742-747.
O'Reilly, D.S. Upton, M.N. Caslake, M.J. Robertson, M. Norrie, J. McConnachie, A. 
Watt, G.C. Packard, C.J. Midspan and WOSCOPS study groups. (2006) Plasma C
180
reactive protein concentration indicates a direct relation between systemic inflammation 
and social deprivation. Heart 92, 533-535.
Palmqvist, R. Sellberg, P. Oberg, A. Tavelin, B. Rutegard, J.N. & Stenling, R. (1999) 
Low tumour cell proliferation at the invasive margin is associated with a poor prognosis 
in Dukes' stage B colorectal cancers. British Journal o f Cancer, 79, 577-581.
Pan, M.R. Chuang, L.Y. & Hung, W.C. (2001) Non-steroidal anti-inflammatory drugs 
inhibit matrix metalloproteinase-2 expression via repression of transcription in lung 
cancer cells. FEBS letters, 508, 365-368.
Panel on Food, Nutrition and the Prevention of Cancer (1997). Colon, Rectum. In Food, 
Nutrition and the Prevention o f  cancer. A Global Perspective, pp. 216-251. 
Washington, DC; Am. Inst. Cancer Res.
Panes, J. (2001) Inflammatory bowel disease: pathogenesis and targets for therapeutic 
interventions. Acta Phvsiolosica Scandinavica , 173, 159.
Papac, R.J. (996) Spontaneous regression of cancer. Cancer Treatment Reviews, 22, 
395- 423.
Paradiso, A. Simone, G. Lena, M.D. Leone, B. Vallejo, C. Lacava, J. Dellapasqua, S. 
Daidone, M.G. & Costa, A. (2001) Expression of apoptosis related markers and clinical 
outcome in patients with advanced colorectal cancer. British Journal o f Cancer, 84:651- 
658.
Pardoll, D.M & Topalian, S.L. (1998) The role of CD4+ T cell responses in antitumor 
immunity. Current opinion in immunolosv, 10, 588-594.
Pasch, B. & Serhan, C.N. (2004) Is C-reative protein an inflammation opsonin that 
signals colon cancer risk? Journal o f  the American Medical Association, 291, 623-624.
181
Peleg, LI. Maibach, H.T. Brown, S.H. & Wilcox, C.M. (1994) Aspirin and nonsteroidal 
anti-inflammatory drug use and the risk of subsequent colorectal cancer. Archives o f  
internal medicine, 154, 394-399.
Phillips, R.K.S. Hittinger, R. Blesovsky, L. Fry, J.S. & Fielding, L.P. (1984) Local 
recurrence following 'curative' surgery for large bowel cancer: I, the overall picture. 
British Journal o f  Sursery. 71,12-16.
Phillips, R.K.S. Kittinger, R. Blesovsky, L. Fry, J.S. & Fielding, L.P. (1984) Large 
bowel cancer: surgical pathology and its relationship to survival. British Journal o f  
Sursery. 71, 604-610.
Piancatelli, D. Romano, P. Sebastiani, P. Adorno, D. & Casciani, C.U. (1999) Local 
expression of cytokines in human colorectal carcinoma: evidence of specific 
interleukin-6 gene expression. Journal o f  immunotherapy, 22, 25-32.
Pihl, E. Hughes, E.S. McDermott, F.T. Milne, B.J. Korner, J.M. & Price A.B. (1980) 
Carcinoma of the colon. Cancer specific long-term survival. A series of 615 patients 
treated by one surgeon. Annals of Surgery. 192, 114-117.
Pohl, C. Hombach, A. & Kruis, W. (2000) Clu'onic inflammatory bowel disease and 
cancer. Hepatosastroenterolosv, 47, 57-70.
Pollard, M. & Luckert, P.H. (1984) Effect of piroxicam on primary intestinal tumors 
induced in rats by N-methylnitrosourea. Cancer Letters, 25, 117-121.
Pollard, M. Luckert, P.H. & Schmidt, M.A. (1983) The suppressive effect of piroxicam 
on autochthonous intestinal tumour in the rat. Cancer letters, 21, 57-61.
Pollard, M. Luckert, P.H. (1980) Indomethacin treatment of rats with dimethylhydrazine 
induced intestinal tumours. Cancer, 64, 1323-1327.
Pollett, W.G. & Nicolls, R.J. (1983) The relationship between the extent of distal 
clearance and survival and local recurrence rates after curative resection for carcinoma 
of the rectum. Annals o f  Surser, 198, 159-163.
182
Porschen, R. Kriegel, A. Langen, C. Classen, S. Hilse, M. Lohe, B. Hengels, K.J. & 
Borchard, F. (1991) Assessment of proliferative activity in carcinomas of the human 
alimentary tract by Ki-67 immunostaining. International Journal o f  Cancer. 47, 686- 
691.
Powell, S.M. Zilz, N. Beazer-Barclay, Y. Bryan, T.M. Hamilton, S.R. Thibodeau, S.N. 
Vogelstein, B. & Kinzler, K.W. (1992) APC mutations occur early during colorectal 
tumorigenesis. Nature. 359, 235-237.
Prall, F. Duhrkop, T. Weirich, V. Ostwald, C. Lenz, P. Nizze, H, Barten, M. (2004) 
Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer 
with and without microsatellite instability. Human Patholosv, 35, 808-816.
Preston, T. Slater, C. McMillan, D.C. Falconer, J.S. Shenkin, A. & Fearon, K.C. (1998) 
Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. 
Journal o f Nutrition, 128, 1355-1360.
Pricolo, V.E. & Potenti, P.M. (2001) Modern Management of Rectal Cancer. Disestive 
Sursery, 18, 1-20.
Pritchard, R.S. Baron, J.A. Gerhardsson, de Verdier. M. (1996) Dietary calcium, 
vitamin D, and the risk of colorectal cancer in Stockholm, Sweden, Cancer 
epidemiolosv. Biomakers and Prevention, 5, 897-900.
Quirke, P. Dixon, M.F. & Clayden, A.D. (1987) Prognostic significance of DNA 
aneuploidy and cell proliferation on rectal adenocarcinomas. Journal o f Patholosv, 151, 
285-291
Reddy, B.S. Nayini, J. Tokumo, K. Rigotty, J. Zang, E. & Kelloff, G. (1990) 
Chemoprevention of colon carcinogenesis by concurrent administation of piroxicam, a 
non-steroidal anti-inflammatory drug with D, L-Alpha-difluoromethylornithine, an 
orniyhine decarboxylase inlribitor, in diet. . Cancer Research, 50, 2562-2568.
Ressing, M.E. van Driel, W.J. Celis, E. Sette, A. Brandt, M.P. Hartman, M. Anliolts, 
J.D. Schreuder, G.M. ter Harmsel, W.B. Fleuren, G.J. Trimbos, B.J. Kast, W.M. & 
Melief CJ. (1996) Occasional memory cytotoxic T-cell responses of patients with
183
human papillomavirus type 16-positive cervical lesions against a human leukocyte 
antigen-A *0201-restricted E7-encoded epitope. Cancer Research, 56, 582-588.
Reynolds, J.R. Armitage, N.C. & Balfour, T.W. (1983) Flexible sigmoidoscopy as 
outpatient procedure. Lancet, 2(8358), 1072.
Reynolds, J.V. Joyce, W.P. & Dolan, J. (1996) Pathological evidence in support of total 
mesorectal excision in the management of rectal cancer. British Journal o f Sursery, 83, 
1112-1115.
Richter, M. Weiss, M. Weinberger, I. Furstenberger, G. & Marian, B. (2001) Growth 
inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase 
inhibitors. Carcinosenesis, 22,17-25.
Riddell, S.R, & Greenberg, P.D. (1995) Principles for adoptive T cell therapy of human 
viral diseases. Annual review o f  immunolosv, 13, 545-86.
Rock, C.L. (1997) Carotenoids: biology and treatment. Pharmacolosv & Therapeutics, 
75,185-197.
Ropponen, K.M. Eskelinen, M.J. Lipponen, P.K. Allava, E. & Kosma, V.M. (1997) 
Prognostic value of tumour -infiltrating lymphocytes (TILs) in colorectal cancer. 
Journal o f Patholosv, 182, 318-324.
Rose, D.S. Maddox, P.H. Brown, D.C. (1994) Which proliferation markers for routine 
immunohistology? A comparison of five antibodies. Journal o f  Clinical Patholosv, 47, 
1010-1014.
Rosenberg, L. Palmer, J.R. Zauber, A.G. Warshauer, M.E. Stolley, P.D. & Shapiro, S.A.
(1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of 
large-bowel cancer. Journal o f National Cancer Institute, 83, 355-358.
Rosenberg, S.A. Kawakami, Y. Robbins, P.F. Wang, R. (1996) Identification of the 
genes encoding cancer antigens: implications for cancer immunotherapy. Advances in 
Cancer Research, 70,145-177.
184
Rosenwald, LB. (2004) The role of translation in neoplastic transformation from a 
pathologist's point of view. Oncosene, 23, 3230-3247.
Rubio, C.A. Emas, S. & Nylander, G. (1977) A critical reappraisal of Dukes' 
classification. Sursery, Gvnecolosv & Obstetrics. 145, 682-684.
Rubio, C.A. Wallin, B. Ware, J. Sueandar, M. & Duvander, A. (1989) Effect of 
indomethacin on autotransplanted colonic tumours. Diseases o f  the Colon & Rectum. 
32, 488-491.
Saleh, H.A. Jackson, H. Khatib, G. & Banerjee, M. (1999) Correlation of bcl-2 
oncoprotein immunohistochemical expression with proliferation index and 
histopathologic parameters in colorectal neoplasia. Patholosv & Oncolosv Research. 5, 
273-279.
Salmon, J.S. Lockhart, A.C. & Berlin, J. (2005) Anti-angiogenic treatment of 
gastrointestinal malignancies. Cancer Investisation. 23, 712-726.
Sandler, R.S. Halabi, S. Baron, J.A. Budinger, S. Paskett, E. Keresztes, R. Petrelli, N. 
Pipas, J.M. Karp, D.D. Loprinzi, C.L. Steinbach, G. & Schilsky, R. (2003) A 
randomized trial of aspirin to prevent colorectal adenomas in patients with previous 
colorectal cancer. New Ensland Journal o f  Medicine, 348, 883-890.
Sandler, R.S. Sandler, D.P. Comstock, G.W. Helsing, K.J. & Shore, D.L. (1988) 
Cigarette smoking, alcohol, and the risk of colorectal cancer in women. Journal o f the 
National Cancer Institute, 80, 1329-1333.
Schwandner, O. Schiedeck, T.H. Bruch, H.P. Duchrow, M. Windhoevel, U. & Broil, R.
(2000) Apoptosis in rectal cancer: prognostic significance in comparison with clinical 
histopathologic, and immunohistochemical variables. Diseases o f the Colon & Rectum, 
43,1227-1236.
Scott, H.R. McMillan, D.C. Forrest, L.M. Brown, D.J. McArdle, C.S. & Milroy, R.
(2002) The systemic inflammatory response, weight loss, performance status and 
survival in patients with inoperable non-small cell lung cancer. British Journal o f  
Cancer, 87, 264-267.
185
Scott, N. Bell, S. M. Sagar, P. Blair, G. E. Dixon, M. F. & Quirke, P. (1993) p53 
expression and K-ras mutation in colorectal adenoma. Gut, 34, 621-624.
Scott, N. Jackson, P. & Ai-Jaberi, T. (1995) Total mesorectal excision and local 
recurrence: A study of tumour spread in the mesorectum distal to rectal cancer. British 
Journal o f  Sursery. 82, 1031-1033.
Secco, G.B. Fardelli, R. & Campora, E. (1990) Prognostic value of the Jass histological 
classification in left colon and rectal cancer: a multivariate analysis. Disestion, 47, 71- 
80.
Shepherd, N.A. Saraga, E.P. Love, S.B. & Jass, J.R. (1989) Prognostic factors in 
colorectal cancer. Histonathologv. 14, 613-620.
Sinha, R. Chow, W.H. Kulldorff, M. Denobile, J. Butler, J. Garcia-Closas, M. Weil, R. 
Hoover, R.N. & Rothman, N. (1999) Well-done, grilled meat increases the risk of 
colorectal cancer. Cancer Research, 59, 4320-4324.
Sinicrope, F.A. Hart, J. Hsu, H.A. Lemoine, M. Michelassi, F. & Stephens, L.C. (1999) 
Apoptotic and mitotic indices predict survival rates in lymph node-negative colon 
carcinomas. Clinical cancer research, 5, 1793-1804.
Skinner, S.A. Penney, A.G. & O'Brien, P.E. (1991) Sulindac inhibits the rate of growth 
and appearance of colon tumours in the rat. Archives o f  Sursery, 13, 541-546.
Slattery, M.L. Benson, J. Curtin, K. Khe-Ni, Ma. Schaeffer, D. & Potter, J.D. (2000) 
Carotenoids and colon cancer. American Journal o f  Clinical Nutrition, 71, 575-582.
Slattery, M.L. Potter, J.D. Duncan, D.M. & Berry, T.D. (1997) Dietary fat and colon 
cancer: assessment of risk associated with specific fatty acids. International Journal o f  
Cancer, 27, 670-677.
Slattery, M.L. West, D.W. Robison, L.M. French, T.K. Ford, M.H. Schuman, K.L. & 
Sorenson, A.W. (1990) Tobacco, alcohol, and caffeine as risk factors for colon cancer 
in a low risk population. Epidemiolosv, 1,141-145.
186
f-L.; ■-■■TV-:
Smalley, W. & DuBois, R.N. (1997) Colorectal cancer and non steroidal anti­
inflammatory drugs. Advanced Pharmacology. 39,1-20.
Smith, G. Carey, F. A. Beattie, J. (2002) Mutations in APC, Kirsten-ras, and p53— 
alternative genetic pathways to colorectal cancer. Proceedings o f the National Academy 
o f Sciences. 99, 9433-9438
Smith, K.A. (1988) Interleukin-2: incepation, impact and implication. Science, 240, 
1169-1176.
Smith, M.L. Hawcroft, G. Hull, M.A. (2000) The effect o f non-steroidal anti 
inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms 
of action. European Journal o f Cancer, 36, 664-674.
Stamatiadis, A.P. Manouras, A.J. Triaiitos, G.N. Katergiannakis, V.A. & Apostolidis, 
N.S. (1992) Combination of serum carcino-embryonic antigen and C-reactive protein a 
useful test in preoperative staging of colorectal cancer. European Journal o f Surgical 
Oncology, 18, 41-43.
Sugamura, K. Makino, M. & Kaibara, N. (1998) Apoptosis as a prognostic factor in 
colorectal carcinoma. Surgery Today. 28,145-150.
Talbot, I. C. Burt, R. Jarvinen, H. & Thomas, G. (2000) Familial adenomatous 
polyposis. In: Pathology & Genetics o f  Tumours o f the Digestive System, ed. Hamilton 
SR, Aaltonen LA. pp. 120-125. Lyon: lARC Press.
Tenjo, T. Toyoda, M. Okuda, J. Watanabe, I. Yamamoto, T. Tanaka, K. Ohtani, M. 
Nohara, T. Kawasaki, H. & Tanigawa, N. (2000) Prognostic significance of p27(kipl) 
protein expression and spontaneous apoptosis in patients with colorectal 
adenocarcinomas. Oncology, 58, 45 -51.
Terry, P. Bergkvist, L. Holmberg, L. & Wolk, A. (2001) No Association between fat 
and any fatty acid intakes and risk of colorectal cancer. Cancer Epidemiology 
Biomarkers & Prevention, 10, 913-914.
187
Thompson, C.B. (1991) Apoptosis in the pathogenesis and treatment of disease. 
Science. 267,1456-1462
Thun, M. J. Namboodiri, M.M. & Health, C.W.Jr. (1991) Aspirin use and reduced risk 
of colon cancer. New England Journal o f Medicine, 325, 1593-1596.
Tillett, W.S. & Francis, T.Jr. (1930) Serological reactions in pneumonia with non­
protein somatic fraction of pneumococcus. Journal o f  Experimental Medicine, 52, 561- 
571.
Tisdale, M.J. (1999) Wasting in cancer. Journal o f Nutrition. 129, 246s-246s.
Toes, R.E.M. Ossendorp, F. Offringa, R. Melief, C.J. (1999) CD4 T cells and their role 
in antitumor immune responses. Journal o f Experimental Medicine, 189, 753-756
Tomlinson, I. Hyas, M. & Novell, M. (1997) Molecular genetics of colon cancer. 
Cancer and Metastasis Reviews, 16, 67- 79.
Turnbull, R.B. Kyle, K. Watson, F.R. & Spratt, J. (1967) Cancer of the colon: the 
influence of the no-touch isolation technique on survival rates. Annals o f  Surgery, 166, 
420- 427.
UICC. Colon (ICD-0 153) (1978) In TNM. Classification o f Malignant Tumours. 
Geneva.
Vakkila, J. & Lotze, M.T. (2004) Inflammation and necrosis promote tumour growth. 
Nature Reviews. Immunology, 4, 641-648.
Valera, V. Yokoyama, N. Walter, B. Okamoto, FI. Suda, Ï .  & Hatakeyama, K. (2005) 
Clinical significance of Ki-67 proliferation index in disease progression and prognosis 
of patients with resected colorectal carcinoma. British Journal o f  Surgery, 92, 1002- 
1007.
Van Cutsem, Eric. & Arends, Jann. (2005) The causes and consequences of cancer- 
associated malnutrition. European Journal o f Oncology Nursing, Suppl 2, 851-63.
188
Verheijen, R. Kuijpers, H.J. Schlingemann, R.O. Boehmer, A.L. van Driel, R. 
Brakenhoff, G.J. & Ramaekers, F.C. (1989) Ki-67 detects a nuclear matrix- ssociated 
proliferation-related antigen. I. Intracellular localization during interphase. Journal o f  
Cell Science, 92, 123-130.
Villunger, A. & Strasser, A. (1999) The great escape: is immune evasion required for 
tumor progression? Nature medicine, 5, 874-875.
Vogelstein, B. Fearon, E. R. Hamilton, S. R. et al. (1988) Genetic alterations dining 
colo-rectal tumor development. New Ensland Journal o f Medicine, 319, 525-532.
Volanakis, J.E. (1997) Acute phase protein in rheumatic disease. In: Arthritis and allied 
conditions: a textbook o f rheumatology, ed. Koopman W J. 13^ '^  ed., pp 505-514. 
Baltimore: Williams & Wilkins.
von Andrian, U.H. & Mackay, G.R. (2000) T-cell function and migration. Two sides of 
the same coin. The New England Journal o f Medicine. 343, 1020-1034.
Waddell, W.R. & Loughry, R.W. (1983) Sulindac for polyposis of colon. Journal o f 
Surgical Oncology. 24, 83-87.
Waddell, W.R. Ganser, G.F. Cerise, E.J. & Lougliry, R.W. (1989) Sulindac for 
polyposis of the colon. American Journal o f Surgery, 157, 175-179.
Watson, A.J. (1995) Review article: manipulation of cell death, the development of 
novel strategies for the treatment of gastrointestinal disease. Alimentary Pharmacology 
& Therapeutics., 9, 215-226.
Welch, J.P. & Donaldson, G.A. (1974) Management of sever obstruction of the large 
bowel due to malignant disease. American Journal o f  Surgery. 127, 492-429.
Whittaker, M.& Goligher, J.C. (1976) The prognosis after surgical treatment for 
carcinoma of the rectum. British Journal o f Surgery, 63, 384-388.
189
Wiggers, T. Arends, J.W. Schutte, B. Volovics, L. & Bosnian, F.T. (1988) A 
multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer. 
61, 386-395.
Wigmore, S.J. Fearon, K.C.H. Maingay, J.P. Lai, P.B.S. & Ross, J.A. (1997) 
Interleukin-8 can mediate acute-phase protein production by isolated human 
hepatocytes. American Journal o f Physiology. 273, E720-E726.
Wigmore, S.J. McMahon, A.J. Sturgeon, C.M. & Fearon, K.C. (2001) Acute-phase 
protein response, survival and tumour recurrence in patients with colorectal cancer. 
British Journal o f  Surgery. 88, 255-60.
Willett, W.C. Stampfer, M.J. Rosner, B.A. & Speizer, F.E. (1990) Relation of meat, fat, 
and fiber intake to the risk of colon cancer in a prospective study among women. New 
England Journal o f  Medicine. 323, 1664-1672.
William, N.S. Durdey, P. Quirke, P. Robinson, P.J. Dyson, J.E. Dixon, M.F. & Bird, 
C.C. (1985) Preoperative staging of rectal neoplasm and its impact on clinical 
management. British Journal o f  Surgery. 72, 868-874.
Williams, A.C. Hague, A. Elder, D.J. Pai’askeva, C. (1996) In vitro models for studying 
colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage 
in the control of proliferation, differentiation and apoptosis. Biochimica et Biophvsica 
Acta. 1288, F9-19.
Williams, N. S. & Johnston, D. (1984) Survival and recurrence after sphincter-saving 
resection and abdominoperineal resection for carcinoma of the middle third of the 
rectum. British Journal o f  Surgery. 71, 278-182.
Wood, D.A. (1968) The NTM system of classification for gastrointestinal cancer. In 
Sixth National Cancer Conference Proceedings, pp 403-415. Philadelphia, JB 
Lippincott
Woolf, N. (1998) Acute inflammation II: cellular events and chemical mediators. In: 
Pathology : Basic and Systemic, ed. Woolf, N. edition. Ch. 5 , pp 51-56.
190
Xavier, P. Belo, L. Beires, J. Rebelo, L Martinez-de-Oüveira, J. Lunet, N. & Barros, H. 
(2006) Serum levels of VEGF and TNF-alpha and their association with C-reactive 
protein in patients with endometriosis. Archives o f  gynecology and obstetrics. 273, 227- 
231.
Xia, D. & Samols, D. (1997) Transgenic mice expressing rabbit C-reactive protein are 
resistant to endotoxemia. Proceedings o f  the National Academy o f  Sciences US A.  94, 
2575-2580.
Xie, W.L. Chipman, J.G. Robertson, D.L. Erikson, R.L. & Simmons, D.L. (1991) 
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated 
by mRNA splicing. Proceedings o f  the National Academy o f  Sciences USA.  88, 2692- 
2696.
Xing, Z. C.D. Richards, T. Braciak, V. Thibault, & Gauldie, J. (1995) Cytokine 
regulation of hepatic acute phase protein expression. In Cytokines and the Liver. Falk 
Symposium 78. Gerok, W. Decker, K. Andus, T. & Gross, V. editors. Pp 164-171. 
Netherlands. Kluwer Academic Publishers Group.
Yamazaki, R. Kusunoki, N. Matsuzaki, T. Hashimoto, S. & Kawai, S. (2002) Selective 
cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and 
induce apoptosis of colon adenocarcinoma cells. FEBS Letters. 531, 278-284.
Yamazoe, Y. Maetani, S. Onodera, H. Nishikawa, T. & Tobe, T. (1992) 
Histopathological prediction of liver metastasis after curative resection of colorectal 
cancer. Surgical Oncology. 1,237-244.
Zhang, S.M. Buring, J.E. Lee, I.M. Cook, N.R. & Ridker, P.M. (2005) C-reactive 
protein levels are not associated with increased risk for colorectal cancer in women. 
Annal o f  Internal Medicine. 142, 425-432.
Zitnik, R.J. & Elias, J.A. (1993) Interleukin-6 and the lung. In Cvtokines of the Lung. J. 
Kelly, editor. Marcel Dekker, Inc. Vol. 61. pp 229-280. New York: NY, ETATS-UNIS
Zouki, C. Beauchamp, M. Baron, C. & Filep, J. G. (1997) Prevention of in vitro 
neutrophil adhesion to endothelial cells tlirough shedding of L-selectin by C-reactive
191
protein and peptides derived from C-reactive protein. Journal o f  Clinical Investigation. 
100, 522-529.
192
APPENDIX: DATA FROM THE PROSPECTIVE STUDY FOR PATIENTS 
WITH OPERABLE COLORECTAL CANCER DESCRIBED IN CHAPTER 
FOUR AND FIVE.
193
APPENDIX: DATA FROM THE PROSPECTIVE STUDY FOR PATIENTS 
WITH OPERABLE COLORECTAL CANCER DESCRIBED IN CHAPTER 
FOUR AND FIVE.
193
I l rJ- OOO-^J-^OrjOON 2 R p; R^  ^  ^  t ^ ^ M ^ o\ 0\ O 0\ N Ô6o o M O \ \ q v i T f m r ^ T ±  (X^od'-^rnfArnfncSM On On On On lO ON
8 8 8 8 O O O O
B I
l l î l l l1  a  1 1 1 1
ai ai oiII
S S S E E
% X .2 o y u .9
P i l l
l î ü l f l l l l l l l
u u u o y .y
1 1 il II I I » ffi XS S
r^ M0\ On ONOn 9> ON OnONONOn OnOs
1 6 1c\ O 00 (N NOO O O fS
| l | | | l l i i l l l l | i l l | | | | i l
l l l l l j l l ' l ' l ' t l - l - l s f f i i i i i ?^ < O M m t ^ T ^ o o ^ m r < N i n a \ r ^ r A r K A 4' V i c : ' - ' * - ' C o<N (N <N <N c4 ON oo (N CN ro
o o o o o oo o o o o o 8 8 8 8 8 o o o o
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
" I O O O O 8 8 8 8 8
O O O O O O Oo o o o o o o
8 é J'TSi 8 8 ? s s(S (S N (N —' 8 8 8 8 8 8 8 8 O O O
l l r-~ NO r-^  r~- VI
Mm^v^Nor-^ooGN
o o  CT) m  o  r '*H o\ fT| r -  o\ —■
r~- oo VI r-. (N t^
oû oo in 00
= 8 8 2ON On On 00
(N‘ 5 0 8 -(N = 5 8 8 8 § g §  = ®P 2 8 8 I  S -8 p 8 8 8 8 8
1 I* g' B
1 1 1 1 1 1
a- 8 m M 8 1*o :s B S
1 .1OT
0
if i
s B
.2 2 .y .y a
I Ioi ai
S' >> S' S'E E E E Ë e s e E
8 0 0 y y B ■§ ■§ ■§0 0 S 0 0 § V g1 % 8 •3 ■3
0 a
■ î0 ÿ . u .y •y 8 .y
i l ill
o  ü  '-p 'C
^ i  i  ^M M M Ù4
B 6
.H u o .a  ü  u
■s -5 s
I Iai ai
O
8
3 ^  ^< < <l> 00 vo V)l l l â(N es ÏN o  ^
ONONONONON<^ ONCr\aNONONON^ ^ 00 00 00 00 00ON On On Os ONON ON On On Ono> d> (U (U
Q  9Tl- l l l i  s
p d. a, tx p rt <: < 3 3 "3Ol 'O o ■3- 00
i l
0 0 0 0 0
- 1I 8 8 8 8 8 8 8 8 8 8 8 8 8 8
pg
” 1
8 8 8 8 8 8 8 8 8
M i l "
p p o o o o o o o o0 0 0 0 0 0 0 0 0 0rs (S ■-' (N
M ?j r-  !P fo p< Si ^ NO r~ Nn r- VI M M 00 ^ ON 'cj- G\ Tÿ- IT)NT) NO 00 00 00
O ' —« r s m ^ v i N O r - ' O o O N O ' —^ { S c n ' S ' N o  ir>>r>Loinv->ir»inir)ioNovDNONONONovo
. 'fVO On On \0r ^ c o m m r - ' r ^ r - ' r - ' o  {^  r-- o rnp  p  <N p  NO «-;00 »—* NONO in NO NO NO rs
°  s  s  § 8 8 8 8
B G& Cd c/)
§ B B B B B
a j V o j i u J J a i i u a j
 ^ I  .2 .2 .2
|gIK (2 Pi S p2
B B B B2-2 u o S E E5 o  '8 8 8 ë
2P -§ .X- I Î Î
o\0\o\o\o\a\o\o\o\0\ ( j \o\o\
l l l l l i l l i i r "  '
0 \  <ys Os 0 \  (T\Os OS Os O s a sOs Os Os Os Os
g S c S •=00 fo Ch
in 8 8 8 S 8 8 8 8 8 8
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
8 8 8 8 8 8 8 8 8 8 8
i ? | 8 8 8 8 8>-< (N H  <N >-• 8 8 8 8 8 8
i n t ^ Oo o o r o O\ o or-r--oor ' t~'VOt--\ooo^vDt^'£>f^vor^v->c^
O ' —' (Nfo^f i nvor^ r ^ r ^ r - - r - r - r - ' r ^ t ^
P <4 . . .in  in  lo VO ^VO VO VO 04 VDTt- rh rn CO <n rn tnVO VO VO vO VO VO VO m in VO 3"m  VO VO VO iJ-
rn r; p O' pTf in 04 p p r-; MO Ov Ov Oti S <ri r~in ■Vf It ':!■ It ‘ 3"
p o o p p o o oo o o o o o o o 8 8 8 8 8 8 8
s s Ë S i-2 0 2
I . . .(2 GO ioe E(30 (30 < <
* I I 51
u o o n) a> O
E i
i l li l l
1 1 1 Î I Î 1 1 1 1m i l
^ i i i i
B B
.2 .2 .2 2 o
I S Ë E •'2 :2i i i i l l
g 6
.2 “  e  u  ua
OV p o\ 11 Ov Ov Ov Ov gv g & & 8; g; 8Ov Ov ov OV o
< < < <^ GO W vt go in oi o I ( o O O O O O z z z g g g ^
8 8 8
fS o o cs cs rs(S ("1 00 in
8 8 8 8 8 8
I i
w 8 8 8 8 4* CN (N 04 04
, . _ o o v o ^ t n c o i n  04 f n O ' - « G N o O . —I
o o o S o(N G^ 04 M 41
m 8 8 8 8 8 8 0 0 0 0
I f P 8 g g p o p o o p o o p o0 0 0 0 0 0 0 0 0 0
8 8 8 8 O O O O O O O Oo o o o o o o o
1; o o o o o o o o S ^  S G 9 9 9 0 0 0 0 0 0 0
r-' 00 «n o 00 NO
o — f sm' t t nvor - ' oogvo  o o o o o o o o o o . — CSm’itinvOt-'OOOvO
I l r- o CO o o ovq <N Tf m m vq\d \d \d ^Tj- <$" Tj- Tf-
as
S S S S §  § 8  8  8  8  8  8  8
E E
l u sPi ai ai PW I  Ia s
o  -a  Tî
< X
§ 0 0 # # 0 # 8 §
i i i i i i i i i i;T5;o\mf^rAr-ûo£;iEï
i  § § i  8g" S' È" & &<  <  M c/p œ
m ^  ^M fv) O O CN
SÎ 5
l îI 8 8 8 8 8 8
8 8 8 8 s  «° ° 8 8 8
ji
I f o o o o s 8 s §
o  o o o o o o o 8 8 8 8 8
Al
?
O  — O N O r o O \ 0 »r i f S ^ r ^ r - ' s t r - ' ^ o r - r ^ o o
r
ill
111
ê | ,
I I I
M H
S S q p S S p S p q S p p p q p S g p S S S S S S S S S o g
8 8 8 8 8 8 8 8 8 8  8 8 8 8 8 8 8 8 8  R P C: Q! % R @
^ tn! — S C? ^r—*T—<r—tr—  ^ O O «—» O fS fS CSp p p p p p o o o o o o o o o o o o o o o o o o o o o o o o
o o o p o o p p p o p o o po o o o . O p p p , ,'5j- >o o Os in■sj- •—> m (N cs —' m
p p p p p p p p p p p p p p po o o o o o o o o
in v o o s r ^ o o i n c n c N
oin <N c4 o\  cNTt <n  ^ 'O in VO
s l 8 8 8 8 8 8 8 8 8 p o p 8 8 8 8 8 8
CO I"- oo r '
8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8» - < o a \ ^ o d r - 4 r ^ o 6 o
m2 ^ a <^0 0 0 0 0 o o o o o o 8 8 8 8 p p p p p p p p po o o o o o o o o o
I I I
1^1
o o o o o op p o q p pin <o in in in r~ 8 8 8 8 o o o o o o o o o ^  o p p p p p p p p ^  in S  in in P  vi in in in 2
P r S m ' ^ ' i n o r ^ o o o v
i î f
m o o o o
tH  CVJ CM CM CN CD oO O C D O O O O O O O O O i H tH  "i.O CM CM T—I iHO  CD O  CD O  O  O
CD o  o  O  OO O O O O O C D C D C D C D O O O
e n  O  e n  tH tH  r H LH Ln tH  i H
O C D O C D O O O O
lits CM o  i H tH PsiC D C D O O O O C D O O O C D C D O CD 1—i ir-i T—I i H CD CD O  CD CD
I
O O O O O a O O C D C D O O O O O O O O O C DC D O C D C D O O O C D O O O O O C D C D C D O O O Oocîvco'diTH(Mcr»cjvc n c M c n c M r s i r o r H H o c s i r ^ c D ' t ^ < L o c r > r - . c nr H T H C M U Î r H T - i r O L O t M 00CnLDCOM3O7LOCMTHCMCSJCMmCMrHTH
I I
O  O  CD CD O  OO  O  CD O  O  O
CM 1-4 M  ( M
CD CD CD CD CD CDCD CD CD CD O  O §
P
r H C O C MO O r ^ L O r ^ C MC T tC n O D r - . U l O O v D s D ' r f G c } tH  CO e n  CM tjDen r~. œ  u") u) iH(MT-tCrvTHt C^DCriTHM3 L n c n p v L D u D c o c n c n s o
O O O C D C D O O C D C D C DO O C D O C D C D C D OtopH.cMCNjcMrovDcnr^c n m ^ ^ c n ^ c n c M c n
C D O O O O O O O C D C D O O O O C D O C D O OO O O O O O O O C DCDOCnTHCMCnrHCnCM^cntf'cfcnco'^
- 1 $I P«
u
Ê
5u ' )Ln^ LnLnLnr ! œr ! 2 ' j LnLnm5 ' j
Ill T-4CMT-4THCsJ<NJCDOtH<MT-4 C\l tH  i H tH  r H CN t—I vjO tH  ( N c n  tH  O C D O O O O O O O O O O r4 iH Ln tH ’«f O  O  O O O
ill o o o o o oO  CD O  O  O  O O O O O O C D C D O O O C 3O O O C D O O O O O O O O  O  O  CD CD ( D CDOOOa3^00r^rHp.CMSÛCnvI5COOO'DCnÇNJLO?JCDCOCnU)OCO  ^m  ^  C\l  1-4 \ D Lf) r 4  C O m C M r O I J ) ' * s ÿ < M r 4 C O ^ D C O  , C n ^ C P > T - 4 i - 4 C O - ^
II ODIP CM CD 1-4 CD r 4C D C D O O O O C D C D C D C D OC M i H i H O J r v J O r H C M i H C M i H OCD CD O  CD CD 1-4 1-4 ( M O  r 4  CD CD O  O  O
t  aill CD CD CD CD CD O  CD CD O  O C D O C D O O C D O OO O C D O C D O O O C D O a Op s  r 4  CD CD CM CM pv  fSJ i H
ÏNJ CM r 4  CM
CD CD O  CD CD CD CD CD CD CD
CM CM CM CM CM
COi -4 C MP %r 4 r ^ C O L O C n C M r N C r * r O ’M < P v C O C O C M p v r 4 MD C M< n L n c ni ^ c n m n - c r \ L n ^ r ^ c n c n o o c o o \ o \ o o ^ c n m v o M D k D P ' ' . c n c o i n
CD CD O  CD O  O  OCD O  O  CD CD CD ( D O O O C D C D O C D O OC D O C D O O O O O C D O  CD CD CD CD CD C3C3 CD CD CD CD CD CD
IlsIIIÙ O  O  CD CD O  CD CD CD CD CD
Pi CD CD CD O  O  CD CD CD CD CD
e î t
m
P i  rH  r~i r - l  C iH  i—t t —f CM CM CM iH  LUO O O O O O O O O C D C Î O O O O  CD O  O  O  O  CD M  r-4  CM CD P I  M  CM
iPH p".ps. CM r4 CM O O O C D O O O OP \ J O D O t M M D ' s J « C O P 4C n r H C n c n L D ' J D ' M * - ^ CD O  O  O  OC D O O O C D O C D O O O C D C D O O O OU l U D P ^ C O f O O O O C T s C M ' ^ - HP l C Mt / ) C MC n C MC O C MC n L O T - 4 C7VCMpvCMCr >
ïlfH H C M r H O i - l C D p g o C M T H C M r HO O C D C D O O O O O C D O T—I CM CM 1—1 1-4 1-4 r 4  CM CO i-4  CM CMO O C D O O O O O C D C D O O
if O O O C D G D C D O O O OO  O  CD CD O O  O  O  O  O  O  O  CD CD O C D O O O O O O C DO O O C D C D O O O
I t i H  CM CM 1-4
% C D C D C D O O O O O O O O O O C D C D C D O O C DO O O O C D C D O O O C D O O O O C D O O C D O O  O  O  O  CD O  CD
1» CD O  CD CD CD O  O  O  CD CD CD O  CD O  CD CD CDO  CD O  O  O  a  O CD CD CD CD CD O  O  CD O  CD
I! CD CD CD O  O  Ln m ui LU en CD o  CD o  o  o  CDm m u i u i L n u i L D ^ L n u i Lf> Ul  Ü1 Ul  Ul
' 5%
CD 1-4 CM m  ^4* CD CD CD CD CD OOCnOrHCMPO^ UlMDtS-OOCriCD O  o  r 4  t H  1-4 1-4 i -4  i-4  t H  ^  t -4 t H CM
T-4 T-4 i-4 r - * ' r 4 ' r4 r 4 T4 r 4 T-4 i-4 r 4 r 4
11!
p!
U!Ü
iU
il.2?
fif
rHTHTHTHfHT-HCMiHT-IOCMi-HT-lTHO O O O O O O O O O O O O O
O O O O O O C D C D O O O O O O O O O O O Oo o o o o o o o o o o o o o o o o
C n r H r H C O i H r H O C N tH 1-4 O  O  CM O  rvJ i H  r H O  r H ( \ l  tH  r HO O O O O O O O O O O O O O O O O O O O O O O
O  O  O  O  O  O  OO  O  O  O  O  O  O o o o o o oo o o o o o
co en th Lf) m coun CM 'sÿ CM tH en
o o o o o o oo o o o o o o
CM CM r H CM r H tH  tH
Ln r H
o o o o o o o o
CM tH  tH CM
• M * r H C M U O C n r ^ L O C O r H ü D r ^ L f >
o o o o o o o o o o o o oo o o o o o o o o o o o o
C M C n O \ f M O G O U l ^ C M ' n ^ O \0 0c n c s j c n ' c f c n c n c n c n c n c n c M c n ’cj'
o o o o o o o c  o o o o o o o o o o o o o
o o o o o oo o o o o o
CM CM r H H  tH CM
r H 1-4 LD M3(X cr»
R
l l î
Lo Ln LD un Lfï Ln (N sn • rsi ■ ‘» IN Lft «J5
JI sII
O O O O C D O O Oo o o o o o o o1-1 CM CM CM CM CM
o o o o o o O O O O a O O C D O O O O C D O O OO C D O O O O O O C D O O O O O O O O O O O C D O O O O O C D O O OOCDOLOOOOLOtnLnLDOCDCDL n c n u i c M ^ u i c n ' c f ^ ^ ' L n o i c o r - . OOOOLOUI OOOOOvi5 C n MD' ç J ' C NC OC ML OL n c n
o o o o o o O O O O O C D O O O O o o o o a o o o o o oO O O O O O O C D O O O O O O C 5 C D O O O O C D O O C D Or^cMcnLOMDcn'jDTHnTHorvcMcnovuio ( \ i r ~ . % o ^ o ^ m u 3 a \ ^ o \ D C M L n c M C M c o rvGO'M»iHLf>Lf)CMCnC M c n c M r H c n ' e f C M c o ^ m c n m c M C M ^ L n f M c n c M f M c n c n c n r H' T^-HCSlT-HCDCMUnCOLOCnCO
CD o o o o o o00 en en CD rH en ^CM CD t H  m  CM tH CM c o o o o c n c M E ^ ' ^ œ a 3 LOLn i >.tH en o en en CM CM CD t H  iH orH tH iH iH rH rH tH
R
CM CM ‘ ‘ CM m CM rH tH
o o o o o o CM o 00 M* 'tf en rH CM
c M L o c n c n s o c ^ ' c j ' v o
o o o CD CD o oCM UD r~. [S. Lf) LD 00
MO u) en ui n* \o
VjO M* MO CO Lf> VD Vû
i l LO cr> LO
rH LO CD M* en 1-H rH rH CM r~ r-~ LT) co vo m o en co œ vo 00
Ag ««I C n C M f M C M C M L n r H ’^ r H C n c n C M C M C M r H r H C n C M C M m U D r H r H ' ï J ’ r H r M r H ^ C n M *OOOOCDOOOCDOOOCDCDOCDOOOCDOCDa OOOOOCDCD
ilÜ) o  o  o  o  ofSJ tH 1H CM CMO  CD O  O  CD O  O  O  CD O CM CM CM CM
CDCDOOOOOOO O O O C D O O O C D O O O O O O O C D O OOOCDCDOOCDCDOCDCDOOOOOOOO
II O C D O O C D O C D O C D OO O O O O C D O C O C D C DV D C MC MÜ l r H G O C n s O x i » t v . CD CD O  O  CD CD CDCDCDOOOOOO C D C D C D O O O C D O a O O O C D O O a o or H C n c n C D V O r H O C n c O T 4i C M C O L O O03v j o c D c r » a > L / ï - M * c n c n t H v r o c n o v oCMCMîMCOi-HCnCMCMCMTHCMrHr-ICM
OOOOC DJ OOOOO i ^ O N ’M ^ C O C O t H O O C D ’Çj'Cri
m C M T H C M i H r H r H L O C M T H C M C O T H C M C O
O O O C D C D O O O O O t D C D C D O O O a ov D O C M U 3 C n O T H C M C D T H M 3 C D C n T i * L n r ^ r ^ C O
■ M < m C M C M r H C M O T H O f M O « M ' i H
inR
I
% vo S R O O O C D O O O O C Dc n v D v o o - ^ c n ’c ÿ c n c M ü i c M L O U i(M CM iH iH tH CM tH iH tH CM CM CM tH
CD O CD O CD O ^CO tcjt çsj CM iH ’«t
c n L OL n ' e j ‘ - t f c o ^ c ^ c n v o o D L n c r > L J i C M ' ç j ' r - w c n m v û L n c n u i
Pv 'cr LO cr» H* tcj* L(7 en
i f
o o o CD CD CDes. en tH vû o cr*U1 ÛD CN. VD U) en s  s  o 5 CTi 00cv [N. co tn
m!îII C M C M C M t H C M C M C M C M C M - ^ ^ iHCMcnTHtHcnmcMC D C D O O O O O C D O O O O O O C D O O CM CM MO en CM tH tHC D O C D C D O O O O C D O O O
TH CM en-«cj< -«sj* 'C f
O O O C D O O O Oa o o o o o o o
rH  CM tH  tNJ <NJ r H r H CM (M
O  CD O  CD CD O O O O C D O C D O O O C D O O O C O C D a O
O O O O O O O O O O O O O O O C D O O O O O O O O C D C D
C D O O O O C D U 1 0 0 C D O L O L O U l L / ) L O L D O L f ) Ü 1 0 r ^ L f > Ü l L J l aC M ' < M L n r ' v ( M r % c M x f o ' ) v o ( n v D ( n c M ( M L n c n m ' ( f L n ^ L r ) L n ' ( f c n H '
O O O O O O O O C D O O O O
C D O O O O C D O O O O O C D O O O C D O O O O C D OC D O O O C D O O O O
C M C D L n r H C M C ^ ’^ C M r H v O C n  L D ^ r ^ c r v œ H ^ T - H t M L o o Q v û ' J O  CnCMCMCMCMCnCMCMCO
£V ON LOVO(MvDCMr>.rOfMCO c M c M c n c M c n c M m c M c n m r Hu i c M c n m c M o v m u i C M c n ^  ' «f CD CM CO v£> CDCO CO CM cn ^
1 5 C D O O O O C D C D C D O O OO L O C D C M O C M C O U l L O C M U l
C M C M O t H O r H U l C O C O r H C M r H H * C M r H t H H ^ ' ^ f M ’ï4«0 CO r H CM Hi
C D O O C D C D O O Or H C O C M r H r ^ r ^ H i i i l
C M r H r H C M r H C M C M r H
O O C D O C D O C D Or ^ O v D C M L O O U l C M CD CD CD CD CD CTS O  CO 0% O
CD CD CD CD CD CD CDHi  VO O  H* CO H*
Hi  Hi  00  LO H* H* M3
CO CO CO CO 
MO CO CO Hi
O O O O O C D O C D O C D OO  LfJ O  OD Ul  t i>
P- .  03  CO 00  
(S. VO IPs or*
O  O  O  CD CD O  CD00  ON CT* Hi  P -  ( M Hi
Ln LO VO LO CD
CM H* vO OO CO CO CO
CD EH CD EH CO 00
i l l
r H C M H i C O O O C M C M H i r H r H C O C M E HCD O  CD CD CD CD
r H C v l C O H i t O v O E H C O C T »
m d m d v o m d v o v o v o v o v o
(MCOHiLOMDEHCOmCDrHCMCOHiLOMDrHCOOOCDC H C H r ^ j > v t H ( N . r ^ j s . G O O o c o c x 500 c o c o c o o o c o a N
[I
i l l0)0 0m
CD O  CD CD O  CD CD O  O  CD
CM r H r H CM
CD CD CD CD CD O  O  CD CD a
CM tH  r H CM CM
O  CD a  CD CD CD OCD CD C3 CD CD O  CD O O O O C D O O O O O O C DO C D C D O a O O O O C D O C D
O L O L f ) C D O i n u ) u o o o a L n L f ) 0 [ s L r ) C3 L n o o i n L O L o o \ û L n o
u
O  CD CD CD O C D C D C D O O O C D C D O O C D O O C D C D O O O O C D O O O OC 5 C D O O C D O O O O C D O O O CD CD CD CD CD O  O  a  O  CDCO ps 00 iH
CM m  CM CO m  r H r H
HiLnHiHiCMOVCrNaVLOLnOrHcnpsHiCMCOCD c r » c n i n H * M 5 H i H i c r » M D c r » < n H * u i H ' v o o r > v D 0vcr * rHHiCOCMrOCSirMHiHirHCMCOCOroCMHirOTHCO
n 00 CD i n  r H ( M r H O O ^ O O O O C D O OO N H i J ^ J C M r - H H i C J S r H f M c r *C n C M ^ C M L O H i r M O r H C M I  I _ J   I _ l   I  I  t  i
%
o o c d o o o o c do o o c r > c r * r - s r o r H c n
r H r H r H CM CM CO CM r H r H r H r H r H CO CM r H r H H  r H CM
CD CD CD O  CD CD CD 0 0 0 0 C D C 3 0 0 0 0H * C O O V O O O C T » r > - O L n C r i H *  "^ , H i v O M ) L n P ~ C O C O C 3 C M H i r H \ O H i ( r * C O  
r o L O - = i ' ' ^ c > i ' ^ \ £ ) L f » i O ’i i ' u i ^ n ' : i ' c o r v s 0 c n - 5i<>j3 > , û L n c v i c s L n c M s o
i f
O O C D C D C D O O O C D C D C DCOHipspsMDrvrOvOCOsDCO
LO 0 0  LO VO VJO CTk PvCOLnCTvOVUDVOOO
M}
m H i C M r H r H H i C O r H C O C M H i H i H i f O r ^ C O r HC D O O O C D O O O O O C D O O O O O
CD r H CM CO O  O  O  O O r H C M C O H i L O v D r v - C O C T i C DT H r H r H r H r H r H r H r H r H r H C M
i0) o N
B J
0) o om
o o o o o o
t H i H CN T—I CM CM
o a o o o o o oo o o o o o o o CD o  o  CD o oCD o o Ü1 LOH* H* QO H* LD CM e n  Hi  H*
CD CD O  O  O  OO  O  O  O  O  CD
O  O  O  CD CD O
O  O  O  O  CD O C D O C D O O O O O O O O O O O O O OO O O C D O O O O O O C D C D C D C D C D C D C D
O  O  CO CO UD HiMDrHCvtNÜlCXJCD
c n c o r H L n v o c M c n c oC O r H O L O O C O C M C n v O L O O H i H i O C DH i C M C O C M C O C M C M C O C M C n r O H i C O C n c o C M C n
r
■a
tH CM en Hi o CM en CD tH co m ps ov CM en M  t H
a  CD CD °  CSJ 00 o CD o CD CD o oO  LO en M3 CD t H CD
vH r H r*t  t H CM
O  CD CD O  O  Ot H en t H O  Hi  CM
t H CM CM tH tH
III
(MII CD
o,*5
i lI I
R
M
O O O O O O O O O O O O O Q O O C O o o o o o c s o o o[ S O C s C r > L O C O O T H L n ' X » r \ J r ' J ' J 3 'J5 r v l OOr H< j Or H- ! l ‘ C B O O O s £ )  
' c j < r ' w C T » < j D L O c r s c > - ' ï i ' o o c o ' j o - ^ m ( M v j o t s \ û ' < i ' i i < ' d < v f l [ S ' d ‘ ' « i ' Lf ) m' d<,
I I
CFV Lf> ^  CM 
LO m 2 GO CM CD
CD CD CD CD CD CD CD
Cs  r H M3 CD P' i  VO t H
v o L O c r > r ^ v O p v H i c r * c r » o o M O H i v o c o c n v O O T P ' . p s p s
If C M H i H i r H H i C M C M t H L n C M C n e M r H C M r H r H C n t H C M H i r H C M t H C n C M C M C MCD CD CD CD CD CD CDCDCDCDCDCDCDCDCDCDCDCDCDCDCDCDCDCD
CD o  CD o  o  o  oO  O  O  O  O  O  O O  O  O  O  CD O  OO  O  O  O  O  O  CD
I
CD O  O  O  CD O  CD CD CD CD CDCD O  O  CD CD O O  O  O  CD O  O  OO  CD CD CD CD CD CD
t o \
s
% % LOO CDVOO [S\ rH \ \\ \ \ \ \ \ \ \°
O O C D C D O C D O OO O O C D O C D C D O
■ f H r H r H C M T H T H r H r H
CD O  CD CD CD O O O O O O O O O
O O O O O O C D O O
CMCnH*LOviDI>.COCr» O i H C M C n H L n v O r ^ C D C r v T H O < N C 0 H * L D « d D r ^ C D C r * O  < M C \ l < M < M ( N C s J C S J O J ( M r s j r O
O O O O O O O Oo o o o o o o o
o o o o o o o o o o oo o o o o o o o o o o o o o o o
I
0 % II LO CM e n  e n  Ps  CO CM r H H* ^  ^ ^o H* o M o o o \ \ à \\ oes
o o o o o o o o o o o oo o o o o o o o o o o o o
r H t H tH  CM t-H r H r H r H CM
o  o  o  o  o  
o  o  o  o  CD o  o  o  a  Q  CD CD o  CD o O O O O O O O C DO C D O O C D C D C D O
o o o o o c n o o o o o o oO O C D O O O O C D C D C D C D CD O  CD O  O C D O O O C D O O O C DO O O O O O O O C D
I
M V)
l i
 ^ ^ ^Hi  CM CM
H* H* CM t »rsj e n CM r H \
\ \ \ \ \ \ \ \ \  \ cr>\ \ g \
O  O  O  O  o  o  o  o  o  o o  o  o  CD CD oO  O  O  O  O O
o o o o o o oo o o o o o o o CD o o o oo o o o o o o o o o o o o o o o o o o o
I
t
pvj vD H o\  \  \ \  \ r u  r H\  \ OJ \  \ CNCN
o o o o o o o o o o o o oo o o o o o o o o o o o o o o o o o o o o oO O O O O O O O O
tH 1—I C\l t H tH
i s
a
O t H c M o H ‘ m v o r ^ o c n o » H C M c n H i t r ? v i D r > - O T c r v oo o o o o o o o o o tH  t H i H t H CM
o o o oCD o  o  o O O O O O O O O C D OO O O O C D O O C D O O O  CD CD CD CD O  O O  O  O
1
O  O  CD O  O  O  O  CD CD CDO  O  CD O  CD O  O C D O O C D C D C D C D OC D C D O O O O O O
\  \  \  \
m
es
o o o o o o oo o o o o a o
tH  CM CM tH  rH *  rH
O O C D C D O C D C D C DC D C D O C D O Q O O
GLASGOW
UNfX'KRSITY
l i b r a r y
